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Abstract 
In recent years Novel Psychoactive Substances (NPS), including diphenidine 
and ephenidine, have emerged and an increase in the number of substances 
encountered each year has increased, even with the introduction of the 
Psychoactive Substances Act (2016).1 More derivatives are also reported 
containing fluorine substituents due to the increased stability.2 The 
appearance of novel fluorinated substances creates analytical challenges for 
their detection. This results in the need for the development of new rapid, 
selective and inexpensive analytical methods for both their separation and 
detection. Colour test reagents are commonly used for the presumptive testing 
of these emerging substances, however as the number of encountered 
compounds increases so does the number of false positives produced with 
these tests.3 Gas Chromatography-Mass Spectroscopy (GC-MS) is also a 
commonly used method for the detection and separation of controlled 
substances, with methods reported previously for fluorinated cathinones.4 
However, it also reports on the tailing of peaks through thermal degradation, 
which makes separation of regioisomers difficult.  
 
This thesis demonstrates the synthesis of a number of fluorinated and non- 
fluorinated diphenidine and ephenidine derivatives. Synthesis of fluorinated 
diphenidine analogues will also outline the ease of production of NPS along 
with the difficulties in their detection and separation. The use of presumptive 
colour testing shows the difficulty of distinguishing between regioisomers, as 
well as the increase to the number of false positives.  
 
The development of GC-MS methods has aided with the separation and 
detection of diphenidine and ephenidine derivatives. A method has also been 
developed and validated for the identification of fluorinated cathinones and 
amphetamines with improved symmetry and a removal of any tailing/fronting. 
Runs for all separation and identification last 20 minutes or longer.   
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60 MHz NMR has the ability to perform 1H and 19F NMR experiments, while 
still providing matching spectrum patterns and splitting to higher-powered 
magnets. This is utilised for the detection of diphenidine, ephenidine, 
cathinone and amphetamine derivatives with the ability to distinguish between 
regioisomers. 2D NMR experiments can also allow for further identification of 
difluorinated ephenidine derivatives. This allows for the possibility of using 60 
MHz NMR as a presumptive test for NPS. The use of 19F NMR experiments 
also provides an ability to perform quantitative analysis. Street samples can 
then be analysed both quantitatively and quantitatively, using 60 MHz NMR, 
with results confirmed by GC-MS. All 1H and 19F NMR experiments occur 
within 5 minutes meaning detection can occur rapidly which aids with forensic 
testing and shows that 60 MHz instrumentation can be utilised at locations 
such as festivals, airport security and police custody.   
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Figure 96: GC spectra for the mixture of 2’-positional halogenated diphenidine 
compounds with the inclusion of common adulterants: benzocaine (B); 
paracetamol (P); caffeine (C) and the internal standard eicosane (E)  
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iodophenidne regioisomers (20j–20l) acquired on a 60 MHz instrument 
Figure 111: Stacked 19F NMR spectra for the fluphenidine regioisomers run 
in DMSO with the inclusion of trifluoroacetic acid (TFA, δ ppm = −76.55)  
Figure 112: 1H NMR spectra run in DMSO (δ ppm = 2.50), measured on a 60 
MHz instrument for the two street samples (SS-H1 and SS-H2)  
Figure 113: Full 1H NMR spectrum for the 2-CP standard (20d), performed on 
a 60 MHz instrument in DMSO-d6 (δ ppm = 2.50)  
Figure 114: GC-MS chromatograph for SS-H1 with the inclusion of internal 
reference eicosane (E, Rt = 14.464 min)  
Figure 115: GC-MS chromatograph for SS-H2 with the inclusion of internal 
reference eicosane (E, Rt = 14.464 min)  
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23a) run in DMSO-d6 (δ ppm = 2.50)  
Figure 130: Stacked 400 MHz 1H NMR aromatic region for the 
fluorodiephenidine regioisomers (FDEP, 23a – 23c)  
Figure 131: 400 MHz 1H NMR spectrum for 2-fluorotrifluoroephenidine (2-
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Abbreviations and Acronyms 
 
ACMD Advisory Council on the Misuse of Drugs 
ADD Attention Deficit Disorder 
ADHD Attention Deficit Hyperactivity Disorder 
BP Brophenidine 
COSY Correlation Spectroscopy 
CP Chlophenidine 
DAT Dopamine transporter 
DEA Drug Enforcement Administration 
DFEP Difluoroephenidine 
ELISA Enzyme-linked immunosorbent assay 
EMCDDA 
European Monitoring Centre for Drugs and Drug 
Addiction 
EWA Early Warning Advisory 
FA Fluoroamphetamine 
FDEP Fluorodiephenidine 
FDMP Fluorodimephenidine 
FEP Fluoroephenidine 
FL Fluorolintane 
FMC Fluoromethcathinone 
FMP Fluoromephenidine 
FP Fluphenidine 
FTFEP Fluorotrifluoroephenidine 
GBL Gamma-butyrolactone 
GC-MS Gas Chromotography - Mass Spectroscopy 
GHB Gamma-hydroxybutyrate 
GMP Greater Manchester Police 
HPLC High Performance - Liquid Chromotography 
IP Iodophenidine 
LC Liquid Chromotography 
LC-MS-MS 
Liquid Chromotography - Tandom Mass 
Spectroscopy 
LOD Limits Of Detection 
LOQ Limit Of Quantification 
MCAT Methcathinone 
MDDP Methylenedioxydiphenidine 
MDMA Methylenedioxymethamphetamine 
MDPV Methylenedioxypyrovalerone 
mg Milligrams 
MHz Megahertz 
MIP Molecularly Imprinted Polymers 
mL Millilitres 
MMC Methylmethcathinone 
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MoDA Misuse of Drugs Act 
MS Mass Spectroscopy 
MXE Methoxetamine 
MXP Methoxphenidine 
NET Norepinephrine transporter 
NMDA N-methyl-D-asperate 
NMR Nuclear Magnetic Resonance 
NPD Naphthenidine 
NPS New Psychoactive Substances 
PCP Phencyclidine 
PFEP Pentafluoroephenidine 
qNMR Quantitative Nuclear Magnetic Resonance 
Rf Retention factor 
RRt Relative Retention time 
RSD Relative Standard Deviation 
Rt Retention time 
SERT Serotonin transporter 
SIM Single Ion Monitoring 
SPE Solid Phase Extraction 
SS Street Sample 
TeFEP Tetrafluoroephenidine 
TFA Trifluoroacetic acid 
TFMMC Trifluoromethylmethcathinones 
TFMXP Trifluoromethoxphenidine 
TLC Thin Layer Chromotography 
TMS Tetramethylsilane 
TOCSY Total Correlation Spectroscopy 
TriFEP Trifluoroephenidine 
UHPLC Ultra-High Pressure Liquid Chromotography 
UNODC United Nations On Drugs and Crime 
VMAT2 Vesicle monoamine transporter 2 
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1. Chapter 1 – Introduction 
1.1. UK Misuse of Drugs Act (1971) 
In the United Kingdom, the main control of drugs and illegal substances is the 
Misuse of Drugs Act (1971), which makes new laws with respect to dangerous 
or otherwise harmful drugs and related matters.5 Prior to the Misuse of Drugs 
Act (1971), substances had been controlled through separate acts and new 
substances were added upon discovery and realisation of the potential for 
harm. Opium was regulated through the Pharmacy Act of 1868, while cocaine 
(Figure 1, 1) and morphine (Figure 1, 2), isolated from opium plants, were 
restricted later through the Poisons and Pharmacy Act 1908.6 The Drugs 
(Prevention of Misuse) Act 1964 was produced to control amphetamine 
(Figure 1, 3a) and its derivatives, including substances such as 
methamphetamine (Figure 1, 3b), which had grown in popularity over previous 
years due to the stimulating and hallucinogenic properties that they exhibit 
upon consumption. 
 
 
Figure 1: Chemical structures of cocaine (1), morphine (2), amphetamine (3a) and 
methamphetamine (3b) 
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The United Kingdom government then produced the Medicines Act (1968) in 
order to control the production and supply of medicines aimed for human use.7 
This act controls whether a drug can be purchased generally over the counter, 
through a pharmacist or through proscribed prescriptions. Punishments for 
possession of harmful drugs obtained for reasons other than medicinal use 
cannot be enforced through the Medicines Act and this lead to the creation of 
the Misuse of Drugs Act (1971).  
 
The Misuse of Drugs Regulations (2001) were produced in order to allow the 
lawful production and possession of controlled substances for legitimate 
circumstances. This regulation covers the administration, possession, 
destruction and disposal of these substances.8 The Misuse of Drugs Act 
(1971) was amended in 2005 to review the classification system of controlled 
substances and amendments were made to schedule 1. Changes were also 
made to policing powers relating to drugs and sentencing punishments.9    
 
It is the duty of the Advisory Council on the Misuse of Drugs (ACMD), founded 
in 1971, to keep under review the situation in the UK regarding drugs that are, 
or appear to be, misused or where misuse appears capable of having harmful 
effects sufficient to constitute a social problem.  
 
Controlled drugs can be placed into three different classes (A, B or C) 
depending on how dangerously the advisory council views them to society. 
The Misuse of Drugs Act (1971) also defines the penalties associated with a 
series of offences including unlawfully supplying, producing or possessing 
controlled substances. Examples of controlled drugs and their classes can be 
seen in Table 1. 
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Table 1: Classifications of controlled substances and examples of drugs in each class 
 
The advisory council is constantly reviewing the list of controlled drugs with 
methamphetamine reclassified from a class B substance to a class A drug in 
January 2007. Ketamine was added as a class C drug in 2006 before being 
reclassified to a class B substance as recently as 2014.10 
 
Substances are also controlled by the controlled substances act, which is part 
of the Comprehensive Drug Abuse Prevention and Control Act (1970). The 
Drug Enforcement Administration (DEA) divided substances into schedules 
based on potential for abuse and addictiveness, as well as whether or not the 
substance has any legitimate medicinal uses.5 Substances deemed to have 
the highest potential for abuse or potential for severe psychological and 
physical dependence are listed under schedule 1. Drugs on schedule 1 have 
no current accepted medicinal use. Schedule 5 substances are deemed to 
have the least potential for abuse.  
 
There are some crossovers between class A substances and schedule 1 
substances with compounds such as heroin and MDMA appearing on both 
lists. There are also differences with substances such as cocaine and 
methadone appearing as class A drug but being placed into schedule 2.  
 
Currently, punishments are scaled based on a substances classification; 
however, processes by which harm is determined can be unclear. New 
Class Examples of controlled substances within class 
A cocaine, methadone, methamphetamine, MDMA and heroin 
B mephedrone, methylone, MDPV, ketamine and cannabis 
C anabolic steroids, GBL, GHB and khat 
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systems are being suggested for assessing the potential harm of controlled 
substances based on physical harm, social harm and dependence.11  
 
Identification of samples is important for prosecution in order to make sure the 
correct punishment is enforced. The maximum sentences for supplying and 
possessing controlled substances can be seen in Table 2. In 2001 the 
regulations were revised to take into account the circumstances where it is 
lawful to possess, or produce and supply substances that have medicinal or 
therapeutic values. These substances were divided into five schedules (Table 
3) with freedom to possess and supply being restricted by the assignment of 
a controlled drug to a schedule. 
 
Table 2: Table showing maximum punishments for possession and supply of controlled 
substances 12 
Drug Class Possession Supply and intent to supply 
A 
7 years imprisonment and 
unlimited fine 
Life imprisonment and unlimited 
fine 
B 
5 years imprisonment and 
unlimited fine 
14 years imprisonment and 
unlimited fine 
C 
2 years imprisonment and 
unlimited fine 
14 years imprisonment and 
unlimited fine 
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Table 3: Drug schedules and an explanation of what constitutes each schedule 13 
Drug Schedule Schedule explanation 
1 
Includes drugs not used medicinally including hallucinogenic drugs 
(such as LSD), ecstasy type substances, raw opium and cannabis. A 
home office license is required for their production, possession and 
supply.   
2 
Includes opiates (such as heroin, morphine and methadone 
hydrochloride), major stimulants, cocaine, ketamine and cannabis-
based products for medicinal uses. Schedule 2 controlled drugs are 
subject to the full controlled drug requirements 
3 
Includes the barbiturates which are subject to the special prescription 
requirements. Safe custody requirements do apply although records 
in registers do not need to be kept. 
4 
Schedule 4 is split into two parts. Part 1 includes drugs that are 
subject to minimal control, such as benzodiazepines and non-
benzodiazepine hypnotics. Part II includes androgenic and anabolic 
steroids. Controlled drug prescription requirements do not apply and 
schedule 4 controlled drugs are not subject to safe custody 
requirements.  
5 
Includes preparations of certain controlled drugs, such as codeine, 
pholcodine or morphine, which due to their low strength, are exempt 
from virtually all controlled drug requirements other than retention of 
invoices for two years. 
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1.2. Psychoactive Substances Act (2016)  
New Psychoactive Substances (NPS), which have recently been controlled by 
the Psychoactive Substances Act (2016),1 have continued to feature 
prominently on the recreational drug scene. Synthetic recreational drugs have 
reportedly been produced since the 1920s with prevalence coming more 
recently through “head shops” and the rise of online markets.14 In 2006, the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) began 
to monitor the number of new compounds reported annually, with the amount 
of substances reported rising sharply from 5 – 45 within 4 years.15 It is reported 
that by 2006 clandestine labs and manufacturers of NPS had begun searching 
through failed pharmaceuticals or “designer medicines” which could be altered 
in order to produce new substances undetected by analytical techniques.16 
The control of popular psychoactive substances such as amphetamine (Figure 
1, 3a) and 3,4-methylenedioxymethamphetamine (MDMA, Figure 2, 3c) led to 
a need for legal alternatives to be produced. 
 
 
Figure 2: Chemical structure of 3,4-methylenedioxymethamphetamine (MDMA), 3c 
Prior to the introduction of the Psychoactive Substances Act (2016), NPS had 
grown in popularity due to their capability of avoiding control, as they are not 
scheduled under the Misuse of Drugs Act (1971), and their ability to mimic 
psychotropic effects of illicit substances. Although “designer drugs” had been 
observed in the late 1970s and early 1980s, production and marketing of these 
substances had dramatically increased in the 21st century and is still prevalent 
in the present day.17  
 
Post mortem and criminal casework studies have been carried out involving 
NPS with 203 cases reported between 2010 and 2012 with 120 NPS observed 
in 2012 alone. From these reports effects and toxicities of the NPS could be 
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seen and reported for future encounters with the substances.18 In 2014, 101 
substances were reported to EU Early Warning System.19 Constant analysis 
of NPS has been on going prior to the introduction of the New Psychoactive 
Substances Act (2016), showing limitations of current techniques, such as 
liquid chromatography, and toxicology information with the introduction of new 
compounds.20 NPS have also been encountered alongside controlled 
substances under the Misuse of Drugs Act (1971).21 
 
Popularity of NPS has also increased due to the ease of accessibility. NPS 
were originally sold in ‘head shops’ and these substances had been 
encountered, in colourful packaging, labelled as ‘plant food’, ‘bath salts’ or ‘not 
fit for human consumption’.22 More than 600 substances had been reported to 
the United Nations on Drugs and Crime Early Warning Advisory (UNODC 
EWA) council by the end of 2016 with the number increasing to just under 800, 
from 110 territories, by the end of 2017 (Figure 3).23 
  
 
Figure 3: Image showing the countries that reported the presence of NPS in 2017, to the 
UNODC and the number of NPS reported.23  
This shows the lack of impact the Psychoactive Substances Act (2016) had on 
the production and distribution of NPS with more substances still being 
reported after the act was established. One reason for the continued increase 
in the number of NPS in circulation is through the emergence of the Dark Web 
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(hidden websites that require encryption or specific software to uncover).24 
There is a danger to the online marketing of these samples as there is a lack 
of knowledge and intelligence surrounding the compounds and information 
based on dosage and side effects may be limited. This can lead to NPS 
becoming more dangerous than substances controlled by the misuse of drugs 
act and more work is needed for harm reduction and detection.25  
 
Synthesis of many NPS occurs through legitimate medical research or as a 
result of clandestine adaptation and derivatisation of drugs previously 
controlled. Although synthesis of these substances can, at times, be 
complicated, it can be carried out in clandestine labs with basic chemistry 
knowledge. Literature has been published showing the synthesis of multiple 
NPS reference standards used for testing.26 It is the slight alteration of 
chemical structures that allows substances to avoid initial detection and allows 
production of samples, which can then be supplied and offered without 
repercussions. 
 
The introduction of the Psychoactive Substances Act (2016) also causes 
analytical challenges for prosecution, due to the differences in sentencing 
compared to the Misuse of Drugs Act (1971), making it essential to be able to 
identify and distinguish substances. NPS can cause significant and life 
threatening side effects, especially when a dosage is taken to match the 
effects of controlled substances, and this means health-care providers must 
be familiar with these novel psychoactive substances. There is also a clear 
importance to developing rapid and mobile techniques, that can be used by all 
involved with medical toxicology and providing primary care, to recognize and 
report these materials as soon as they are encountered.27, 28  
 
Many of the NPS that are encountered or seized in criminal cases can be 
classified as synthetic cathinones (e.g. mephedrone and MDPV),29 
piperazines (e.g. N-benzylpiperazine) and pyrrolidines (e.g. prolintane),30 
benzodiazepines,31, 32 piperidines (e.g. diphenidine),33, 34 aminoindanes (e.g. 
MDAI) or phenethylamines (e.g. NBOMe derivatives) (Figure 4).35, 36 
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Synthetic cannabinoid receptor agonists are a class of psychoactive 
substances that have also been encountered more frequently in the past few 
years and have shown prevalence in prisons.37 These principle classes of 
substances are discussed in the subsequent sections. 
 
 
Figure 4: Image showing the classification of NPS reported to the EU early warning 
system.23   
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1.3. Amphetamines 
Amphetamine (Figure 1, 3a) is a substance that belongs to the 
phenethylamine (Figure 5, 3d) class of psychoactive drugs. Amphetamines 
are controlled substances and are scheduled as a class B drug under the 
Misuse of Drugs Act (1971).5 Many controlled substances, including the class 
methamphetamine (Figure 1, 3b) and 3,4-methylenedioxymethamphetamine 
(MDMA) (Figure 2, 3c), are derived from the amphetamine structure and are 
described as “substituted amphetamines”. Along with cocaine, amphetamines 
are one of the most commonly used illicit substances and this prevalence 
along with abuse of methamphetamine has led to a dramatic increase in the 
number of emergency department visits for amphetamine intoxication.38, 39 
 
 
Figure 5: Chemical structure of phenethylamine (3d) 
Amphetamines are abused due to the stimulating and physiological effects 
they generate. MDMA, also known for its entactogenic effects inducing a 
pleasant and relaxed feeling of happiness that results in consumers becoming 
addicted to the substance.40 Methamphetamine also provides stimulating 
effects as well as sympathomimetic effects through interaction with the 
sympathetic nervous system receptors.41 Reports have shown that the 
biological effects observed when comparing amphetamine and 
methamphetamine do not differ significantly in the stratum, however dopamine 
release is increased in the prefrontal cortex to a greater extent through 
amphetamine use as opposed to methamphetamine.42 Amphetamines also 
increase the levels of norepinephrine in a corresponding manner to the release 
of dopamine.43 Reports by Shoblock et al. suggest there is no difference in the 
addictive nature or psychostimulant potency between amphetamine and 
methamphetamine.44   
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Amphetamines were initially used as a treatment for narcolepsy, however 
research has shown therapeutic uses for the treatment of disorders such as 
Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder 
(ADHD) as well as uses in cases of obesity and depression.45  
 
The enzyme-linked immunosorbent assay (ELISA) based test has become a 
screening test developed for analysis of amphetamines in a forensics 
laboratory environment. It is a biochemical technique that will allow detection 
of an analyte through the use of antibodies. An enzyme will link to this antibody 
and a detectable signal is emitted usually in the form of a colour change. 
Testing has been carried out using ELISA tests on a number of matrixes 
including blood plasma, oral fluids, sweat and hair samples for the detection 
of amphetamines.46, 47 ELISA testing relies on the production of antibodies, for 
the enzyme binding to occur, which means the drug must have previously 
been encountered. This becomes a problem when novel designer drugs are 
first observed as a slight alteration in structure will mean specific immunoassay 
kits will no longer recognise target compounds. This has been reported with 
designer drugs of amphetamine and methamphetamine, where amphetamine 
specific ELISA tests have been unable to produce a positive result for any of 
the amphetamine designer drugs at concentrations representative of forensic 
samples. 48      
 
As well as ELISA testing, liquid chromatography (LC) and ultra-high pressure 
liquid chromatography (UHPLC) have been utilised for the detection of 
amphetamine both qualitatively and quantitatively.49, 50 Tandem mass 
spectroscopy has also been attached to the chromatography analysis in order 
to provide further identification information. 
 
In recent years the mono-fluorinated substituted derivatives, 
fluoroamphetamine (Figure 6, FA, 4) have been discovered in forensic cases 
and on the recreational drug’s market, mainly around Europe, incorrectly 
marketed as amphetamine and MDMA.51, 52 4’-fluoroamphetamine (4-FA) has 
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been reportedly detected in both urine and serum using validated GC-MS 
methods.53, 54  
 
 
Figure 6: Chemical structure of regioisomeric fluoroamphetamine (4) 
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1.4. Cathinones 
As listed in the Misuse of Drugs Act (1971), cathinone derivatives are currently 
controlled as class B substances. Cathinone (Figure 7, 5) is an alkaloid 
present in the khat bush leaves and was discovered twenty-five years ago. 
Inhabitants of East Africa and Southern Arabia chewed khat due to the 
stimulating properties that consumers experienced. After testing and analysis, 
it was soon discovered that the pharmaceutical profile of cathinone closely 
resembled that of amphetamine.55 
 
Figure 7: Chemical structure of cathinone (5) 
Cathinones are phenylisopropylamine compounds, with a carbonyl at the 
benzylic position of the molecule.4 Prior to the Psychoactive Substances Act 
(2016), cathinone (5) and synthetic cathinone derivatives had been 
encountered as pure substances but also as the active ingredients (or in 
combination with other psychoactive substances) in street samples such as 
“bath salts”. 56, 57  
 
Cathinone is a hydrophobic (lipophilic) molecule meaning it can cross cell 
membranes easily and block the uptake of neurotransmitters or increase their 
secretion.(Hugins, 2014) Similar to amphetamines, cathinones act on 
dopamine, serotonin and epinephrine transporters, increasing their levels and 
identified biological targets for cathinones include acetylcholine, serotonin, 
dopamine, norepinephrine, histamine and sigma-1 receptors, voltage-gated 
sodium and calcium ion channels, plasma membrane transporters for 
serotonin, norepinephrine and dopamine (SERT, NET and DAT respectively) 
and the vesicle monoamine transporter 2 (VMAT2).4  
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The khat plant was used to help with depression due to the stimulating effects 
that it provides. Khat was also used to help with obesity as the substance has 
a tendency to suppress the appetite. Effects that were also reported including 
a feeling of calm during the periods were khat was chewed, feelings of elation 
and an increase in alertness. However, migraines, insomnia, feelings of 
anxiety and aggression, paranoia, high blood pressures and heart problems 
have all been reported as side effects that occur after constant usage of khat 
plants.58 
 
Cathinone and its derivatives are not detectable using the ELISA-based 
amphetamine test, showing the desperate need for an alternative rapid 
screening test.59 Detection of cathinone has been reported for urine and 
plasma from khat users using techniques such as GC-MS and high 
performance - liquid chromatography (HPLC).60, 61 
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1.4.1. Methcathinone 
Methcathinone (Figure 8, 6), also known as ephedrone or MCAT, is a 
substituted cathinone and an illicit drug scheduled as a class B drug under the 
Misuse of Drugs Act (1971). Methcathinone is a monoamine alkaloid and the 
stimulating properties that methcathinone provide means that it is abused as 
a recreational drug. 
 
Figure 8: Chemical structure of methcathinone (6) 
Reports have suggested that users complain of the need for increased 
dosages, when using synthetic cathinones, such as methcathinone, and a 
frequent need to reuse in order to prolong effects. Studies also show that there 
is a threefold increase in activity in certain areas of the brain, compared to β-
keto-amphetamines, when being used for its stimulating effects. This shows 
the potential danger of overdosing that surrounds the use of cathinones and 
the threat to health that these substances pose. It has been reported that 
methcathinone has an addictive nature with symptoms of withdrawal being 
experienced after prolonged usage or administration of high dosages.62, 63 
 
Detection of methcathinone has been reported utilizing a variety of 
chromatographic methods such as GC-MS and LC/MS-MS. This has included 
methcathinone samples that have been discovered alongside 
phenalkylamines as well as cathinone in both urine specimens and human 
blood plasma. This has shown that methcathinone can be detected using 
these techniques, however, it has also been reported that when using GC-MS 
to detect methcathinone a second peak is observed and characterized as 2,3-
enamine, produced through thermal oxidation during heating in the column. 
This is similar to the thermal degradation seen with the fluoroamphetamines. 
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This shows that difficulties do arise when testing cathinones through this 
instrumentation and alternative methods may be needed to detect these 
samples especially when purity testing or testing of mixtures is required.64-66 
 
1.4.2. 4’-Methylmethcathinone 
4-Methylmethcathinone (4-MMC) is a stimulant drug similar in structure to 
ephedrone and is another synthetic derivative of cathinone. 4-
Methylmethcathinone (Figure 9, 7c, 4-MMC) is also known as mephedrone, 
however the regioisomers of 4-methylmethcathinone, 2-methylmethcathinone 
and 3-methylmethcathinone (Figure 9, 7a and 7b respectively) have also been 
observed and reported in the literature. 67 
 
 
Figure 9: Chemical structures of the methylmethcathinone regioisomers (7a – 7c) 
Investigations show that users complain of the need for high doses (200 mg 
of 4-methylmethcathinone taken orally) and a frequent need to reuse as the 
effects only last around 2-4 hours. Some users also reported to taking as much 
as two grams in a 4 hour period to prolong the psychoactive effects of the 
drug.68 This is an important fact as if a greater amount of 4-MMC is needed in 
order to match the effects of other recreational drugs then there is an 
increased risk that overdoses will occur, leading to emergency cases where 
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people’s health is at severe risk. 4-methylmethcathinone targets similar 
receptors to those reported for cathinone and ephedrone.69  
 
Analysis for the detection of mephedrone has been reported via GC-MS 
methods along with quantitative analysis using LC-MS. This has been applied 
to hair samples where a positive test has shown the presence of mephedrone. 
There are also reports of quantitative and qualitative analysis of mephedrone 
being performed on blood samples taken from fatalities linked to the drug. 
NMR analysis is also available for the structural elucidation of the mephedrone 
isomers and can be used as reference spectra.70-73  
 
 
1.4.3. 4’-Fluoromethcathinone (flephedrone) 
4’-Fluoromethcathinone (4-FMC), also known as flephedrone, is a new 
psychoactive substance that was discovered in samples that were previously 
sold as “plant feeders” from head shops and internet retailers. The samples 
were observed as capsules as well as white powders and the majority of 
samples seized were either 4’-fluoromethcathinone (Figure 10, 8c, 4-FMC) or 
3-fluoromethcathinone (Figure 10, 8b, 3-FMC). The position of the fluorine on 
the benzyl ring was determined using reference samples synthesized and 
purchased from suppliers.68  
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Figure 10: Chemical structures of fluoromethcathinone regioisomers (FMC, 8a–8c) 
Fluoromethcathinone regioisomers are reported to induce the release of 
dopamine in a similar manner to both methcathinone and 
methylmethcathinone.68, 74  
 
Detection and analysis of flephedrone and the regioisomers including 2-
fluoromethcathinone (Figure 10, 8a, 2-FMC) has been reported previously 
although it has not been as extensively covered when compared to 
methcathinone and its methyl derivatives. Detection of the 4-FMC isomer has 
been applied using both GC-MS and high resolution LC-MS. This analysis has 
been performed on urine and liver microsomes as well as on street samples 
where FMC may be cut with adulterants such as benzocaine or caffeine. 4-
FMC has also been detected in hospital cases where it has been taken along 
with other psychoactive substances.68, 75, 76 
 
Again as with other amphetamines and cathinones the fluorine derivatives 
show thermal degradation in the injection heating with GC-MS analysis. 
Reports have shown difficulties in attempts to separate the 3- and 4-FMC 
isomers when run using matching methods showing a need for new methods 
to be developed or new techniques to be introduced.77 Baseline separation 
has been achieved for all three regioisomers, using GC-MS, however this was 
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done through heptafluorobutyrylation derivatisation which can be time 
consuming as sample preparation.78 It has also been shown through 
characterisation of the 3- and 4- isomers that the 19F NMR provides differing 
chemical shifts and can be used to distinguish between isomers, however this 
has not been done on mixtures or for all three isomers.68 
 
Fluorine is commonly used in pharmaceuticals to increase polarity in 
compounds, which also effects receptor binding and biological activity. 2 
Fluorine is one of the most electronegative elements and has a higher bond 
energy with carbon when compared to the hydrogen-carbon bond. This means 
the carbon-fluorine bond is stronger and more stable, meaning it is less 
sensitive to metabolic degradation and metabolic rates are slowed. Adding 
fluorine to compounds can also increase their lipophilicity, which is the ability 
to dissolve in fats. This is due to the fluorine-carbon bond being more 
hydrophobic than the carbon-hydrogen bond. This usually results in increased 
cell membrane penetration and increased drug bioavailability. 79, 80 The most 
common general anaesthetic agents now contain fluorine as they have been 
shown to be safer longer lasting. 81  
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1.4.4. Ortho-, meta- and para- trifluoromethylmethcathinone 
Trifluoromethylmethcathinones (TFMMC) are trifluoromethyl (CF3) analogues 
of methcathinone where the substituent may reside at the 2-, 3- and 4- position 
of the aromatic ring (Figure 11, 9a, 9b and 9c respectively). 
 
 
Figure 11: Chemical structures of the trifluoromethylmethcathinone regioisomers (TFMMC, 
9a – 9c) 
The report by Cozzi et al. also shows that 3-trifluoromethylmethcathinone and 
4-trifluoromethylmethcathinone were both 10-fold more potent than 
methcathinone as uptake inhibitors and releasing agents at the serotonin 
transporter, but 2-trifluoromethylmethcathinone was both a weak uptake 
inhibitor and releaser. This is an important fact due to the different isomers 
having different effects biologically. It is important medically, as well as 
forensically, to be able to separate them in order to determine what substances 
have been sold or taken for health concerns. At the norepinephrine and 
dopamine transporters (NET and DAT) all trifluoromethylmethcathinone 
isomers were less potent than methcathinone as uptake inhibitors and 
releasers. The research highlights that in medical and psychiatric conditions 
trifluoromethylmethcathinones may have therapeutic values and uses. The 
decrease in DAT activity also shows that there is a lower likelihood of abuse 
and dependence of the drug compared to methcathinone.4  
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Literature has shown separation of the three TFMMC regioisomers using GC-
MS analysis, however degradation has been shown in a similar manner to the 
FMC isomers, which would make quantification analysis difficult. No validation 
or quantification analysis has been performed using GC-MS. Again in a similar 
manner to the FMC isomers 19F-NMR analysis has shown distinguishable 
chemical shifts, although no mixtures or calibrations for quantification have 
been performed.82 4-TFMMC has also been analysed using a developed LC-
MS method, along with its metabolites.83  
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1.5. PCP to MXE 
Multiple substances, now controlled by the Misuse of Drugs Act (1971), existed 
prior to the production of diphenidine (13a, figure 15) and these were 
introduced in order to replace the previous substance that had been controlled. 
Phencyclidine (Figure 12, 10, PCP) was first discovered and synthesized in 
1956 and was marketed as an anaesthetic pharmaceutical drug, however it 
soon became popular on the illicit drugs market and through street vendors.84 
PCP, also referred to as angel dust, is a member of the arylcyclohexylamine 
class and became popular due to its hallucinogenic and dissociative 
properties. Other side effects with PCP usage include euphoria and a loss of 
ego boundaries, however, negative side effects also include paranoia, 
withdrawal symptoms and suicidal thoughts. It has been reported that the 
effects observed through PCP abuse are due to the substance selectively 
interacting with a specific (PCP receptor) binding site that is linked closely to 
the N-methyl-D-asperate (NMDA) receptor.85 
 
Figure 12: Chemical structure of phencyclidine (PCP, 10) 
Ketamine (Figure 13, 11) is a NMDA antagonist and was first developed as a 
surgical anaesthetic to replace PCP due to quicker recovery times and less 
severe side effects experienced. Similar to PCP, ketamine also displays 
dissociative properties and can also be used to treat chronic pain utilizing its 
potential to provide pain relief, sedation and memory loss. Ketamine interacts 
with NMDA receptors in a similar manner to PCP and inhibits its actions, which 
gives it its sedative qualities.86-88 
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Figure 13: Chemical structure of ketamine (11) 
Within a few years of medical use, an increase of illicit use was observed for 
ketamine. It quickly became labelled as a class C drug in 2006 and in 2013 it 
was reclassified to a class B drug, based on the advisory council’s advice on 
the potential harm that the substance can cause. Many users noted severe 
hallucinatory effects known as a “K-hole” and long-term users were reported 
to suffer irreversible damage to the body such as renal failure. Other side 
effects included abnormal heart rates leading to either extreme high or low 
blood pressure, anorexia and vomiting.89-91 
 
Methoxetamine (Figure 14, 12, MXE) is an analogue of ketamine and grew in 
popularity as a legal alternative, which still provided the same dissociative 
effects to consumers due to the similarities in chemical structure. MXE is 
believed to be abused-due to the prolonged and enhanced effects exhibited 
prior to consumption. Like ketamine and PCP, MXE is an NMDA antagonist, 
which will provide sedation and anaesthetic effects as well as analgesia and 
amnesia. MXE is also a dopamine reuptake inhibitor.92, 93 Methoxetamine 
became commercially available in 2010 with negative side effects such as 
severe nausea, vomiting, diarrhoea, paranoia, and anxiety linked to 
consumption of MXE.94, 95  
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Figure 14: Chemical structure of methoxetamine (MXE, 12) 
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1.6. Diphenidine and methoxphenidine 
Diphenidines, one of the most recent classes to emerge prior to the NPS act, 
has been sold on the illicit drugs market and via online vendors. Diphenidine 
(Figure 15, 13a) acts as an NMDA antagonist and its 2-methoxy substituted 
derivative methoxphenidine (Figure 15, 13b, 2-MXP) was marketed in 2013 as 
a replacement for the recently controlled compound methoxetamine (MXE).96 
 
 
Figure 15: Chemical structures of diphenidine (13a) and the methoxphenidine regioisomers 
(MXP, 13b – 13d) 
Diphenidine and MXP were both sold as designer drugs for their dissociative 
properties and the effects of anaesthesia and euphoria that they provide, in a 
similar manner to PCP, ketamine and MXE. Both diphenidine and MXP are 
controlled by the New Psychoactive Substances Act (2016), however, new 
diphenidine derivatives are constantly being produced, including the 
regioisomers of 2-MXP, 3-methoxphenidine (Figure 15, 13c, 3-MXP) and 4-
methoxphenidine (Figure 15, 13d, 4-MXP). These samples create new 
challenges to prosecute correctly, and also analytically, as a lack of reference 
material and data on these substances is available. 
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Diphenidine and MXP have been involved with a number of intoxications and 
fatalities both as individual components and also when used in combination 
with one another.97, 98 Diphenidine and MXP have also been encountered in 
mixtures along with other psychoactive drugs such as synthetic cannabinoids 
like AB-CHMINACA, 5F-AMB and 5F-AB-PINACA.99 Characterization of 
diphenidine has been performed on a full range of analytical techniques such 
as 1H NMR, 13C NMR, HR-ESI-MS, ESI-MS-MS, GC-(EI/CI)-MS and ATR-
IR.96 Detection of diphenidine has been carried out on a number of samples 
including blood, tissue, gastric fluid and hair.100, 101 
 
McLaughlin et al. reported the full characterization of the MXP regioisomers 
using the same analytical techniques in 2016.102 The increasing prevalence 
and detection of both diphenidine and methoxphenidine shows the need for 
rapid tests to be developed due to the lack of reference standards and data 
available especially for newly emerging substances. A validated UHPLC 
method for the separation of the three MXP isomers has also been reported.103 
The regioisomers of MXP have also been detected and quantified using 
molecularly imprinted polymers (MIPs).104 
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1.7. Lefetamine and ephenidine 
Lefetamine (Error! Reference source not found.Figure 16, 14) a class B 
substance, related to the 1,2-diphenylethylamine class of compounds, that 
was first synthesised and reported in 1945 and has been reported to have 
effects similar to substances such as codeine and other opiates.105 Although 
initial abuse of lefetamine was observed in Japan during the 1950s, it was then 
introduced in Italy in the 1980s for its use in pain relief in surgery before quickly 
becoming a substance of abuse.106 It was shown to be a weaker opiate agonist 
than most opiates such as morphine and abuse of the substance tended to 
lead to many users experiencing severe withdrawal symptoms.107, 108 In 2008, 
lefetamine and a couple of designer drugs based on lefetamine have been 
encountered in Germany and possibly shows the re-emergence of this class 
of compounds as a drug of abuse again.109   
 
Figure 16: Chemical structure of lefetamine (14) 
Lefetamine and its metabolites have been identified in rat urine as well as 
human liver, showing the potential for detection in human urine. Both GC-MS 
and liquid chromatography-high resolution-tandem mass spectrometry (LC-
HR-MS/MS) were utilised in order to detect lefetamine in these matrixes.110  
 
Ephenidine (Figure 17, 15) is a recent substance to emerge on the NPS drugs 
market with its presence being reported in 2017, but there is little literature 
published on its toxicological effects and methods of identification. Ephenidine 
was also first marketed as a replacement for PCP, MXE and ketamine for its 
use as a dissociative anaesthetic. It is a structural isomer of lefetamine with 
the dimethyl side chain replaced with an ethyl chain. In a similar way to 
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diphenidine, ephenidine acts as an NMDA receptor antagonist and has been 
reported in a few intoxications in France.34, 111, 112  
 
Figure 17: Chemical structure of ephenidine (15) 
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1.8. Prolintane and fluorolintane 
Prolintane (Figure 18, 16) was first synthesised and reported around the same 
time as lefetamine, however it has been used as a substance of abuse since 
it was first marketed in Europe as an anti-fatigue agent.113  
 
Figure 18: Chemical structure of prolintane (16) 
Similar in structure to the synthetic cathinones pyrovalerone (Figure 19, 17) 
and methylenedioxypyrovalerone (Figure 19, 18), it was abused for its 
stimulating properties similar to that of amphetamine. Hallucinations, 
psychosis, and deaths have been reported after overdosing on prolintane. 
Metabolic studies have been carried out in both rats and rabbits and GC-MS 
has been utilised as a method of analysis.114-116  
 
Figure 19: Chemical structures of pyrovalerone (17) and methylenedioxypyrovalerone (18) 
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Fluorolintane (Figure 20, 19) has also been synthesised in a manner similar to 
diphenidine, ephenidine and lefetamine and is also an NMDA receptor 
antagonist with dissociative properties.117 The main structural difference from 
diphenidine to fluorolintane derives from the alteration of the piperidine ring to 
a pyrrolidine ring. There is no current literature related to the toxicology of 
fluorolintane or its detection, however no reports of overdosing related to this 
substance have been published. 
 
Figure 20: Chemical structure of fluorolintane regioisomers (19) 
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1.9. Presumptive Testing  
In forensic testing, presumptive tests are vital as a rapid response to the 
presence of possible controlled substances and can act as an important harm 
reduction tool. The main form of presumptive testing used by police forces and 
forensic laboratories comes in the form of colour test reagents (Figure 21). The 
United Nations on Drugs and Crime (UNODC) has guidelines based on the 
production of test reagents and the positive reactions of commonly 
encountered controlled substances and NPS.118 Colour tests are preferred 
due to their inexpensive nature and ability to provide a fast and simple result, 
without any analytical instrumentation. However, presumptive colour tests can 
only identify the possible presence of a specific class being present and not 
which specific substance is present. A problem also arises with the 
introduction of multiple new substances as this increases the number of false 
positives that can be associated with a specific testing reagent.3  
 
 
Figure 21: Common presumptive colour testing kit used by law enforcement officers 
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Multiple reports have been published based on the presumptive testing of 
specific classes of controlled substances especially classes such as 
amphetamines, piperazines and opiates as well as substances such as 
cocaine and ketamine.119-122 The advisory council on the misuse of drugs has 
previously reported on the prevalence of cathinones on online markets and the 
need to increase knowledge of cathinones in relation to their reaction to 
screening tests.70, 123 There is also a lack of literature on the presumptive 
testing of diphenidine and its analogues.  
In order to determine the specific substance that is present in a sample 
confirmatory testing would be needed. These techniques are usually more 
expensive and require more expertise to perform.  
 
No reported colour testing has been reported on the fluoroamphetamine 
regioisomers meaning further experimental work is needed to expand on this. 
Cathinones such as the trifluoromethylmethcathinones (TFMMC) have been 
analysed using the Zimmerman reagent and produce a purple colour when 
tested.70 No presumptive reagent testing has been performed on any of the 
diphenidine derivatives meaning this testing needs to be performed and 
reported.  
 
Colour tests for specific classes are reported and shows the ability of forensic 
presumptive tests to quickly identify classes based on colour changes. These 
reports also show the difficulties of these reagents to identify differing 
regioisomers, due to the lack of distinctive differences in colour and very 
similar λmax values following UV spectral analysis. Commonly used reagents 
and the changes observed by commonly encountered controlled substances 
can be seen in Table 4.124, 125 
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Table 4: Commonly used presumptive colour test reagents along with compound classes 
tested and common colour changes. 
Test reagent Common drugs tested Reported colour changes 
Marquis reagent 
Opiates Violet or reddish/Purple 
Amphetamine Red/Brown 
MDMA Purple/Black 
Methoxetamine Pink 
Nitric acid reagent 
Heroin Yellow 
Morphine Red 
Scotts reagent 
Cocaine Blue 
Diphenidines Blue 
Mandelin Reagent 
Acetaminophen Green 
Cocaine Deep yellow 
Methamphetamine Dark Green 
Liebermann Reagent 
Cocaine Yellow 
Methcathinone  Bright Yellow 
4-fluoroamphetamine Orange 
Zimmerman Reagent 
Methcathinone Purple 
Diazepam Red/Purple 
Froehde Reagent  
Cathinone  No reaction 
Amphetamine  Red 
MDMA Black 
4-fluoromethcathinone No reaction 
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1.10. Gas Chromatography–Mass Spectroscopy 
In order to definitively detect whether a specific substance is present, rather 
than just a possible class, further testing to presumptive tests are commonly 
required. These techniques are usually more expensive and require more in 
depth expertise to perform, however they can provide results for use 
evidentially, with more repeatability and less room for false positives and 
methodical errors. In a similar way to presumptive testing, the constantly 
changing face of NPS requires the development of new confirmatory testing 
methods that are both quick and accurate. 
 
Gas chromatography–mass spectrometry (GC-MS, Figure 22) is the most 
common technique used as a confirmative test for the detection of controlled 
drug substances and NPS. This is due to the ability of gas chromatography to 
separate volatile substances with good resolution and of mass spectrometry 
to provide detailed structural information through fragmentation patterns.  
 
Figure 22: Image of a GC-MS instrument 
Sample preparation is usually straightforward with samples analysed as 
organic solutions after any extraction or derivatisation necessary. The sample 
solution is then injected and vaporised before being carried though a 
chromatographic column by a carrier gas, allowing for separation of samples 
to occur through interaction with the stationary phase. An electron beam is 
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produced which allows for electron ionisation of the sample and this produces 
a molecular ion. Due to the large amount of energy involved, the molecular ion 
will usually fragment further into smaller ions, detected by the mass 
spectrometer, which will provide a pattern that is characteristic of the 
substance in question. Multiple controlled substances and NPS have been 
detected using GC-MS, including opiates, cathinones, amphetamines and 
piperazines with multiple methods being developed for their detection in 
multiple matrixes including bodily fluids.70, 126-128   
 
The fluoroamphetamines have previously been analysed using GC-MS 
analysis with all three of the regioisomers analysed but not reportedly 
separated, with retention times overlapping especially between the 3’ (figure 
23, a) and 4’ (figure 23, b) positional isomers. It is also reported that thermal 
degradation occurs during analysis of the fluoroamphetamine regioisomers, 
with tailing occurring in the chromatographs of all samples. Acetylation of the 
compounds was shown to help increase the separation between regioisomers. 
129 GC-MS also has a difficulty in separating these regioisomers as reports 
have shown that all three regioisomers produce the same mass spectra (figure 
24). 
 
Figure 23: GC-MS chromatographs for the 3- (a) and 4- (b) fluoroamphetamine 
regioisomers 
a b 
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Figure 24: Mass spectrum for the fluoroamphetamine regioisomers.  
GC-MS analysis of the three fluoromethcathinone regioisomers again 
highlights the problem this technique has with separating regioisomers as the 
2’ and 3’ regioisomers cannot be separated and thermal degradation is again 
shown through the tailing of peaks in the chromatographs, especially in the 2’ 
isomer (figure 25). 68 
 
 
Figure 25: GC-MS chromatographs for the 2’ and 3’-fluoromethcathinone regioisomers68  
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The GC-MS analysis of the three trifluoromethylmethcathinone regioisomers 
has been reported and shows that the three isomers can be distinguished even 
though they are not baseline separated (figure 26). In a similar manner to the 
fluoromethcathinone regioisomers the trifluoromethylmethcathinone 
regioisomers show thermal degradation with the tailing of peaks. 82  
 
 
Figure 26: GC-MS chromatograph of the 2’ (1), 3’ (2) and 4’-trifluoromethylmethcathinone 
(3) regioisomers 82 
Reports regarding GC-MS analysis of controlled substances, especially those 
which are fluorinated, show difficulty in identification and separation of 
regioisomers. Reports of tailing due to thermal degradation makes baseline 
separation difficult and regioisomers produce matching mass spectra when 
using this technique. Due to these reasons the use of NMR as a technique for 
identification becomes more important.  
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1.11.  Nuclear Magnetic Resonance (NMR) spectroscopy     
Nuclear magnetic resonance (NMR) spectroscopy is a technique used to 
provide complete structural analysis of chemical structures and allows both 
quantitative and qualitative analysis of complex mixtures.130 NMR 
spectroscopy takes advantage of the magnetic properties and spin properties 
that all the nuclei possess. In the synthesis of organic molecules and 
psychoactive substances isotopes with spin ½ become the main focus. These 
isotopes include 1H, 13C and 19F which can all be used to fully characterize 
reference and seized samples. For spin ½ nuclei two spin states will exist 
when an external magnetic field (B0) is present; one spin in line with the 
magnetic field (+ ½) and one spin opposed to the field (-½). Both will be parallel 
to the magnetic field, (z-plane), however the two spins will possess a 
difference in energy that will increase as the strength of the magnetic field 
increases. If a radio frequency (RF) pulse is applied, with enough energy, the 
nuclei will be forced out of alignment, such that they have a component in the 
transverse plane. The nuclei can now be thought as being in a high energy 
state - they will relax back once the RF pulse is turned off. Energy is released 
as the nuclei relax and this is observed and measured as a Free Induction 
Decay (FID).131, 132  
 
1H NMR can yield a number of key information points regarding hydrogen 
atoms that are present in sample molecules. Using 1H NMR the number of 
protons in a structure can be determined based on the number of signals 
observed in the spectra. Each equivalent hydrogen will produce a separate 
peak, so if two hydrogens are present in the same chemical environment they 
will produce just one signal. A ratio of equivalent protons can be determined 
by integrating the sample peaks to show relative intensities. This will show 
how many protons exist within the same chemical environment. Chemical shift 
values will provide information on the magnetic field effects of nearby nuclei 
on the proton nucleus and can give information on the atoms bonded to the 
hydrogen or the functional groups in which the hydrogen atom exists. Finally, 
the number of protons that neighbor a specific proton can be determined 
based on the splitting pattern of the sample signals.133  
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Internal standards, such as tetramethylsilane (TMS) can be added to samples 
allowing comparison of spectra to other samples identified or to literature data 
provided for reference samples. Research and literature also shows the typical 
chemical shift values that are observed when common laboratory solvents are 
present in a sample when dissolved in deuterated solvents.134 Research has 
shown that 1H NMR has been used to analyze a number of psychoactive 
substances including cathinones and compared to reference standards.135, 136 
Quantitative NMR (qNMR) has also been performed on a variety of drug 
samples in order to extensively analyze samples.130 
 
This means that more than just the structural characterization can be obtained 
and levels of impurities present can be evaluated and composition of mixtures 
can be determined. Research for samples containing synthetic cannabinoids 
that have been encountered individually and in herbal blends has shown the 
ability to determine percentages of samples in mixtures.137 There are some 
difficulties when using 1H as the nucleus to run qNMR especially when testing 
mixtures as the spectrum can become convoluted and difficult to distinguish 
due to multiple sample signals. Fluorine NMR (19F NMR) can be utilised for 
fluorinated samples to perform quantitative and qualitative NMR due to the 
simplistic nature of the spectrum produced. 
 
NMR can be carried out using a 60 MHz magnet, which allows a smaller 
instrument to be used. This lower magnetic field results in lower resolution of 
spectra although splitting patterns are not lost completely compared to higher 
magnetic fields. 60 MHz NMR has advantages over other confirmatory tests 
such as GC-MS due to the ease of sample preparation, cost of 
instrumentation, the possibility of it being field deployable and the need of less 
expertise for data analysis. The simplicity of 19F NMR spectra means less 
interpretation is needed and therefore less expertise is needed in determining 
samples present. The instrument being field deployable allows the possibility 
of the technique to be used at locations such as police custody suits, airport 
terminal security and music festivals. Sample run times are also significantly 
quicker for both 1H and 19F experiments compared to GC-MS runs. GC-MS 
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still produces lower limits of detection and quantification compared to NMR 
and is more reproducible with lower standard deviations produced when 
multiple runs of the same sample are performed. In the case of fluorinated 
amphetamines and cathinones it has been shown that degradation occurs, 
when GC-MS is run meaning tailing occurs and identification of compounds 
becomes harder based on retention times. This is why 60 MHz analysis should 
be performed on all fluorinated amphetamine and cathinone derivatives.  
 
1.11.1. Fluorine (19F) NMR  
In a similar manner to the proton nucleus, the fluorine nucleus has a nuclear 
spin of ½ so the technique is similar to that of 1H NMR. 19F NMR enables the 
determination of the number of fluorine atoms present in a molecule. Signals 
for 19F NMR may split if an uncoupled experiment is run due to coupling 
occurring to other ½ spin nuclei such as other fluorine atoms and hydrogen 
atoms. The 19F isotope has a 100% natural abundance and will be highly 
responsive to NMR techniques due its high magnetogyric ratio. 19F NMR 
produces a much larger chemical shift range in comparison to 1H NMR and 
this means that molecules that possess more than one fluorine atom may 
usually have peaks that are well separated and spectra that is easier to 
interpret. 
 
The simplicity of 19F NMR spectra will allow not only qualitative analysis and 
comparison between samples in mixtures and reference standards but also 
quantitative analysis in a simpler manner when internal references are added. 
Due to the lower number of sample peaks likely in mixtures quantitative 
analysis becomes easier to perform using 19F NMR. Fluorotrichloromethane 
(CFCl3) and trifluroacetic acid (CF3COOH) are two of the more commonly used 
internal reference standards and can be chosen depending on the chemical 
shift ranges of the samples in question.  
 
The coupling that fluorine experiences between other ½ spin nuclei allows 
further two dimensional fluorine experiments to be performed in order to fully 
elucidate and explain the coupling interactions present in a molecule. 
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1.11.2. 60 MHz NMR screening 
NMR is more capable of identifying a possible compound based on every 
compound having a specific 1H NMR spectrum. This gives it an advantage 
over GC-MS when trying to screen drug samples for potential controlled 
substances. When using a 60 MHz instrument over a higher-powered 
instrument, such as a 400 MHz spectrometer, slight details may decrease such 
as clear coupling constants, however spectra for differing compounds will still 
be unique. This means that when an unknown sample is encountered the NMR 
spectra can be compared to a known reference and the sample can be 
identified. 60 MHz NMR also has other advantages and disadvantages 
compared to GC-MS which can be seen in Table 5. 
 
Table 5: Advantages and disadvantages of using 60 MHz NMR compared to GC-MS 
Advantages Disadvantages 
 A 60 MHz instrument has a simpler 
interface and doesn’t require special 
expertise to operate 
 Cheaper instrument 
 Cost per sample – GC-MS forensic 
analysis can cost between £120-£200 
per sample whereas NMR analysis is 
performed for the cost of consumables 
(around £50 for 10 DMSO solvent 
ampules and NMR tubes from Sigma 
Aldrich)  
 Quicker analysis times. 5 minute runs 
for both 1H and 19F experiments 
compared to runs > 10 mins for GC-MS 
analysis.  
 Field deployable 
 NMR not currently utilised in forensic 
laborites and 60 MHz NMR is not 
currently used for evidence gathering 
 Higher LOD for NMR meaning more 
sample is needed to test using NMR 
 Difficulty with mixture analysis as 
signals for different compounds will 
coalesce 
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1.12. Aims and Objectives 
Since the introduction of the Misuse of Drugs Act, illicit drug suppliers and 
clandestine labs have been looking at ways to avoid detection and alter 
structures of controlled substances. One way this is achieved is to add fluorine 
into the molecule and research into drug development has shown this to have 
effects regarding enhancement of biological activity and increased chemical 
and metabolic stability.2 It is of vital importance both forensically and from a 
criminological point of view that substances can be identified in a rapid and 
accurate manner. This is due to differences in sentencing between substances 
belonging to the New Psychoactive Substances Act (2016) and those that 
belong to the Misuse of Drugs Act (1971). The changing face of new 
psychoactive substances, with the alteration of structures and the changing 
drugs market from “head shops” to the “dark web” has provided an even 
greater analytical challenge for the detection of NPS. The main aim of this 
report will be to show the ease of structure alteration in NPS and develop 
analytical methods that will aid with the detection of these compounds. A 60 
MHz instrument will be used in order to perform a rapid screening method, 
where runs will ideally last between 5-10 minutes. This system can then be 
used by people with limited scientific backgrounds or training due to the ease 
of sample preparation and processing. This system could then be utilised 
within airport, police custody, festival and other public event environments as 
a “field deployable” system, where quick analysis is necessary for prosecution, 
safety and healthcare purposes. Both qualitative and quantitative analysis will 
be performed and can be compared to GC-MS analysis, which is currently the 
main analytical method used within Forensic Science testing. The method can 
also be compared to colour testing as a presumptive testing method, as colour 
tests have been previously performed by law enforcement to show the 
possibility of NPS being present. However, this report will show that with the 
increase in novel psychoactive substances there is also an increase in the 
number of false positives to already controlled drugs, under the Misuse of 
Drugs Act 1971,  with which the colour tests are intended. Colour testing will 
also be used in order to see whether positional isomers can be distinguished 
based on colour change. 
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Initially, chapter three will show testing on trifluoromethylmethcathinone and 
fluoromethcathinone regioisomers (8a-8c, 9a-9c) as well as the three 
fluoroamphetamine regioisomers (4a-4c). Full characterization will be 
performed in order to compare with previous literature data that has been 
reported for these compounds. A GC-MS method will be developed in order to 
try and achieve possible separation of these nine compounds for identification. 
19F NMR experiments will be run, on a 60 MHz instrument, to show the 
possibility of using this technique as an initial presumptive testing experiment. 
This experiment will provide a simplified spectrum, with only 1-2 peaks, which 
is easier to interpret by non-scientifically trained personal. Quantitative 
analysis will be performed using this technique to then show that concentration 
of samples can be determined with the same precision to GC-MS in a quicker 
run. GC-MS is currently used in forensic environments for evidence collection 
and therefore if the 60 MHz instrument can perform to the same standard then 
there is a possibility it can be used for this purpose in forensic laboratories. 
Street samples will then be analysed in order to show the ability of both 
methods to identify active components and provide quantitative analysis.  
 
Chapter four will show the synthesis of thirteen diphenidine derivatives 
including diphenidine (13a) and the three methoxphenidine regioisomers (13b-
13d). Full characterisation will be performed and a GC-MS method will be 
developed and validated with two samples bought from online vendors tested 
to show the ability of GC-MS to separate and identify this class of compounds. 
This chapter will show how altering structures slightly can alter analytical data 
produced in order to try to avoid detection from previously encountered drugs. 
It will also help to identify drugs that may emerge in future.    
 
Chapter five will look into the synthesis of halogenated (fluoro-, bromo-, chloro- 
and iodo-) diphenidine derivatives. Addition of different halogenated 
substituents will effect bioavailability as lipophilicity will increase as the 
halogenated substituent is changed from fluorine to iodine. This will mean that 
the iodine compounds will have a higher affinity for the lipid phase and an 
increased, however it will also have a negative effect on oral adsorption. 138  
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Full characterisation will be performed, and analysis will be performed using 
both GC-MS and NMR in order to show whether differences can be seen when 
different halogen substituents are used and when regioisomers of the same 
halogen are observed.  
 
In chapter six, a range of substances will be synthesised, based on the 
synthesis of diphenidine, where the amine used will be altered in order to 
achieve slightly differing side chains and rings on the final compound 
produced. Chapter seven will show the ease of synthesis of slightly altered 
chemical structures of an original compound backbone. Monofluorinated 
compounds will be produced in each case and these compounds will be 
separated using GC-MS instrumentation. 19F NMR and 1H NMR on a 60 MHz 
instrument will also be tested as a possible replacement for current 
presumptive tests. This chapter will show that even though the colour tests will 
not be able to distinguish regioisomers by colour the 60 MHz instrument will 
produce unique proton and fluorine spectrum that can identify an individual 
compound from 24 structurally similar compounds.    
 
Chapter seven will show the synthesis of six difluoroephenidine regiosomers 
as well as trifluoro-, tetrafluoro- and pentafluoroephenidine compounds. These 
nine compounds will be fully characterised and GC-MS and 19F NMR 
experiments will be utilised in order to show potential separation of these 
compounds. Further to this, a number of 2D NMR experiments will be 
performed on a 60 MHz NMR spectrometer in order to further distinguish 
between the six difluorinated isomers. This will show that as well as 
presumptive testing on the 60 MHz NMR, further longer experiments can be 
performed that will further confirm the presence of specific drugs. 
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2.  Chapter 2 – Experimental methods 
All reagents and chemicals were purchased from Sigma Aldrich (Gillingham, 
UK) or Fluorochem Limited (Hadfield, UK) and used without further 
purification. Solvents were purchased from Sigma Aldrich and Fisher Scientific 
(Loughborough, UK). 1H, 13C and 19F NMR for characterisation was acquired 
on a JEOL (JEOL, Tokyo, Japan) NMR spectrometer operating at a proton 
resonance frequency of 400 MHz. All NMR data has been discussed in the 
relevant results sections (Chapter 3 - Chapter 7). Presumptive 1H and 19F NMR 
analysis was performed on a Pulsar (Oxford Instruments, Abingdon, UK) NMR 
spectrometer operating at a resonance frequency of 60 MHz. Trifluoroacetic 
acid was added (0.1 % v/v), as an internal reference, to samples requiring 
analysis using a 19F experiment. Infrared spectra were obtained in the range 
4000 – 400 cm-1 using a Thermo Scientific Nicolet iS10ATR-FTIR instrument 
(Thermo Scientific, Rochester, USA). All IR spectra have been included in the 
supplementary information. All test street samples were provided by Greater 
Manchester Police (GMP) personnel, in accordance with the legislation and 
under the approved Memorandum of Understanding operating between the 
MANchester DRug Analysis and Knowledge Exchange (MANDRAKE) and 
GMP. All controlled substances and restricted materials were synthesised, 
stored, used and destroyed in accordance with Home Office regulations and 
the Misuse of Drugs Act (1971). 5    
 
The fluoroamphetamine (FA, 4a – 4c), fluoromethcathinone (FMC, 8a – 8c) 
and trifluoromethylmethcathinone (TFMMC, 9a – 9c) regioiosmers were 
synthesised previously at Manchester Metropolitan University (MMU) and 
Strathclyde University under home office license. 70, 83, 139 Diphenidine (13a) 
and twelve of its derivatives (13b – 13m) were also synthesised prior to the 
project at Manchester Metropolitan University.  
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2.1. Synthetic Methods 
2.1.1. Synthesis of the diphenidine derivatives and analogues  
Twelve halogenated diphenidine derivatives, 18 diphenidine analogues and 9 
polyfluorinated ephenidine derivatives were synthesised as part of the project 
using different aldehydes and amines. Compound names and abbreviations 
along with the aldehyde and amine used can be seen in Table 6.   
Table 6: List of diphenidine derivatives and analogues synthesised including abbreviations 
and compound numbers along with the aldehyde and amine used in synthesis 
Compound 
no. 
Compound name Abbreviation Aldehyde used (X) Amine used (NHR) 
15a 2-fluoroephenidine 2-FEP 2-fluorobenzaldehyde  ethylamine 
15b 3-fluoroephenidine 3-FEP 3-fluorobenzaldehyde ethylamine 
15c 4-fluoroephenidine 4-FEP 4-fluorobenzaldehyde ethylamine 
15d 2,3-difluoroephenidine 2,3-DFEP 2,3-difluorobenzaldehyde ethylamine 
15e 2,4-difluoroephenidine 2,4-DFEP 2,4-difluorobenzaldehyde ethylamine 
15f 2,5-difluoroephenidine 2,5-DFEP 2,5-difluorobenzaldehyde ethylamine 
15g 2,6-difluoroephenidine 2,6-DFEP 2,6-difluorobenzaldehyde ethylamine 
15h 3,4-difluoroephenidine 3,4-DFEP 3,4-difluorobenzaldehyde ethylamine 
15i 3,5-difluoroephenidine 3,5-DFEP 3,5-difluorobenzaldehyde ethylamine 
15j 2,3,4-trifluoroephenidine TriFEP 2,3,4-trifluorobenzaldehyde ethylamine 
15k 
2,3,4,5-
tetrafluoroephenidine 
TeFEP 
2,3,4,5-
tetrafluorobenzaldehyde 
ethylamine 
15l 
2,3,4,5,6-
pentafluoroephendine 
PFEP 
2,3,4,5,6-
pentafluorobenzaldehyde 
ethylamine 
19a 2-fluorolintane 2-FL 2-fluorobenzaldehyde pyrrolidine 
19b 3-fluorolintane 3-FL 3-fluorobenzaldehyde pyrrolidine 
19c 4-fluorolintane 4-FL 4-fluorobenzaldehyde pyrrolidine 
20a 2-fluphenidine 2-FP 2-fluorobenzaldehyde piperidine 
20b 3-fluphenidine 3-FP 3-fluorobenzaldehyde piperidine 
20c 4-fluphenidine 4-FP 4-fluorobenzaldehyde piperidine 
20d 2-chlophendine 2-CP 2-chlorobenzaldehyde piperidine 
20e 3-chlophenidine 3-CP 3-chlorobenzaldehyde piperidine 
20f 4-chlophenidine 4-CP 4-chlorobenzaldehyde piperidine 
20g 2-brophenidine 2-BP 2-bromobenzaldehyde piperidine 
20h 3-brophenidine 3-BP 3-bromobenzaldehyde piperidine 
20i 4-brophenidine 4-BP 4-bromobenzaldehyde piperidine 
20j 2-iodophenidine 2-IP 2-iodobenzaldehyde piperidine 
20k 3-iodophenidine 3-IP 3-iodobenzaldehyde piperidine 
20l 4-iodophenidine 4-IP 4-iodobenzaldehyde piperidine 
21a 2-fluoromephenidine 2-FMP 2-fluorobenzaldehyde methylamine 
21b 3-fluoromephenidine 3-FMP 3-fluorobenzaldehyde methylamine 
21c 4-fluoromephenidine 4-FMP 4-fluorobenzaldehyde methylamine 
22a 2-fluorodimephenidine 2-FDMP 2-fluorobenzaldehyde dimethylamine 
22b 3-fluorodimephenidine 3-FDMP 3-fluorobenzaldehyde dimethylamine 
22c 4-fluorodimephenidine 4-FDMP 4-fluorobenzaldehyde dimethylamine 
23a 2-fluorodiephenidine 2-FDEP 2-fluorobenzaldehyde diethylamine 
23b 3-fluorodiephenidine 3-FDEP 3-fluorobenzaldehyde diethylamine 
23c 4-fluorodiephenidine 4-FDEP 4-fluorobenzaldehyde diethylamine 
24a 2-fluorotrifluoroephenidine 2-FTFEP 2-fluorobenzaldehyde trifluoroethylamine 
24b 3-fluorotrifluoroephenidine 3-FTFEP 3-fluorobenzaldehyde trifluoroethylamine 
24c 4-fluorotrifluoroephenidine 4-FTFEP 4-fluorobenzaldehyde trifluoroethylamine 
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Figure 27: General structure of diphenidine and all its derivatives and analogues  
Synthesis of all diphenidine derivatives and analogues were synthesised using 
an adaptation of the published method from Le Gall et al.140 (figure 26). The 
following modifications were applied to the published method: To a dried round 
bottomed flask (250 mL) containing zinc dust (2.0 g, 30 mmol) suspended in 
acetonitrile (40 mL), was added benzyl bromide (0.4 mL) and trifluroacetic acid 
(0.2 mL). The resulting solution was stirred for 5 minutes and then benzyl 
bromide (3.0 mL, 25 mmol), the required amine (0.99 mL, 10 mmol) followed 
by the pre-requisite benzaldehyde (11 mmol), were introduced to the mixture, 
and the solution was stirred at room temperature for an additional 1 h. The 
resulting solution was poured into a saturated aqueous NH4Cl solution (150 
mL) and extracted with dichloromethane (2 × 100 mL). The combined organic 
layers were dried (MgSO4) and concentrated in vacuo to give a crude yellowish 
oil. The oil was then dissolved in diethyl ether (150 mL) and concentrated 
sulphuric acid (0.75 mL) was added dropwise, to the vigorously stirred 
solution. After five minutes, the precipitated ammonium salt was filtered, 
washed with diethyl ether (2 × 50 mL) and air dried for 5-10 minutes. The 
ammonium salt was re-dissolved in aqueous sodium hydroxide (5% w/v, 150 
mL) and then extracted with dichloromethane (2 × 100 mL). The combined 
organic fractions were again dried (MgSO4) and concentrated in vacuo to give 
a yellow oil. The oil was dissolved in diethyl ether (200 mL), treated with 
hydrogen chloride (4M in dioxane, 3.0 mL, 12 mmol) and left to stand for 5 
minutes. The crystallized products were filtered and washed sequentially with 
the minimum amount of ice-cold acetone and if necessary an ice-cold mixture 
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of ethyl acetate-diethyl ether (1:5) to afford the corresponding hydrochloride 
salts as colourless to off-white powders. 
 
2-Fluoroephenidine (2-FEP, 15a) afforded 2.24 g (64%) of a white powder. MP 
189 °C. 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.27 (t, 3H, J = 8.12 
Hz, NHCH2CH3), 2.75 – 2.81 (m, 1H, NHCH2CH3), 2.85 – 2.95 (m, 1H, 
NHCH2CH3), 3.18 – 3.24 (m, 1H, NHCHCH2), 3.78 (dd, 1H, J = 13.1, 5.2 Hz, 
NHCHCH2), 4.78 – 4.88 (m, 1H, NHCHCH2), 6.98-7.08 (m, 2H, Ar-H), 7.12 – 
7.21 (m, 4H, Ar-H), 7.30 – 7.42 (m, 2H, Ar-H), 7.98 – 8.08 (m, 1H, Ar-H), 9.47 
– 9.80 (br s., 1H, NH), 10.05 – 10.28 (br s., 1H, NH); 13C NMR (400 MHz, 
DMSO-d6) δ 11.95, 39.25, 41.41, 55.80, 116.41, 122.64, 126.02, 127.74, 
129.25, 129.99, 130.52, 132.09, 136.60, 161.32 (d, C-F, J = 246.30); 19F NMR 
(400 MHz, DMSO-d6) δ -118.77; IR: 2950 cm-1 (C-H), 1240 cm-1 (C-F), 1550 
cm-1 (N-H), 1450 cm-1 (C=C benzene). TLC Rf: 0.56 
 
3-Fluoroephenidine (3-FEP, 15b) afforded 2.10 g (60%) of a white powder. 
MP 174 °C. 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.22 (t, 3H, J = 7.3 
Hz, NHCH2CH3), 2.62 – 2.66 (m, 1H, NHCH2CH3), 2.83 (m, 1H, NHCH2CH3), 
3.16 - 3.19 (m, 1H, NHCHCH2), 3.64 (dd, 1H, J = 13.3 3.7 Hz, NHCHCH2), 
4.51 – 4.57 (m, 1H, NHCHCH2), 6.88 (s, 2H, Ar-H), 6.98 (m, 1H, Ar-H), 7.00 – 
7.10 (m, 4H, Ar-H), 7.20 (dd, 1H, J = 13.7 8.2 Hz, Ar-H), 7.25 (d, 1H, J = 9.6 
Hz, Ar-H), 9.73 (br s., 1H, NH), 10.14 (br s., 1H, NH); 13C NMR (400 MHz, 
DMSO-d6) δ 11.96, 39.86, 41.25, 62.60, 116.51 (d, J = 23.0 Hz), 116.77 (d, J 
= 21.1 Hz), 126.13, 127.56, 129.26, 130. 11, 131.65, 136.80, 138.51, 162.98 
(d, C-F, J = 245.4 Hz); 19F NMR (400 MHz, DMSO-d6) δ -111.43; IR: 1300 cm-
1 (C-F), 1460 cm-1 (benzene C=C), 1550 cm-1 (N-H stretch), 2950 cm-1 (C-H), 
3080 cm-1 (C-H benzene); TLC Rf: 0.61 
 
4-Fluoroephenidine (4-FEP, 15c) afforded 1.79 g (51%) of a white powder. MP 
177 °C. 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.22 (t, 3H, J = 7.3 Hz, 
NHCH2CH3), 2.61 (m, 1H, NHCH2CH3), 2.81 (m, 1H, NHCH2CH3), 3.16 (dd, 
1H, J = 13.1, 11.7 Hz, NHCHCH2), 3.63 (dd, 1H, J = 13.3, 4.1 Hz, NHCHCH2), 
4.51 (m, 1H, NHCHCH2), 7.42 (m, 2H, Ar-H), 7.54 (m, 1H, Ar-H), 7.60 (dd, 2H, 
J = 8.20, 1.63 Hz, Ar-H), 7.62 (m, 2H, Ar-H), 7.97 (dd, 2H, J = 8.75, 5.5 Hz, 
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Ar-H), 9.66 (br s., 1H, NH), 10.08 (br s., 1H, Ar-H); 13C NMR (400 MHz, DMSO-
d6) δ 11.95, 39.95, 41.16, 62.41, 116.50 (d, J = 21.1 Hz), 127.56, 129.25, 
130.12, 131.94, 132.04, 136.97, 163.1 (d, C-F, J = 246.3); 19F NMR (400 MHz, 
DMSO-d6) δ -112.20; IR: 1300 cm-1 (C-F), 1460 cm-1 (benzene C=C), 1550 
cm-1 (N-H stretch), 2950 cm-1 (C-H), 3080 cm-1 (C-H benzene); TLC Rf: 0.58 
          
2,3-Difluoroephenidine (2,3-DFEP, 15d) afforded 1.82 g (52%) of an off-white 
powder. MP 202 °C. 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.25 (t, 
3H, J = 7.5 Hz, NHCH2CH3), 2.78 (m, 1H, NHCH2CH3), 2.92 (m, 1H, 
NHCH2CH3), 3.18 (m, 1H, NHCHCH2), 3.68 (dd, 1H, J = 13.1, 5.5 Hz, 
NHCHCH2), 4.79 (m, 1H, NHCHCH2), 7.02 (d, 2H, J = 8.8 Hz, Ar-H), 7.18 (m, 
3H, Ar-H), 7.38 – 7.50 (m, 2H, Ar-H), 7.82 (dd, 1H, J = 13.1, 7.8 Hz, Ar-H), 
9.70 (br s., 1H, NH), 10.17 (br s., 1H, NH); 19F NMR (400 MHz, DMSO-d6) δ -
140.18, -144.23; IR: 1280 cm-1 (C-F), 1480.6 cm-1 (benzene C=C), 2706 cm-1 
(C-H), 2973 cm-1 (C-H benzene); TLC Rf: 0.87 
 
 2,4-Difluoroephenidine (2,4-DFEP, 15e) afforded 1.80 g (51%) of a white 
powder. MP 195 °C. 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.20 (t, 
3H, J = 7.2 Hz, NHCH2CH3) , 2.78 (m, 1H, NHCH2CH3), 2.93 (m, 1H, 
NHCH2CH3), 3.18 (m, 1H, NHCHCH2), 3.65 (dd, 1H, J = 12.8, 4.1 Hz, 
NHCHCH2), 4.79 (m, 1H, NHCHCH2), 6.95 (m, 3H, Ar-H), 7,11 – 7.25 (m, 4H, 
Ar-H), 8.05 (m, 1H, Ar-H); 19F NMR (400 MHz, DMSO-d6) δ -110.70, -114.48; 
IR: 1281 cm-1 (C-F), 1489 cm-1 (benzene C=C), 2706 cm-1 (C-H), 2956 cm-1 
(C-H benzene); TLC Rf: 0.75 
 
2,5-Difluoroephenidine (2,5-DFEP, 15f) afforded 2.00 g (57%) of a white 
powder. MP 211 °C. 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.20 (t, 
3H, J = 7.5 Hz, NHCH2CH3) , 2.78 (m, 1H, NHCH2CH3), 2.93 (m, 1H, 
NHCH2CH3), 3.18 (m, 1H, NHCHCH2), 3.65 (m, 1H, NHCHCH2), 4.79 (m, 1H, 
NHCHCH2), 7.00 – 7.38 (m, 7H, Ar-H), 7.91 (dd, 1H, J = 11.2, 4.8 Hz, Ar-H), 
9.62 (br s., 1H, NH), 10.08 (br s., 1H, NH); 19F NMR (400 MHz, DMSO-d6) δ -
118.58, -124.18; IR: 1190 cm-1 (C-F), 1496 cm-1 (benzene C=C), 2710 cm-1 
(C-H), 2974 cm-1 (C-H benzene); TLC Rf: 0.80 
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2,6-Difluoroephenidine (2,6-DFEP, 15g) afforded 2.24 g (64%) of a white 
powder. MP 205 °C. 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.28 (t, 
3H, J = 7.0 Hz, NHCH2CH3) , 2.95 (m, 2H, NHCH2CH3), 3.18 (m, 1H, 
NHCHCH2), 3.65 (dd, 1H, J = 12.8, 4.8 Hz, NHCHCH2), 4.75 (m, 1H, 
NHCHCH2), 7.02 – 7.20 (m, 7H, Ar-H), 7.50 (dd, 1H, J = 11.2, 4.2 Hz, Ar-H), 
9.18 (br s., 1H, NH), 10.26 (br s., 1H, NH); 19F NMR (400 MHz, DMSO-d6) δ -
113.68; IR: 1202 cm-1 (C-F), 1475 cm-1 (benzene C=C), 2670 cm-1 (C-H), 2944 
cm-1 (C-H benzene); TLC Rf: 0.83 
 
3,4-Difluoroephenidine (3,4-DFEP, 15h) afforded 1.89 g (54%) of a white 
powder. MP 188 °C. 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.20 (t, 
3H, J = 7.5 Hz, NHCH2CH3) , 2.78 (m, 1H, NHCH2CH3), 2.93 (m, 1H, 
NHCH2CH3), 3.18 (m, 1H, NHCHCH2), 3.65 (m, 1H, NHCHCH2), 4.79 (m, 1H, 
NHCHCH2), 7.05 (m, 2H, Ar-H), 7.12 – 7.30 (m, 4H, Ar-H), 7.42 (dd, 1H, J = 
12.8, 5.2 Hz, Ar-H), 7.72 (d, 1H, J = 8.4 Hz, Ar-H), 9.68 (br s., 1H, NH), 9.95 
(br s., 1H, NH); 19F NMR (400 MHz, DMSO-d6) δ -139.56, -139,70; IR: 1282 
cm-1 (C-F), 1520cm-1 (benzene C=C), 2709 cm-1 (C-H), 2971 cm-1 (C-H 
benzene); TLC Rf: 0.84 
 
3,5-Difluoroephenidine (3,5-DFEP, 15i) afforded 1.82 g (52%) of an off-white 
powder. MP 194 °C. 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.25 (t, 
3H, J = 7.5 Hz, NHCH2CH3) , 2.65 (m, 1H, NHCH2CH3), 2.86 (m, 1H, 
NHCH2CH3), 3.18 (m, 1H, NHCHCH2), 3.61 (m, 1H, NHCHCH2), 4.60 (m, 1H, 
NHCHCH2), 7.02 (m, 3H, Ar-H), 7.14 – 7.38 (m, 5H, Ar-H) 9.70 (br s., 1H, NH), 
10.06 (br s., 1H, NH); 19F NMR (400 MHz, DMSO-d6) δ -110.62; IR: 1322 cm-
1 (C-F), 1467cm-1 (benzene C=C), 2799 cm-1 (C-H), 2969 cm-1 (C-H benzene); 
TLC Rf: 0.80 
 
Trifluoroephenidine (TriFEP, 15j) afforded 2.03 g (58%) of a white powder. MP 
199 °C. 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.25 (t, 3H, J = 7.0 Hz, 
NHCH2CH3) , 2.80 (m, 1H, NHCH2CH3), 2.91 (m, 1H, NHCH2CH3), 3.22 (m, 
1H, NHCHCH2), 3.72 (m, 1H, NHCHCH2), 4.75 (m, 1H, NHCHCH2), 7.01 (m, 
2H, Ar-H), 7.19 (m, 3H, Ar-H), 7.50 (t, 1H, J = 9.2 Hz, Ar-H), 7.96 (dd, 1H, J = 
12.8, 3.8 Hz, Ar-H), 9.90 (br s., 1H, NH), 10.32 (br s., 1H, NH); 19F NMR (400 
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MHz, DMSO-d6) δ -163.00, -138.89, -135.30; IR: 1282cm-1 (C-F), 1500 cm-1 
(benzene C=C), 2698 cm-1 (C-H), 2968 cm-1 (C-H benzene); TLC Rf: 0.72 
 
Tetrafluoroephenidine (TeFEP, 15k) afforded 1.86 g (53%) of a white powder. 
MP 205 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.25 (t, 3H, J = 7.0 
Hz, NHCH2CH3) , 2.82 (m, 1H, NHCH2CH3), 2.95 (m, 1H, NHCH2CH3), 3.20 
(m, 1H, NHCHCH2), 3.68 (m, 1H, NHCHCH2), 4.81 (m, 1H, NHCHCH2), 7.08 
(m, 2H, Ar-H), 7.24 (m, 3H, Ar-H), 8.22 (m, 1H, Ar-H), 9.89 – 10.30 (br s., 2H, 
NH); 19F NMR (400 MHz, DMSO-d6) δ -157.68, -156.32, -142.77, -139.52; IR: 
1280cm-1 (C-F), 1475 cm-1 (benzene C=C), 2748 cm-1 (C-H), 2914 cm-1 (C-H 
benzene); TLC Rf: 0.74  
 
Pentafluoroephenidine (PFEP, 15l) afforded 1.92 g (55%) of a white powder. 
MP 189 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.28 (t, 3H, J = 7.8 
Hz, NHCH2CH3) , 3.03 (m, 1H, NHCH2CH3), 3.18 (m, 1H, NHCH2CH3), 3.40 
(m, 1H, NHCHCH2), 3.71 (m, 1H, NHCHCH2), 4.80 (m, 1H, NHCHCH2), 7.15 
– 7.28 (m, 5H, Ar-H), 9.67 (br s., 1H, NH), 10.50 (br s., 1H, NH); 19F NMR (400 
MHz, DMSO-d6) δ -163.30, -153.79, -140.90; IR: 1288 cm-1 (C-F), 1475 cm-1 
(benzene C=C), 2752 cm-1 (C-H), 2914 cm-1 (C-H benzene); TLC Rf: 0.70 
 
2-Fluphenidine (2-FP, 20a) afforded 1.40 g (40%) of a white powder. MP 194 
°C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.32 (m, 1H, PPR-H), 1.68, 
(m, 1H, PPR-H), 1.70 – 1.82 (m, 3H, PPR-H), 2.05 (m, 1H, PPR-H), 3.48 (m, 
1H, PPR-H), 3.51 (m, 1H, NHCHCH2), 3.70 (m, 1H, PPR-H), 3.88 (dd, 1H, J = 
13.2, 3.8 Hz, NHCHCH2), 4.89 (dd, 1H, J = 12.8, 4.1 Hz, NHCHCH2), 7.00 – 
7.18 (m, 6H, Ar-H), 7.28 – 7.40 (m, 2H, Ar-H), 8.00 (m, 1H, Ar-H), 11.45 (s, 
1H, NH); 13C NMR (400 MHz, DMSO-d6 δ ppm = 39.51) δ 21.45, 21.68, 35.50, 
48.22, 51.80, 116.45, 116.81, 125.95, 127.50, 129.82, 130.04, 132.15, 132.60, 
136.22, 161.80 (d, J = 221.5 Hz); 19F NMR (400 MHz, DMSO-d6) δ -115.71; 
IR: 2985 cm-1 (C-H), 1250 cm-1 (C-F), 1560 cm-1 (C=C benzene); TLC Rf: 0.65 
 
3-Fluphenidine (3-FP, 20b) afforded 1.15 g (35%) of a white powder. MP 224 
°C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.28 (m, 1H, PPR-H), 1.68 
– 2.10 (m, 5H, PPR-H), 2.60 – 2.70 (m, 2H, PPR-H), 3.41 (m, 1H, PPR-H), 
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3.50 (t, 1H, J = 8.4 Hz, NHCHCH2), 3.70 – 3.89 (m, 2H, PPR-H, NHCHCH2), 
4.71 (dd, 1H, J = 12.8, 3.8 Hz, NHCHCH2), 7.00 – 7.30 (m, 6H, Ar-H), 7.38 – 
7.48 (m, 2H, Ar-H), 7.54 (d, 1H, J = 7.2 Hz, Ar-H), 11.45 (s, 1H, NH); 13C NMR 
(400 MHz, DMSO-d6 δ ppm = 39.51) δ 22.05, 22.88, 35.41, 49.00, 52.40, 
69.62, 116.80, 117.00, 117.77, 117.99, 127.03, 127.49, 128.79, 129.60, 
134.99, 136.87, 162.44 (d, J = 205.5 Hz); 19F NMR (400 MHz, DMSO-d6) δ -
110.96; IR: 2980 cm-1 (C-H), 1305 cm-1 (C-F), 1570 cm-1 (C=C benzene); TLC 
Rf: 0.61 
 
4-Fluphenidine (4-FP, 20c) afforded 1.54 g (44%) of a white powder. MP 183 
– 184 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.23 (m, 1H, PPR-
H), 1.61 (m, 1H, PPR-H), 1.72 (m, 2H, PPR-H), 1.80 – 2.01 (m, 2H, PPR-H), 
2.52 (m, 2H, PPR-H), 3.35 (m, 1H, PPR-H), 3.45 (m, 1H, NHCHCH2), 3.73 (m, 
1H, PPR-H), 3.76 (d, 1H, J = 7.8 Hz, NHCHCH2), 4.65 (dd, 1H, J = 12.2, 3.8 
Hz, NHCHCH2), 6.98 – 7.20 (m, 7H, Ar-H), 7.59 (d, 2H, J = 7.2 Hz, Ar-H), 
11.29 (s, 1H, NH); 13C NMR (400 MHz, DMSO-d6 δ ppm = 39.51) δ 22.06, 
22.87, 35.51, 48.68, 52.27, 69.48, 115.93, 116.14, 126.98, 128.05, 128.77, 
129.61, 133.38, 133.46, 137.03, 162.50 (d, J = 220 Hz); 19F NMR (400 MHz, 
DMSO-d6) δ -110.78; IR: 2980 cm-1 (C-H), 1305 cm-1 (C-F), 1570 cm-1 (C=C 
benzene); TLC Rf: 0.62 
 
2-Chlophenidine (2-CP, 20d) afforded 1.51 g (43%) of a white powder. MP 
199 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.38 (m, 1H, PPR-H), 
1.62 – 1.90 (m, 4H, PPR- 
H), 2.09 (m, 1H, PPR-H), 3.15 (m, 1H, PPR-H), 3.24 (m, 1H, PPR-H), 3.27 (m, 
1H, PPR-H), 3.43 (m, 1H, NHCHCH2), 3.46 (m, 1H, PPR-H), 3.88 (m, 1H, 
NHCHCH2), 5.00 (dd, 1H, J = 12.8 3.8 Hz, NHCHCH2), 7.00 (m, 2H, Ar-H), 
7.12 (m, 3H, Ar-H), 7.36 (d, 2H, J = 7.8 Hz, Ar-H), 7.49 (m, 1H, Ar-H), 8.27 (d, 
1H, J = 7.5 Hz, Ar-H), 11.67 (br s., 1H, NH); 13C NMR (400 MHz, DMSO-d6 δ 
ppm = 39.51) δ 21.87, 23.00, 35.85, 49.55, 52.48, 66.20, 127.12, 127.97, 
128.05, 129.86, 130.45, 130.94, 131.84, 131.99, 135.65, 136.20; IR: 2950 cm-
1 (C-H), 1570 cm-1 (C=C benzene), 689 cm-1 (C-Cl); TLC Rf: 0.71 
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3-Chlophenidine (3-CP, 20e) afforded 1.89 g (54%) of a white powder. MP 172 
°C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.29 (m, 1H, PPR-H), 1.65 
(m, 1H, PPR-H), 1.70 – 2.10 (m, 4H, PPR-H), 2.61 (m, 2H, PPR-H), 3.40 (m, 
1H, PPR-H), 3.52 (m, 1H, NHCHCH2), 3.75 – 3.85 (m, 2H, PPR-H, 
NHCHCH2), 4.71 (d, 1H, J = 8.2 Hz, NHCHCH2), 7.00 - 7.20 (m, 4H, Ar-H), 
7.42 (m, 2H, Ar-H), 7.60 (dd, 1H, J = 8.2, 3.3 Hz, Ar-H), 7.70 (s, 2H, Ar-H), 
11.36 (s, 1H, NH); 13C NMR (400 MHz, DMSO-d6 δ ppm = 39.51) δ 22.01, 
22,89, 35.26, 49.01, 52.36, 69.51, 127.04, 128.83, 129.60, 129.99, 130.10, 
130.93, 133.79, 134.61, 136.82; IR: 2900 cm-1 (C-H), 1565 cm-1 (C=C 
benzene), 699 cm-1 (C-Cl); TLC Rf: 0.73 
 
4-Chlophenidine (4-CP, 20f) afforded 1.72 g (49%) of a white powder. MP 170 
°C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.26 (m, 1H, PPR-H), 1.64 
(m, 1H, PPR-H), 1.70 – 2.05 (m, 4H, PPR-H), 2.50 - 2.60 (m, 2H, PPR-H), 
3.39 (m, 1H, PPR-H), 3.48 (m, 1H, NHCHCH2), 3.71 (m, 1H, PPR-H), 3.80 
(dd, 1H, J = 12.8, 3.6 Hz, NHCHCH2), 7.00 – 7.20 (m, 5H, Ar-H), 7.43 (d, 2H, 
J = 8.8 Hz, Ar-H), 7.60 (d, 2H, J = 7.4 Hz, Ar-H), 11.42 (s, 1H, NH); 13C NMR 
(400 MHz, DMSO-d6 δ ppm = 39.51) δ 21.52, 22.37, 34.83, 48.23, 51.81, 68. 
93, 126.50, 128.31, 128.95, 129.11, 130.86, 132.55, 134.19, 136.42; IR: 2865 
cm-1 (C-H), 1540 cm-1 (C=C benzene), 710 cm-1 (C-Cl); TLC Rf: 0.73 
 
2-Brophenidine (2-BP, 20g) afforded 1.65 g (47%) of a white powder. MP 185 
°C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.40 (m, 1H, PPR-H), 1.70 
– 1.90 (m, 4H, PPR-H), 2.04 (m, 1H, PPR-H), 2.68 (m, 1H, PPR-H), 2.76 (m, 
1H, PPR-H), 3.26 (m, 1H, PPR-H), 3.44 (m, 1H, NHCHCH2), 3.88 (m, 2H, 
PPR-H, NHCHCH2), 4.95 (m, 1H, NHCHCH2), 7.00 (d, 2H, J = 7.5 Hz, Ar-H), 
7.12 (m, 3H, Ar-H), 7.28 (dd, 1H, J = 9.2, 3.1 Hz, Ar-H), 7.54 (m, 2H, Ar-H), 
8.25 (d, 1H, J = 9.2 Hz, Ar-H), 11.55 (s, 1H, NH); 13C NMR (400 MHz, DMSO-
d6 δ ppm = 39.51) δ 21.31, 22.37, 22.49, 36.01, 49.45, 51.88, 68.50, 126.43, 
126.66, 128.13, 128.50, 129.19, 130.96, 131.20, 132.56, 133.13, 135.58; IR: 
2870 cm-1 (C-H), 1540 cm-1 (C=C benzene), 550 cm-1 (C-Br); TLC Rf: 0.80 
 
3-Brophenidine (3-BP, 20h) afforded 1.72 g (49%) of a white powder. MP 200 
°C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.64 (m, 1H, PPR-H), 1.60 
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– 2.15 (m, 5H, PPR-H), 2.50 – 2.68 (m, 2H, PPR-H), 3.38 – 3.55 (m, 2H, PPR-
H, NHCHCH2), 3.70 – 3.87 (m, 2H, PPR-H, NHCHCH2), 4.69 (d, 1H, J = 9.8 
Hz, NHCHCH2), 7.00 - 7.20 (m, 4H, Ar-H), 7.33 (d, 2H, J = 7.2 Hz, Ar-H), 7.57 
(d, 1H, J = 7.2 Hz, Ar-H), 7.65 (d, 1H, J = 7.0 Hz, Ar-H), 7.83 (s, 1H, Ar-H), 
11.62 (s, 1H, NH); 13C NMR (400 MHz, DMSO-d6 δ ppm = 39.51) δ 21.51, 
22.29, 34.77, 48.45, 51.85, 68.98, 121.85, 126.49, 128.28, 129.06, 129.89, 
130.63, 132.33, 133.31, 134.39, 136.34; IR: 2900 cm-1 (C-H), 1520 cm-1 (C=C 
benzene), 570 cm-1 (C-Br); TLC Rf: 0.77  
 
4-Brophenidine (4-BP, 20i) afforded 2.14 g (61%) of a white powder. MP 198 
– 200 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.23 (m, 1H, PPR-
H), 1.58 – 2.05 (m, 5H, PPR-H), 2.50 – 2.60 (m, 2H, PPR-H), 3.35 (m, 1H, 
PPR-H), 3.45 (m, 1H, NHCHCH2), 3.70 (m, 1H, PPR-H), 3.80 (m, 1H, 
NHCHCH2), 4.64 (dd, J = 12.4, 3.8 Hz, NHCHCH2), 6.95 – 7.18 (m, 6H, Ar-H), 
7.45 – 7.55 (m, 3H, Ar-H), 11.43 (s, 1H, NH); 13C NMR (400 MHz, DMSO-d6 δ 
ppm = 39.51) δ 21.89, 22.45, 35.80, 48.31, 53.88, 70.06, 123.87, 127.60, 
129.83, 130.05, 132.14, 132.88, 133.74, 137.68; IR: 2865 cm-1 (C-H), 1600 
cm-1 (C=C benzene), 560 cm-1 (C-Br); TLC Rf: 0.79 
 
2-Iodophenidine (2-IP, 20j) afforded 0.91 g (26%) of a white powder. MP 230 
°C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.37 (m, 1H, PPR-H), 1.70 
– 1.82 (m, 4H, PPR-H), 2.04 (m, 1H, PPR-H), 2.60 – 2.90 (m, 2H, PPR-H), 
3.16 (m, 1H, PPR-H), 3.32 (m, 1H, NHCHCH2), 3.75 – 3.85 (m, 2H, PPR-H, 
NHCHCH2), 4.74 (m, 1H, NHCHCH2), 6.94 (d, 1H, J = 9.2 Hz, Ar-H), 7.08 (m, 
3H, Ar-H), 7.50 (d, 1H, J = 11.2 Hz, Ar-H), 7.73 (dd, 2H, J = 13.2, 4.8 Hz, Ar-
H), 8.13 (d, 2H, J = 9.2 Hz, Ar-H), 11.46 (br s., 1H, NH); 13C NMR (400 MHz, 
DMSO-d6 δ ppm = 39.51) δ 21.89, 23.10, 37.52, 50.72, 53.27, 74.21, 105.86, 
127.59, 128.33, 129.92, 130. 15, 130.97, 132.01, 136.18, 140.83; IR: 2940 cm-
1 (C-H), 1550 cm-1 (C=C benzene); TLC Rf: 0.83 
 
3-Iodophenidine (3-IP, 20k) afforded 1.89 g (54%) of an off-white powder. MP 
249 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.22 (m, 1H, PPR-H), 
1.52 – 2.00 (m, 5H, PPR-H), 2.50 – 2.70 (m, 2H, PPR-H), 3.30 – 3.50 (m, 2H, 
PPR-H, NHCHCH2), 3.62 – 3.80 (m, 2H, PPR-H, NHCHCH2), 4.59 (m, 1H, 
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NHCHCH2), 6.95 – 7.20 (m, 6H, Ar-H), 7.59 – 7.70 (m, 2H, Ar-H), 7.92 (s, 1H, 
Ar-H), 11.31 (br s., 1H, NH); 13C NMR (400 MHz, DMSO-d6 δ ppm = 39.51) δ 
20.96, 22.89, 35.47, 48.91, 52.16, 69.58, 95.80, 127.48, 129.84, 130.28, 
131.63, 131.90, 135.78, 137.05, 138.92, 139.70; IR: 2865 cm-1 (C-H), 1620 
cm-1 (C=C benzene); TLC Rf: 0.80 
 
4-Iodophenidine (4-IP, 20l) afforded 2.10 g (60%) of a white powder. MP 255 
°C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.29 (m, 1H, PPR-H), 1.65 
– 2.10 (m, 5H, PPR-H), 2.50 – 2.61 (m, 2H, PPR-H), 3.40 – 3.52 (m, 2H, PPR-
H, NHCHCH2), 3.70 – 3.85 (m, 2H, PPR-H, NHCHCH2), 4.65 (dd, 1H, J = 12.8, 
3.8 Hz, NHCHCH2), 7.00 – 7.15 (m, 5H, Ar-H), 7.38 (d, 2H, J = 8.2 Hz, Ar-H), 
7.73 (d, 2H, J = 9.4 Hz, Ar-H), 11.43 (s, 1H, NH); 13C NMR (400 MHz, DMSO-
d6 δ ppm = 39.51) δ 21.50, 22.58, 36.70, 51.00, 57.62, 71.58, 98.14, 126.77, 
128.51, 131.30, 131.96, 132.86, 134.22, 136.78, 137.45, 139. 43; IR: 2930 cm-
1 (C-H), 1600 cm-1 (C=C benzene); TLC Rf: 0.84      
 
2-Fluoromephenidine (2-FMP, 21a) afforded 2.10 g (60%) of a white powder. 
MP 155 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 2.45 (t, 3H, J = 7.6 
Hz, CH3) 3.18 (m, 1H, NHCHCH2), 3.65 (dd, 1H, J = 7.2, 3.2 Hz, NHCHCH2), 
4.72 (m, 1H, NHCHCH2), 7.00 – 7.20 (m, 4H, Ar-H), 7.28 – 7.45 (m, 3H, Ar-
H), 7.90 (t, 2H, 5.4 Hz, Ar-H), 9.68 (,br s., 1H, NH), 10.16 (br s., 1H, NH); 13C 
NMR (400 MHz, DMSO-d6 δ ppm = 39.51) δ 31.15, 38.57, 57.78, 116.60, 
122.23, 123.79, 124.17,  125.69, 125.81, 128.92, 129.15, 129.76, 131.91, 
136.08, 161.84 (d, J = 206.5 Hz); 19F NMR (400 MHz, DMSO-d6) δ -118.24; Rf 
0.58 
 
3-Fluoromephenidine (3-FMP, 21b) afforded 1.68 g (48%) of a white powder. 
MP 162 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 2.29 (s, 3H, CH3), 
3.18 (m, 1H, NHCHCH2), 3.55 (m, 1H, NHCHCH2), 4.60 (m, 1H, NHCHCH2), 
7.05 (m, 3H, Ar-H), 7.18 – 7.25 (m, 4H, Ar-H), 7.62 (m, 2H, Ar-H), 9.65 (br s., 
2H, NH); 13C NMR (400 MHz, DMSO-d6 δ ppm = 39.51) δ 31.40, 36.87, 60. 
21, 115.89, 122.20, 123.52, 124.35, 124.81, 125.73, 127.60, 129.06, 1209.76, 
131.89, 134.56, 160.54 (d, J = 221.0 Hz); 19F NMR (400 MHz, DMSO-d6) δ -
111.26; Rf 0.50 
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4-Fluoromephenidine (4-FMP, 21c) afforded 1.99 g (57%) of a white powder. 
MP 178 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 2.41 (s, 3H, CH3), 
3.18 (m, 1H, NHCHCH2), 3.60 (m, 1H, NHCHCH2), 4.51 (dd, 1H, J = 7.2, 3.8 
Hz, NHCHCH2), 7.02 (d, 2H, J = 7.2 Hz, Ar-H), 7.10 – 7.25 (m, 5H, Ar-H), 7.55 
(m, 2H, Ar-H); 13C NMR (400 MHz, DMSO-d6 δ ppm = 39.51) δ 31.58, 39.26, 
63.18, 116.78, 127.13, 128.96, 130.07, 131,82, 136.91, 162.80 (d, J = 225 
Hz); 19F NMR (400 MHz, DMSO-d6) δ -111.94; Rf 0.52 
 
2-Fluorodimephenidine (2-FDMP, 22a) afforded 1.54 g (44%) of a white 
powder. MP 183 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 2.68 (d, 
3H, J = 7.2 Hz, CH3), 2.88 (d, 3H, J = 7.2 Hz, CH3), 3.48 (m, 1H, NHCHCH2), 
3.71 (m, 1H, NHCHCH2), 4.98 (dd, 1H, J = 7.2, 3.4 Hz, NHCHCH2), 7.00 – 
7.22 (m, 4H, Ar-H), 7.29 (m, 2H, Ar-H), 7.40 (m, 1H, Ar-H), 8.04 (m, 2H, Ar-
H), 11.49 (br s., 1H, NH); 13C NMR (400 MHz, DMSO-d6 δ ppm = 39.51) δ 
35.38, 41.92, 42.14, 63.04, 116.18, 116.41, 119.52, 125,42, 127.22, 128.83, 
129.51, 131.40, 136.26, 161.40 (d, J = 202.5 Hz); 19F NMR (400 MHz, DMSO-
d6) δ -115.80; Rf 0.63 
 
3-Fluorodimephenidine (3-FDMP, 22b) afforded 1.61 g (46%) of a white 
powder. MP 188 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 2.56 (d, 
3H, J = 7.2 Hz, CH3), 2.78 (d, 3H, J = 6.8 Hz, CH3), 3.40 (m, 1H, NHCHCH2), 
3.69 (m, 1H, NHCHCH2), 4.73 (m, 1H, NHCHCH2), 7.00 – 7.20 (m, 6H, Ar-H), 
7.30 – 7.40 (m, 2H, Ar-H), 7.46 (d, 1H, J = 5.8 Hz, Ar-H), 11.61 (br s., 1H, NH); 
13C NMR (400 MHz, DMSO-d6 δ ppm = 39.51) δ 35.63, 41.82, 69.40, 116.83, 
117.40, 117.62, 127.18, 128.83, 129.59, 131.19, 134.88, 136.59, 162.57 (d, J 
= 214 Hz); 19F NMR (400 MHz, DMSO-d6) δ –110.71; Rf 0.64 
 
4-fluorodimephenidine (4-FDMP, 22c) afforded 1.44 g (41%) of a white 
powder. MP 197 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 2.46 (s, 
3H, CH3), 2.72 (s, 3H, CH3), 3.39 (m, 1H, NHCHCH2), 3.65 (m, 1H, 
NHCHCH2), 4.70 (dd, J = 7.8, 3.2 Hz, NHCHCH2), 7.00 – 7.20 (m, 7H, Ar-H), 
7.62 (m, 2H, Ar-H), 11.58 (br s., 1H, NH); 13C NMR (400 MHz, DMSO-d6 δ 
ppm = 39.51) δ 35.70, 41.69, 69.19, 116.18, 127.03, 128.81, 129.61, 133.07, 
82 
136.70, 162.88 (d, J = 210.5 Hz); 19F NMR (400 MHz, DMSO-d6) δ –110.64; 
Rf 0.61 
 
2-Fluorodiephenidine (2-FDEP, 23a) afforded 1.89 g (54%) of a white powder. 
MP 181 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.17 (t, 3H, J = 7.2 
Hz, CH2CH3), 1.38 (t, 3H, J = 7.2 Hz, CH2CH3), 2.79 (m, 2H, CH2CH3), 3.23 
(m, 2H, CH2CH3), 3.41 (m, 1H, NHCHCH2), 3.80 (m, 1H, NHCHCH2), 4.85 (m, 
1H, NHCHCH2), 6.95 – 7.15 (m, 4H, Ar-H), 7.30 – 7.42 (m, 3H, Ar-H), 8.15 (t, 
2H, J = 7.8 Hz, Ar-H), 11.48 (br s., 1H, NH); 13C NMR (400 MHz, DMSO-d6 δ 
ppm = 39.51) δ 8.50, 35.50, 43.77, 44.97, 59.43, 115.54, 120.02, 125.06, 
128.25, 129.05, 130.84, 131.76, 135.75, 160.61 (d, J = 220 Hz); 19F NMR (400 
MHz, DMSO-d6) δ –117.89; Rf 0.59  
 
3-Fluorodiephenidine (3-FDEP, 23b) afforded 1.92 g (55%) of a white powder. 
MP 177 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.15 (t, 3H, J = 9.2 
Hz, CH2CH3), 1.33 (t, 3H, J = 8.5 Hz, CH2CH3), 2.74 (m, 1H, CH2CH3), 2.85 
(m, 1H, CH2CH3), 3.40 (m, 1H, NHCHCH2), 3.74 (m, 1H, NHCHCH2), 4.65 (m, 
1H, NHCHCH2), 7.00 – 7.20 (m, 5H, Ar-H), 7.30 – 7.40 (m, 3H, Ar-H), 7.65 (d, 
1H, J = 7.2 Hz, Ar-H), 11.45 (br s., 1H, NH); 13C NMR (400 MHz, DMSO-d6 δ 
ppm = 39.51) δ 9.23, 36.38, 45.11, 66.89, 116.59, 117.26, 127.01, 128.73, 
129.70, 131.07, 136.67, 162.44 (d, J = 210.5 Hz); 19F NMR (400 MHz, DMSO-
d6) δ –111.03; Rf 0.61 
 
4- Fluorodiephenidine (4-FDEP, 23c) afforded 2.38 g (68%) of a white powder. 
MP 177 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 1.18 (t, 3H, J = 7.8 
Hz, CH2CH3), 1.36 (t, 3H, J = 7.2 Hz, CH2CH3), 2.73 (m, 2H, CH2CH3), 3.16 
(m, 2H, CH2CH3), 3.41 (m, 1H, NHCHCH2), 3.78 (m, 1H, NHCHCH2), 4.66 (m, 
1H, NHCHCH2), 7.00 – 7.25 (m, 7H, Ar-H), 7.70 (d, 2H, J = 7.4 Hz, Ar-H), 
11.40 (br s., 1H, NH); 13C NMR (400 MHz, DMSO-d6 δ ppm = 39.51) δ 9.40, 
36.44, 44.79, 45.13, 66.75, 115.92, 129.96, 128.71, 129.70, 132.91, 132.99, 
136.84, 162.89 (d, J = 218.5 Hz); 19F NMR (400 MHz, DMSO-d6) δ –111.29; 
Rf 0.64 
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2-Fluorotrifluoroephenidine (2-FTFEP, 24a) afforded 1.44 g (41%) of a white 
powder. MP 204 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 3.15 (m, 
1H, CH2CF3), 3.50 – 4.00 (m, 3H, CH2CF3, NHCHCH2), 4.71 (m, 1H, 
NHCHCH2), 7.00 – 7.50 (m, 8H, Ar-H), 7.91 (d, 1H, J = 7.8 Hz, Ar-H), 9.17 (br 
s., 2H, NH); 13C NMR (400 MHz, DMSO-d6 δ ppm = 39.51) δ 46.50, 57.21, 
116.24, 123.79, 126.92, 129.12, 129.57, 131.65, 137.59, 161.75 (d, J = 221.5 
Hz); 19F NMR (400 MHz, DMSO-d6) δ –66.20, -117.81; Rf 0.55 
 
3-Fluorotrifluoroephenidine (3-FTFEP, 24b) afforded 1.29 g (37%) of a white 
powder. MP 211 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 3.15 (m, 
1H, CH2CF3), 3.40 – 4.00 (m, 3H, CH2CF3, NHCHCH2), 4.49 (m, 1H, 
NHCHCH2), 7.05 (m, 2H, Ar-H), 7.15 – 7.25 (m, 4H, Ar-H), 7.38 (m, 3H, Ar-H), 
9.15 (br s., 2H, NH); 13C NMR (400 MHz, DMSO-d6 δ ppm = 39.51) δ 48.25, 
56.17, 115.91, 122.47, 124.93, 128.19, 129.54, 129.91, 130.82, 131.53, 
134.63, 161.69 (d, J = 217 Hz); 19F NMR (400 MHz, DMSO-d6) δ –66.20, -
110.54; Rf 0.48 
 
4-Fluorotrifluoroephenidine (4-FTFEP, 24c) afforded 1.57 g (45%) of a white 
powder. MP 206 °C; 1H NMR (400 MHz, DMSO-d6 δ ppm = 2.50) δ 3.12 (m, 
1H, CH2CF3), 3.40 – 4.00 (m, 3H, CH2CF3, NHCHCH2), 4.52 (m, 1H, 
NHCHCH2), 7.00 (m, 3H, Ar-H), 7.10 – 7.25 (m, 4H, Ar-H), 7.50 (d, 2H, J = 7.4 
Hz, Ar-H), 9.08 (br s., 1H, NH); 13C NMR (400 MHz, DMSO-d6 δ ppm = 39.51) 
δ 45.89, 64.11, 116.33, 127.89, 128.54, 129.18, 131.89, 136.91, 162.15 (d, J 
= 208.8 Hz); 19F NMR (400 MHz, DMSO-d6) δ –66.20, -110.79; Rf 0.50                                     
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2.2. Presumptive Test Reagents 
Presumptive tests reagents were prepared according to the United Nations 
recommended guidelines.118 The following standard presumptive tests applied 
in this study: (i) Marquis; (ii) Mandelin; (iii) Simon’s; (iv) Robadope’s; (v) 
Scott’s; (vi) Zimmerman test(s). Sample solutions were prepared at 10 mg mL-
1 by dissolving the reference standards in distilled water. Negative control 
samples (distilled water) were used in all tests in order to indicate clearly when 
a positive result occurred.  
 
Marquis Test: 1% formaldehyde (37% aqueous solution) in concentrated 
sulphuric acid (10 mL). 5 drops of test sample in distilled water (10 mg mL-1) 
was placed into a dimple well of a white spotting tile and 5 drops of the test 
reagent added. The Marquis test was used on all synthesised samples to 
presumptively identify alkaloids. Any immediate colour change or other 
noticeable effect occurring was noted and observations were made again after 
a 5 minute period.  
 
Mandelin Test: 1% ammonium metavanadate in concentrated sulphuric acid 
(10 mL). 5 drops of test sample in distilled water (10 mg mL-1) was placed into 
a dimple well of a white spotting tile and 5 drops of the test reagent added. 
The Mandelin test was used on all synthesised samples to presumptively 
identify alkaloids. Any immediate colour change or other noticeable effect 
occurring was noted and observations were made again after a 5 minute 
period.  
 
Simon’s Test: Reagent 1: 2% aqueous sodium carbonate solution (10 mL); 
Reagent 2: 1% aqueous sodium nitroprusside solution (10mL); Reagent 3: 
50% methanolic acetaldehyde solution (10 mL). 5 drops of test sample in 
distilled water (10 mg mL-1) was placed into a dimple well of a white spotting 
tile and 5 drops of the test reagent added. The Simon’s test was used on all 
synthesised samples to presumptively identify alkaloids and any secondary 
amines. Any immediate colour change or other noticeable effect occurring was 
noted and observations were made again after a 5 minute period.  
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Robadope’s Test: Reagent 1: 2% aqueous sodium carbonate solution (10 
mL); Reagent 2: 1% aqueous sodium nitroprusside solution (10 mL); Reagent 
3: 50% methanolic acetone solution (10 mL). 5 drops of test sample in distilled 
water (10 mg mL-1) was placed into a dimple well of a white spotting tile and 5 
drops of the test reagent added. The Robadope’s test was used on all 
synthesised samples to presumptively identify alkaloids and primary amines. 
Any immediate colour change or other noticeable effect occurring was noted 
and observations were made again after a 5 minute period.  
 
Scott’s Test: 1% cobalt thiocyanate in a 50% aqueous glycerine solution (10 
mL). 5 drops of test sample in distilled water (10 mg mL-1) was placed into a 
dimple well of a white spotting tile and 5 drops of the test reagent added. The 
Scott’s test was used on all synthesised samples to presumptively identify 
cocaine and other tertiary amines. Any immediate colour change or other 
noticeable effect occurring was noted and observations were made again after 
a 5 minute period. 
 
Zimmerman Test: Reagent 1: 1% solution of 1,3-dinitrobenzene in methanol 
(10 mL); Reagent 2: 15% aqueous potassium hydroxide solution (10 mL). 5 
drops of test sample in distilled water (10 mg mL-1) was placed into a dimple 
well of a white spotting tile and 5 drops of the test reagent added. The 
Zimmerman test was used on all synthesised samples to presumptively 
identify cathinones. Any immediate colour change or other noticeable effect 
occurring was noted and observations were made again after a 5 minute 
period. 
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2.3. Thin Layer Chromatography 
Thin layer chromatography (TLC) was carried out on aluminium-backed SiO2 
plates (Merck, Germany) and spots were visualised using ultra-violet light (254 
nm). The mobile phase used was dichloromethane: methanol (9:1 v/v) 
containing 0.8% ammonia (7 N in methanol). The developed plate was viewed 
under UV light (254 nm) and any spots noted. The plate was sprayed with 
modified Dragendorff-Ludy-Tenger reagent the blood-red spots marked with a 
pencil and the Retention Factor (Rf) calculated for each analyte.102  For all 
diphenidine and ephenidine derivatives, including the halogenated samples, 
Relative Retention Factors (RRf) were calculated with respect to diphenidine 
(13a). Six repetitive tests of all compounds were conducted and negative 
control samples were used in all tests. 
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2.4. Gas Chromatography – Mass Spectroscopy (GC-MS) 
2.4.1. GC-MS of diphenidine derivatives 
An Agilent 6850 GC connected to a MS5973 mass selective detector (Agilent 
Technologies, Wokingham, UK) was used to perform GC-MS analysis on the 
thirteen diphenidine derivatives (10a–10m, Chapter 4). The mass 
spectrometer was operated in the electron ionisation mode at 70 eV. 
Separation was achieved with a capillary column (HP5 MS, 30 m Å~ 0.25 mm 
i.d. 0.25 μm), using a non-polar (5%-phenyl)-methylpolysiloxane stationary 
phase, with helium as the carrier gas at a constant flow rate of 1.0 mL min-1. 
Manual injections were performed with the GC injection temperature set to 
280°C and the mass selective detector split temperature set to 300°C. The 
split ratio was set to 100:1, while the MS source and quadrupole temperatures 
were set at 230°C and 150°C respectively. Mass spectra were obtained in full 
scan mode (50–550 amu). All samples (qualitative analysis) were prepared as 
1 mg mL-1 solutions in methanol. Eicosane was added to each sample (1 mg 
mL-1) and a 2 μL injection volume was used. Three commonly encountered 
adulterants benzocaine, caffeine and procaine were added into the mixture. 
 
2.4.2. GC-MS of cathinones, amphetamines, halogenated 
diphenidine derivatives, ephenidines and diphenidine analogues    
GC-MS analysis of all fluorinated cathinone and amphetamine regioiosmers 
(chapter 3), halogenated diphenidines (chapter 5), diphenidine analogues 
(chapter 6) and the fluorinated ephenidine regioisomers (chapter 7), was 
performed on a 7890 B GC system connected to a 5977B mass spectrometer 
(Agilent Technologies, Wokingham, UK). Similar to the diphenidine analysis, 
an electron ionisation mode at 70 eV was used with a HP5 MS capillary column 
(30 m Å~ 0.25 mm i.d. 0.25 μm), using a non-polar (5%-phenyl)-
methylpolysiloxane stationary phase and helium as the carrier gas at a flow 
rate of 1 mL min-1. The split ratio was set to 50:1 with the MS source and 
quadrupole temperatures set at 230°C and 150°C respectively. All samples 
were again prepared as 1 mg mL-1 solutions in methanol for initial qualitative 
analysis with eicosane added as an internal standard at 1 mg mL-1, before 
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being diluted 1 in 10 to create a 100 μg mL-1 sample and eicosane solution for 
analysis. 1 μL of sample was injected using an Agilent Technologies 7693 
Autosampler (Agilent Technologies, Wokingham, UK). 
 
2.4.3. Oven Temperature Programmes 
2.4.3.1. Initial screening method 1 
All thirteen of the diphenidine derivatives (13a–13m) along with the 
halogenated derivatives (20a–20l) and the polyfluorinated ephenidine 
regioisomers (15d–15l) were run on an initial screening method. The oven 
temperature programme can be seen in Table 7. 
 
Table 7: Oven temperature programme for the initial screening of diphenidine and 
ephenidine derivatives  
Time (min) Temperature (oC) Rate (oC min-1) Hold Time (min) 
0 60-300 10 2 
 
2.4.3.2. Initial screening method 2 
All the fluorinated cathinone and amphetamine derivatives along with the 
monofluorinated diphenidine analogues were run on a different initial 
screening run to determine whether samples could be initially separated. This 
oven temperature programme can be seen in Table 8.  
 
Table 8: Oven temperature programme for the initial screening of monofluorinated 
cathinones, amphetamines and diphenidine analogues 
Time (min) Temperature (oC) Rate (oC min-1) Hold Time (min) 
0 50-290 30 15 
 
2.4.3.3. Developed cathinone and amphetamine method 
A new oven temperature programme was developed to help further separate 
the regioisomers of fluoroamphetamine (FA, 4a–4c), fluoromethcathinone 
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(FMC, 8a–8c) and trifluoromethylmethcathinone (TFMMC, 9a-9c) isomers. 
Table 9 shows the developed oven temperature programme.  
Table 9: Developed oven temperature programme for the separation of fluorinated 
cathinone and amphetamine regioisomers 
Time (min) Temperature (oC) Rate (oC min-1) Hold Time (min) 
0 50-290 30 15 
 
2.4.3.4. Developed diphenidine derivatives method 
A new oven temperature programme was developed for the separation of a 
range of diphenidine derivatives (13a–13m). The oven temperature 
programme can be seen in Table 10. 
 
Table 10: Developed oven temperature programme for the separation of thirteen 
diphenidine derivatives 
Time (min) Temperature (°C) Rate (°C min-1) Hold Time (min) 
0 60 – 170 10 13 
24 170 – 200 20 12 
37.5 200 – 260 10 0 
43.5 260 – 280 20 1 
 
2.4.3.5. Developed halogenated diphenidines method 
An oven programme was developed for all twelve halogenated diphenidine 
derivatives (20a-20l) in order to achieve separation. The temperature 
programme can be seen in Table 11. The oven temperature used produced 
an overall run time of 33 minutes. 
 
Table 11: Oven temperature programme for the separation of the halogenated diphenidines 
Time (min) Temperature (oC) Rate (oC min-1) Hold Time (min) 
0 80-210 10 0 
13 210-240 2 0 
28 240-280 20 3 
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2.4.3.6. Developed diphenidine analogues method 
A developed method was created for the separation of the diphenidine 
analogues. A single ion monitoring (SIM) detection mode was also used for 
the identification of classes of compounds with the SIM ions chosen shown in 
Table 12 and the developed oven temperature programme shown in Table 12.  
 
Table 12: SIM ions used for all of the diphenidine analogue regioisomers 
Compound Abbreviation  (No.) SIM ion used 
fluoroephenidine FEP (15a–15c) 152.1 
fluorolintane FL (19a–19c) 178.1 
fluphenidine FP (20a–20c) 192.1 
fluoromephenidine FMP (21a–21c) 138.1 
fluorodimephenidine FDMP (22a–22c) 152.1 
fluorodiephenidine FDEP (23a–23c) 180.1 
fluorotrifluoroephenidine FTFEP (24a–24c) 206.1 
 
Table 13: Developed oven temperature programme for the diphenidine analogues 
Time (min) Temperature (oC) Rate (oC min-1) Hold Time (min) 
0 90 - 160 5 0 
14 160 - 180 1 0 
34 180 - 290 30 2 
 
2.4.3.7. Developed polyfluorinated ephenidines method 
A developed oven temperature programme was made for the attempted 
separation of the polyfluorinated ephenidines (15d–15l). The temperature 
programme can be seen in Table 14. 
 
Table 14: Developed oven temperature programme for the attempted separation of the 
polyfluorinated ephenidine isomers 
Time (min) Temperature (oC) Rate (oC min-1) Hold Time (min) 
0 170-220 2 0 
25 220-240 10 0 
27 240-300 30 2 
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2.4.4. Standards and test solution preparation 
2.4.4.1. Reference standard preparation 
All reference samples were prepared as 100 μg mL−1 solutions for initial GC-
MS screening analysis. 4–5 mg of the reference materials were taken and 
dissolved in the matching volume of a 1 mg mL-1 eicosane in methanol solution 
in order to create a 1 mg mL-1 sample and eicosane solution. This was then 
diluted by a factor of ten in methanol to create the final 100 μg mL−1 sample 
and eicosane solution. Eicosane was added as an internal reference. 
 
2.4.4.2. Fluorinated cathinone, amphetamine and diphenidine 
analogues calibration standards 
Five calibration standards were prepared for the fluorinated cathinone, 
amphetamine and diphenidine analogue isomers. Calibration solutions were 
prepared in the range of 100–500 μg mL-1 with each solution containing 100 
μg mL-1 eicosane as an internal standard. Each calibration standard was run 
6 times. Two percentage recovery samples were prepared at 80%, 100% and 
120% of a target concentration of 300 μg mL-1 and injected twice.  
 
2.4.4.3. Diphenidine derivatives calibration standards 
10.0 mg of analytes (10a–10m), benzocaine, caffeine and procaine were 
weighed into a 20.0 mL clear glass volumetric flask and diluted to volume with 
methanol to give a solution containing all components at 500 μg mL−1. This 
solution was then further diluted with methanol and 1 mL of eicosane (1.0 mg 
mL-1 in methanol) added (in each case) to give calibration standards 
containing 25.0 μg mL−1, 50.0 μg mL−1, 100.0 μg mL−1, 200.0 μg mL−1 and 
250.0 μg mL−1 of each analyte and the internal standard at 100 μg mL-1.  Two 
percentage recovery samples were prepared at 80%, 100% and 120% of a 
target concentration of 100 μg mL-1 and injected twice.  
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2.4.4.4. Halogenated diphenidine calibration standards 
Five calibration standards were prepared for the halogenated diphenidine 
derivatives in the range 100–300 μg mL-1. All solutions contained 100 μg mL-
1 eicosane as an internal standard. An original stock solution was made at 1 
mg mL-1 before dilution and all solutions were repeated six times. Two 
percentage recovery samples were prepared at 80%, 100% and 120% of a 
target concentration of 200 μg mL-1 and injected twice. 
 
2.4.4.5. Diphenidine analogues calibration standards 
Five calibration standards were prepared for the diphenidine analogues in the 
range 100–500 μg mL-1. All solutions contained 100 μg mL-1 eicosane as an 
internal standard. An original stock solution was made at 1 mg mL-1 before 
dilution and all solutions were repeated six times. Two percentage recovery 
samples were prepared at 80%, 100% and 120% of a target concentration of 
300 μg mL-1 and injected twice. 
 
2.4.5. Street sample preparation 
2.4.5.1. Fluoroamphetamine street samples 
Two street samples were obtained from Greater Manchester Police (GMP). 
GC-MS solutions were initially made at a concentration of 100 μg mL-1 for 
qualitative analysis. A solution was then prepared at a concentration of 300 μg 
mL-1 containing 100 μg mL-1 eicosane in order to fall in the middle of the 
calibration series. Both test samples were injected in duplicate.  
 
2.4.5.2. Diphenidine street sample analysis 
The street samples of diphenidine (1.0 g) and methoxphenidine (1.0 g) were 
obtained as off-white crystalline powders, from “Buy Research Chemicals UK” 
(http://www.brc-chemicals.com) and used without further purification. The 
individual samples were homogenized and arbitrarily labelled, SS-1 and SS-
2, prior to analysis. 10.0 mg of the test substance was weighed into a 50.0 mL 
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clear glass volumetric flask and diluted to volume with methanol. This solution 
was then further diluted (1:2, 10 mL) with methanol to give a test solution 
containing 100.0 μg mL−1 of the sample. The test samples were injected in 
duplicate. 
 
10.0 mg of the street sample was weighed (in triplicate) accurately into a 50.0 
mL clear glass volumetric flask and diluted to volume with methanol for 
qualitative analysis. This solution was then further diluted (1:2, 10 mL) with 
methanol and 1.0 mL of eicosane (1.0 mg mL-1 in methanol) added (in each 
case) to give a test solution containing 100.0 μg mL−1 of the sample and the 
internal standard at 100.0 μg mL-1. The test samples were injected in duplicate. 
 
2.4.5.3. Halogenated diphenidine street samples 
Two street samples were obtained from GMP presumed to contain a 
halogenated diphenidine derivative. The samples were prepared at a 
concentration of 100 μg mL-1- for initial qualitative screening. Solutions of 200 
μg mL-1 were then prepared for quantitative analysis, of both street samples, 
in order to fit with the calibration series. 100 μg mL-1 eicosane was also added 
to both solutions to fit with the calibration standards. Both test samples were 
injected in duplicate.  
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2.5. NMR spectroscopy 
Deuterated water (D2O) and deuterated dimethyl sulfoxide (DMSO) were used 
as the solvent of choice for the fluorinated cathinone and amphetamine 
isomers, while deuterated dichloromethane (DCM) and DMSO were used for 
the diphenidine derivatives and analogues. All deuterated solvents were 
purchased from Sigma-Aldrich. 1H NMR analysis was performed at 21.2 ⁰C 
with 8 scans and a relaxation delay of 5 seconds. The offset value was set at 
7.5 ppm scanning a range of 15 ppm in order to observe the amine proton in 
the diphenidine samples. Where D2O is used with the cathinone and 
amphetamine isomers, no amine proton will be observed due to the 
exchanging of this proton with deuterium ions. 13C NMR experiments were 
also run at 21.2 ⁰C using 2048 scans and a relaxation delay of 1 second. 19F 
NMR, run at 21.2 ⁰C, was obtained over 8 scans with an offset value of 0 ppm 
and chemical shift range of 400 ppm. A 3 second relaxation delay was applied 
to all samples.  
 
For all 19F NMR and 1H NMR compound screening, a 60 MHz Pulsar NMR 
spectrometer (Oxford Instruments, Oxfordshire, UK), performing 32 scans with 
a filter file of 8000 Hz and a relaxation delay of 5 seconds for a 1H NMR 
experiment. 19F NMR experiments were run using 16 scans and a 3 second 
relaxation delay with a filter file of 5000 Hz. 
  
All samples were made up with 20 mg of the hydrochloride salt dissolved in 
600 µL of solvent (33.3 mg mL-1) for 1H NMR experiments and 10 mg of sample 
in 600 µL of solvent (16.7 mg mL-1) for 19F NMR experiments for both 400 MHz 
and 60 MHz analysis. Trifluoroacetic acid (TFA, δ = -76.55 ppm) was added, 
as an internal standard, for the 19F NMR analysis, on both the 400 MHz and 
60 MHz spectrometers, at 0.03% v/v. 
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2.5.1. Quantitative 19F NMR on 60 MHz instrument 
In order to show the potential of using a 60 MHz NMR instrument, to perform 
quantitative analysis, a calibration series was performed with a couple of 
fluorinated examples from different classes. A stock solution was made by 
taking 75 mg of sample and dissolving into a 5 mL volumetric flask containing 
D2O for the cathinone and amphetamine isomers and DMSO–d6 for the 
diphenidine and ephenidine isomers (15 mg mL-1). A blank stock solution of 
D2O or DMSO-d6 was also made (5 mL). 0.5 µL of TFA (0.01% v/v) was added 
to both the sample stock solution and the blank solvent stock solution. Specific 
amounts of the sample stock solution were used and mixed with the blank 
solvent stock solution, to a total volume of 600 µL, in order to create samples 
ranging in concentration from 15 mg mL-1 to 5 mg mL-1. The volumes used in 
order to create the calibration standards can be seen in Table 15. 
 
Table 15: Calibration standard preparation for 19F NMR quantitative analysis 
Sample stock volume 
used (µL) 
Blank D2O stock volume 
used (µL) 
Concentration (mg mL-1) 
600 0 15 
480 120 12 
400 200 10 
320 280 8 
200 400 5 
 
2.5.2. Street sample preparation 
The two FA street samples were prepared at a concentration of 15 mg mL-1 
using a matching method to the preparation of the 15 mg mL-1 calibration 
solution. 0.1% v/v TFA was used as an internal standard in order to for 
integrated areas to be calculated.  
 
2.5.3. 60 MHz 2-dimensional NMR experiments 
19F NMR J-resolved and 19F-TOCSY (Total Correlation Spectroscopy) 
experiments were performed for the difluoroephenidine regioisomers using the 
60 MHz Pulsar spectrometer. All samples were prepared as 33.3 mg mL-1 
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solutions by dissolving 20 mg of DFEP samples in 600 µL of DMSO-d6. 0.03% 
v/v TFA was also added to the sample.  
 
For the 19F J-resolved experiment a 1250 cm-1 filter file was used with a 
relaxation delay of 3 seconds. An 8.4 µs 90⁰ pulse length and a 16.8 µs 180⁰ 
pulse length was used with 128 and 2048 points collected for the F1 and F2 
axis respectively. 32 scans were performed for the J-resolved experiment, 
while 8 scans were performed for the 19F TOCSY experiment. Offset 
frequencies were set in order for the spectra to be set at the midpoint of all 
fluorine chemical shift values representative of the compounds involved. A 
5000 Hz filter file was used for the TOCSY experiment with a 2-second 
relaxation delay and an 8.4 µs 90⁰ pulse length. Along the F1 and F2 axis, 128 
and 1024 points were collected respectively. 
     
97 
3. Chapter 3 – Fluorinated cathinones and 
amphetamines 
3.1. Overview 
Fluorinated amphetamine and cathinone derivatives have been encountered 
previously, with literature reported on the characterisation and attempted 
separation of these compounds.53, 82 Problems were seen with regards to full 
separation in the case of the fluoroamphetamines and tailing of peaks due to 
thermal degradation.4  
 
Based on this the synthetic fluoroamphetamine (4a–4c), fluoromethcathinone 
(8a–8c) and trifluoromethylmethcathinone (9a–9c) will be prepared and fully 
characterised (using a range of techniques) in order to confirm their structure 
with the published literature. A GC-MS method will be developed to separate 
all nine of the fluorinated compounds as well as produce mass spectroscopy 
data to use as reference spectra. 60 MHz NMR will be used in order to show 
the potential for its use as a replacement presumptive test with comparisons 
made to spectra produced on a 400 MHz instrument and differences between 
regioisomers reported.  
 
Qualitative analysis of the regioisomers will be obtained by utilising a 
developed GC-MS method and acquiring 19F NMR spectra on a 1.4 T NMR 
spectrometer. Calibration graphs will be created which will aid the 
determination of the amounts of amphetamine and cathinones present in 
potential street samples.  
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3.2. Synthesis 
The three fluoroamphetamine regioisomers (FA, 4a–4c, figure 28) were all 
prepared as hydrochloride salts at Manchester Metropolitan University, under 
Home Office license using the methods reported by Rosner et al 139 with 
purities shown to be >95%, by both GC-MS and NMR.  The compounds were 
prepared in the following yields: 37% (2-FA, 4a); 45% (3-FA, 4b) and 41% (4-
FA, 4c).   
 
Figure 28: Reaction scheme for the synthesis of FA isomers (4a–4c) 
The three fluoromethcathinone (FMC, 8a–8c, figure 29) isomers were 
prepared similarly, using the synthesis method reported by Archer et al.68 All 
reference samples were shown to have purities >95% with the following yields 
from the prerequisite 2-, 3- or 4-fluoropropiophenone: 57% (2-FMC, 8a); 49% 
(3-FMC, 8b); 61% (4-FMC, 8c) respectively. 
 
Figure 29: Reaction scheme for the synthesis of FMC isomers (8a–8c) 
Trifluoromethylmethcathinone hydrochlorides (TFMMC, 9a–9c, figure 30) 
were prepared at the University of Strathclyde under home office license, using 
previously reported methods from Khreit et al. 83 The hydrochloride salts were 
recrystallized from acetone to give reference materials with purities >95% with 
the following yields from the prerequisite 2-, 3- or 4-
trifluoromethylpropiophenone: 69% (2-TFMMC, 9a); 23% (3-TFMMC, 9b) and 
62% (4-TFMMC, 9c). 
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Figure 30: Reaction scheme for the synthesis of TFMMC isomers (9a – 9c) 
All samples tested were colourless to off–white powders with full structural 
characterisation carried out through 1H NMR (Figure 31 - Figure 36), 19F NMR 
(Table 166) 13C NMR (supplementary data: Figure 14 - Figure 19), and FTIR 
(supplementary data: Figure 63 - Figure 68). Purities of all samples was 
measured through GC-MS and 400 MHz NMR analysis. The hydrochloride 
salts were determined to be soluble (10 mg mL-1) in deionised water, 
methanol, dichloromethane and dimethyl sulfoxide. 
 
The three fluoroamphetamine regioisomers (4a–4c) show very similar 1H NMR 
spectra with slight differences in the aliphatic peak shifts and the only main 
differences occurring in the aromatic regions. This occurs due to the location 
of the fluorine substituent of the benzene ring and the changes in symmetry 
affecting the chemical shifts of the proton environments. In all three cases the 
peak representing the CH3 group can be seen at a chemical shift of 1.13 ppm. 
This shows coupling to the chiral centre proton at 3.38 ppm, in all three cases, 
in the corresponding 1H-1H COSY NMR spectra. This coalesces with the water 
peak at 3.33 ppm in the 1H NMR spectra so cannot be properly observed. In 
DMSO, the two different proton environments of the CH2 group adjacent to the 
chiral centre manifest as two separate peaks. These are observed at 2.69 and 
3.03 ppm. The amine protons are seen at 8.28 ppm representing three protons 
due to it being the hydrochloride salt of a primary amine. The aromatic region 
for the para-substituted fluoroamphetamine shows symmetry with only two 
peaks representing the four protons at chemical shifts of 7.17 and 7.30 ppm, 
with roofing effects observed. The aromatic regions for the ortho- and meta-
substituted isomers do not show the matching symmetry to the 4’ isomer. All 
aromatic regions show slight differences based on splitting patterns through 
the coupling to adjacent protons.  
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The fluoromethcathinone regioisomers (8a–8c) is similar to the 
fluoroamphetamine structure, however there are differences in the aliphatic 
region of the 1H spectra. The CH3 group adjacent to the chiral centre is seen 
at 1.46 ppm and shows coupling to the chiral centre proton in the 1H-1H COSY 
NMR. This is similar to the FA regioisomers with the chiral centre proton peak 
seen at 5.22 for the 3’ and 4’ isomers. The peak for the chiral proton in the 2’ 
isomer is shifted upfield, compared to the 3’ and 4’ isomers, to 4.89 ppm. The 
peak representing the CH3 adjacent to the amine is seen at 2.59 ppm and 
shows coupling to the amine proton at 9.55 ppm. In the 4’ isomer the amine 
peak is one peak representing the two amine protons, while the 3’ and 2’ 
isomers are split into 2 peaks representing two protons. The aromatic region 
peaks are seen between 7.2–8.5 ppm with the 4’ isomer again showing 
symmetry.  
 
The trifluoromethylmethcathinone (TFMMC, 9a–9c) isomers show similar 
aliphatic regions to the FMC isomers. The two CH3 groups are seen at 1.46 
and 2.59 ppm, which is similar to the FMC isomers. The chiral proton for the 
3’ and 4’ isomers can be seen at 5.25 ppm. This is again similar to the FMC 
isomers with the 2’ isomer shifted upfield in a similar manner. The aromatic 
regions between the three isomers show slight differences in order to 
distinguish between the three. The matching aromatic regions of both the FMC 
and TFMMC using 1H NMR spectroscopy can make it difficult to identify 
specific compounds.  
 
In order to help identify these compounds, 19F NMR spectroscopy was 
employed. The table of chemical shifts can be seen in Table 16, with an 
exemplar spectrum containing a mixture of the FMC and TFMMC shown in 
Figure 37. Trifluoroacetic acid (δ ppm = -76.55) was added in order to 
accurately measure the chemical shifts of each sample peak. From the results 
it is shown that the 19F nucleus in each compound has a distinctive chemical 
shift value that can be used for identification purposes. 
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Table 16: 19F NMR chemical shift values for all fluorinated amphetamine and cathinone 
regioisomers reference to TFA (δ ppm = -76.55) 
 
Compound 
no. 
Compound 19F chemical shift 
(δ ppm) 
4a 2-fluoroamphetamine -115.40 
4b 3-fluoroamphetamine -112.97 
4c 4-fluoroamphetamine -117.28 
8a 2-fluoromethcathinone -110.61 
8b 3-fluoromethcathinone -112.72 
8c 4-fluoromethcathinone -103.02 
9a 2-trifluoromethylmethcathinone -58.89 
9b 3-trifluoromethylmethcathinone -63.70 
9c 4-trifluoromethylmethcathinone -64.18 
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Figure 31: General 400 MHz 1H NMR spectrum for the 4-fluroamphetamine hydrochloride (4-FA, 4a) run in DMSO-d6 (δ ppm = 2.50) 
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 Figure 32: Stacked 400 MHz aliphatic region of the three fluoroamphetamine (FA, 4a – 4c) hydrochloride regioisomers run in DMSO-d6 (δ ppm = 2.50)  
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Figure 33: Stacked 400 MHz aromatic region of the three fluoroamphetamine (FA, 4a – 4c) hydrochloride regioisomers run in DMSO-d6 (δ ppm = 2.50)    
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Figure 34: General 400 MHz 1H NMR spectrum for 4-fluoromethcathinone (4-FMC, 8c) run in DMSO-d6 (δ ppm = 2.50) 
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Figure 35: Stacked 400 MHz aromatic region of the three fluoromethcathinone (FMC, 8a – 8c) hydrochloride regioisomers run in DMSO-d6 (δ ppm = 2.50)  
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Figure 36: Stacked 400 MHz aromatic region of the three trifluoromethylmethcathinone (FMC, 9a – 9c) hydrochloride regioisomers run in DMSO-d6 (δ ppm = 
2.50)    
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Figure 37: 19F NMR spectrum for a mixture of FMC (8a–8c) and TFMMC (9a–9c) regioiosmers with TFA added as an internal reference (δ ppm = -76.55) 
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3.3. Presumptive Testing 
Presumptive testing was carried out on all of the fluoroamphetamine (4a–4c), 
fluoromethcathinone (8a–8c) and trifluoromethylmethcathinone (9a–9c) 
regioisomers using the United Nations recommended guidelines.118 A range of 
tests were used to fully detail possible colour changes including (i) Marquis; 
(ii) Mandelin; (iii) Simon’s; (iv) Robadope’s; (v) Scott’s and (vi) Zimmerman 
test reagents. A solution of each reference standard (10 mg mL-1) was 
prepared in deionised water and a couple of drops placed into a dimple well of 
a white spotting tile. The required presumptive test reagent (1-2 drops) was 
then added and any colour change upon initial addition of the reagents were 
noted and observations were made again after a five minute time period (Table 
17). Blank solutions of deionised water were used in order to show the natural 
colour of the test reagents prior to being added to sample solution. 
 
All monofluorinated cathinone and amphetamine regioisomers produce a 
positive reaction when tested against the Marquis reagent. It is expected that 
the colour change occurs due to the reaction of compound molecules with 
sulfuric acid with the same mechanism that has been reported for MDMA 
(Figure 38).3, 141   
 
Figure 38: Reaction scheme for the reaction between methcathinone and the Marquis 
reagent 
No positive reaction was seen for either the fluorinated amphetamines or 
cathinones when tested against the Mandelin and Scott’s reagents.  
 
It has been reported that altering the Simon’s reagent by changing the 
acetaldehyde with acetone, to produce the Robadope’s reagent, can help with 
the initial detection of primary amines.142 This is different to the Simon’s 
reagent that is used to detect secondary amines. The use of these two 
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reagents can help to distinguish between the monofluorinated amphetamine 
and methcathinones. All the fluoromethcathinone (8a–8c) and 
trifluoromethylmethcathinone (9a–9c) regioisomers produce green/brown 
colours with Simon’s reagent, however the difference in colours is not 
significant enough to be able to identify unknown samples. The 
fluoroamphetamine (4a–4c) regioisomers do not react with Simon’s reagent, 
but give a brown colour with Robadope’s reagent, with no differences in colour 
between each positional isomer.  
 
The Zimmerman reaction relies on the presence of an activated methylene 
group, which under alkaline conditions, reacts with 1,3-dinitrobenzene to give 
an intensely coloured Meisenheimer complex (Figure 39).143 This is the reason 
the six cathinone samples produce a positive result with the Zimmerman test, 
however it cannot be used to distinguish between the different regioisomers 
within a class. The fluoroamphetamine regioisomers do not produce a positive 
reaction with the Zimmerman reagent due to the loss of the carbonyl.  
 
Figure 39: Reaction scheme for the reaction between methcathinone (6) and the 
Zimmerman reagent 
From the colour changes it is observed that the Marquis reagent cannot 
discriminate between any of the nine compounds. The Zimmerman reagent 
can be used as a selective test for the presence of the cathinone regioisomers 
with the Simon’s reagent providing a clearer indication that the substances are 
methcathinones (secondary amines). The combination of the Zimmerman and 
Simon’s reagent allow discrimination between the three fluoromethcathinone 
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(FMC) regioisomers, however the discrimination between the three 
trifluoromethylmethcathinone (TFMMC) regioisomers is less clear. The 
Robadope reagent provides a more selective test for the fluoroamphetamine 
(FA) regioisomers, however it does not provide any discrimination between the 
three compounds.
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Table 17: Colour changes reported for fluoroamphetamine (4a–4c), fluoromethcathinone (8a–8c) and trifluoromethylmethcathinone (9a–9c) regioisomers 
using a range of presumptive test reagents   
 Marquis Mandelin  Simon’s Robadope Scott’s Zimmerman 
 
Colour change 
Colour after 5 
minutes 
Colour change 
Colour  after 5 
minutes 
Colour change 
Colour after 
5 minutes 
Colour change 
Colour after 
5 minutes 
Colour 
change 
Colour 
change after 
5 minutes 
Colour 
change 
Colour change 
after 5 minutes 
4a orange colourless - - - - Brown brown - - - - 
4b orange colourless - - - - Brown brown - - - - 
4c orange colourless - - - - Brown brown - - - - 
8a orange/yellow colourless - -- green green - - - - light red light red 
8b yellow colourless - - pale brown pale brown - - - - purple purple 
8c yellow/orange colourless - - grey grey - - - - purple purple 
9a yellow colourless - - green green - - - - red red 
9b orange colourless - - pale brown pale brown - - - - light purple light purple 
9c orange colourless - - pale brown pale brown - - - - light purple light purple 
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3.4. Gas chromatography – mass spectroscopy 
All amphetamine and cathinones were analysed using gas chromatography–
mass spectroscopy (GC-MS). Samples were prepared with a simple solvation 
in methanol (1 mg mL-1) and dilution (100 μg mL-1) with no derivatisation 
required. All samples were run individually before being run as mixtures in 
order to determine retention times and elution orders. A table of retention times 
for all compounds can be seen in Table 18, along with relative retention times 
in relation to the internal standard eicosane (E) 
 
From the initial screening method it was seen that all the fluoroamphetamine 
regioisomers eluted rapidly (< 4 mins) and were only just seen after the mass 
spectrometer solvent delay. There is no clear separation in the retention times 
as indicated in the Relative retention times (RRt). The FMC and TFMMC 
regioisomers also elute very quickly on the screening run with elution times 
between 4.6 and 4.8 mins. The small gap between elution times for the FMC 
and TFMMC isomers shows that there is no clear separation between the six 
compounds. A new method was developed in order to try to separate all 
isomers based on retention times. This was done by slowing the rate initially 
from 30°C min-1 to 10°C min-1 before slowing the ramp down further to 2°C 
min-1 to begin to separate the FMC and TFMMC isomers. The table showing 
retention times and relative retention times to eicosane, for the developed 
method, can be seen in Table 19.  
 
From the developed method retention times it is seen that the compounds 
begin to show greater separation than previously reported. The retention times 
increase compared to the screening method and this helps to ensure that 
peaks are not lost, in the solvent delay, as the methanol is pushed through the 
column by the helium carrier gas. The fluoroamphetamine regioisomers begin 
to separate compared to the initial screen where coelution between the 3’ and 
4’ positional isomers was an issue. The superimposed spectra of all three 
fluoroamphetamine isomers can be seen in Figure 40 and shows that peaks 
can be distinguished, although baseline separation has not been achieved. 
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The superimposed spectra of both the FMC and TFMMC isomers can be seen 
in Figure 41. This image shows that all six of the fluorinated cathinone 
compounds can be distinguished based on retention times. The elution order 
can be determined based on the developed method with the order being as 
follows: 3-TFMMC  2-FMC  4-TFMMC  3-FMC  4-FMC  2-TFMMC. 
The 3-TFMMC and 2-FMC peaks are not fully baseline resolved, however all 
other compounds are fully baseline separated. This shows that using the 
developed method unknown street samples that contain either fluorinated 
amphetamines or cathinones can be identified. The RRt recorded suggest that 
there may not be any baseline separation, however the values only appear 
close to 2.d.p due to the significantly higher retention time of the eicosane 
(30.85 minutes compared to 7.28 minutes).  
 
The developed method was validated individually for a mixture of the 
fluoromethcathinone isomers and then the trifluoromethylmethcathinone 
isomers. All correlation coefficients are above an acceptable level (>0.99) for 
the FMC and TFMMC compounds, with limits of detection (LOD) and limits of 
quantification (LOQ) values shown in Table 20. LOD values range between 
8.0 – 16.0 μg mL-1 and LOQ values ranging from 24.0 – 45.0 μg mL-1. All 
relative standard deviation percentages fall below an acceptable 5% and can 
also be seen in Table 20. The retention times have been listed to 2.d.p as a 
difference in 0.01 minutes will begin to see peaks start to separate from one 
another even though the relative retention time (RRt) appears to have the 
same value.   
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Table 18: GC retention times for the monofluorinated amphetamine (4a–4c) and cathinone 
(8a–8c) regioisomers and trifluoromethylmethcathinone (9a–9c) regioisomers, including 
relative retention times (RRt) relative to eicosane (E, Rt = 7.281 mins) 
 
  
Compound 
no. 
Compound 
Abbreviation 
Compound retention time 
(Rt / mins) 
Relative Retention 
time (RRt) 
4a 2-FA 3.80 0.52 
4b 3-FA 3.84 0.53 
4c 4-FA 3.85 0.53 
8a 2-FMC 4.67 0.64 
8b 3-FMC 4.71 0.65 
8c 4-FMC 4.73 0.65 
9a 2-TFMMC 4.76 0.65 
9b 3-TFMMC 4.61 0.63 
9c 4-TFMMC 4.65 0.64 
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Table 19: GC retention times for the monofluorinated amphetamine (4a–4c) and cathinone 
(8a–8c) regioisomers and trifluoromethylmethcathinone (9a–9c) regioisomers, including 
relative retention times (RRt) relative to eicosane (E, Rt = 30.850 mins) using the developed 
GC oven temperature programme 
 
  
Compound 
no. 
Compound 
Abbreviation 
Compound retention time 
(Rt / mins) 
Relative Retention 
time (RRt) 
4a 2-FA 5.25 0.17 
4b 3-FA 5.39 0.17 
4c 4-FA 5.43 0.18 
8a 2-FMC 10.12 0.33 
8b 3-FMC 10.48 0.34 
8c 4-FMC 10.68 0.35 
9a 2-TFMMC 11.07 0.36 
9b 3-TFMMC 10.06 0.33 
9c 4-TFMMC 10.33 0.33 
117 
 
 
Figure 40: Superimposed GC chromatographs of the three fluoroamphetamine (4a–4c) 
regioisomers 
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Figure 41: Superimposed GC chromatographs for the fluoromethcathinone (FMC, 8a–8c) 
and trifluoromethylmethcathinone (TFMMC, 9a–9c) regioisomers 
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Table 20: Validation values for the FMC (8a–8c) and TFMMC (9a–9c) regioisomers including LOD, LOQ and %RSD for all calibration standards 
    Precision (%RSD) n = 6 
Analyte 
Correlation 
coefficient (R2) 
LOD 
(μg mL-1) 
LOQ 
(μg mL-1) 
100 μg mL-1 200 μg mL-1 300 μg mL-1 400 μg mL-1 500 μg mL-1 
2-FMC, 8a 0.994 14.19 40.96 0.94 4.91 3.10 0.38 0.26 
3-FMC, 8b 0.992 15.96 44.22 2.82 2.05 1.92 0.63 0.38 
4-FMC, 8c 0.990 8.05 24.21 4.35 4.18 2.43 0.83 0.44 
2-TFMMC, 9a 0.993 11.50 33.82 2.48 3.30 1.92 2.80 1.88 
3-TFMMC, 9b 0.993 8.89 25.63 0.98 1.00 1.20 0.47 1.33 
4-TFMMC, 9c 0.994 8.88 26.72 1.63 1.41 1.37 0.50 1.03 
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The mass spectroscopy data can also be used to help identify the compound 
present with the FMC, TFMMC and FA classes all producing different spectra. 
The mass spectroscopy data cannot, however, be used to distinguish between 
isomers within a class. The spectra for each of the three classes can be seen 
in Figure 45 – Figure 46. The FA isomers shows a base peak of m/z = 44.1, 
which represents an ion containing the +CH2CH3 chain bonded to the amine, 
along with a secondary peak of 109 representing a fluorine substituted 
tropylium cation (Figure 42).  
 
Figure 42: MS fragmentation for the fluoroamphetamine (FA, 4a–4c) regioisomers 
The FMC isomers show a primary base peak with an m/z of 58 representing 
the amine bonded to the methyl group and a +CH2CH3 similar to the 
fluoroamphetamine fragmentation. The secondary base peak of m/z 95.0 is 
produced from the phenyl ring with the fluorine substituent. There is also a 
peak with an m/z charge of 123.0 representing the substituted phenyl with the 
addition of the carbonyl group (Figure 43) 
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Figure 43: MS fragmentation for the fluoromethcathinone (FMC, 8a–8c) regioisomers 
The TFMMC isomers have a similar mass spectroscopy fragmentation pattern 
to the FMC isomers with a base peak of m/z 58 and a peak at m/z 95.0. 
However, the main difference with the TFMMC isomers is that the secondary 
base peak has an m/z value of 145.0. This represents the phenyl cation with 
the trifluoromethyl group substituent (Figure 44). 
 
Figure 44: MS fragmentation pattern for the trifluoromethylmethcathinone (TFMMC, 9a-9c) 
regioisomers 
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The differences in the mass spectroscopy helps to identify the class of 
compound present with the retention times helping to identify which isomer is 
present. It is also seen in the chromatographs of all compounds that there is 
no tailing due to thermal degradation with symmetry shown in all peaks. This 
could be a result of using higher split ratios or lower injection volumes and inlet 
temperatures.    
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Figure 45: Mass spectra for the fluoroamphetamine (4a–4c) and fluoromethcathinone (8a-
8c) 
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Figure 46: Mass spectrum for the trifluoromethylmethcathinone (9a–9c) regioisomers 
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3.5. 60 MHz NMR presumptive testing 
All fluorinated amphetamines and cathinones were run on a 60 MHz Pulsar 
NMR instrument to acquire 1H and 19F NMR data. This was done in order to 
show the possibility of identifying these compounds in unknown street 
samples. The spectra produced for both the 1H and 19F NMR experiments 
produce very similar characteristic patterns to those produced when 
structurally elucidating compounds synthesised, using a 400 MHz instrument. 
The splitting patterns can still be seen, however the resolution is reduced due 
to the reduced power of the external magnetic field. Due to the reduced 
resolution peaks appear broader, however comparison of spectra can still 
show differences between isomers within a class. This means that the 60 MHz 
instrument can be used as a presumptive test by providing structural 
information to enable regioisomers to be distinguished by eye.  
 
All spectra were run in DMSO-d6 (δ ppm = 2.50) in order to provide a clear 
reference point for all spectra which could then be stacked to facilitate ease of 
comparison. In the case of 19F experiments, trifluoroacetic acid was added as 
an internal standard (δ ppm = -76.55) in order to produce accurate sample 
chemical shift values. In all 1H cases a water peak is seen at a chemical shift 
of 3.30 ppm. In the case of the fluoroamphetamine regioisomers (Figure 47) 
all peaks observed when characterisation data was acquired are present in 
the 60 MHz spectra. The CH3 is seen as a clear doublet at 1.13 ppm, showing 
that splitting patterns can still be seen. The CH2 and CH peaks can also be 
seen at the same chemical shifts as with the 400 MHz instrument. When 
stacked the three FA regioisomers show matching aliphatic regions with the 
aromatic regions showing clear differences based on the splitting caused by 
the fluorine substituent moving around the benzene ring.  
 
The fluoromethcathinone (Figure 48) and trifluoromethylmethcathinone 
(Figure 49) regioisomers show matching spectral patterns to the 400 MHz 
characterisation with matching aliphatic regions for both sets of classes. This 
is due to the only difference occurring in the substituent group concerning 
fluorine is that the fluorine in the FMC isomers contrasts with a CF3 group for 
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the TFMMC isomers. This means that the only differences observed for the 
regioisomers occurs in the aromatic regions of the spectra. There are also 
clear differences between the FMC and TFMMC compounds when the 
substituent is in matching positions of the benzene ring. The differences in the 
spectra for all nine compounds shows that the technique can be used to 
identify unknown samples. 
 
The 19F NMR experiments for all compounds show matching chemical shifts 
to those seen when using 400 MHz instruments, however the peak widths are 
increased. The table containing all 19F NMR chemical shifts can be seen in 
Table 21 with the stacked spectra of all trifluoromethylmethcathinone isomers 
seen in Figure 50. The monofluorinated cathinone and amphetamine 
regioisomers are seen in a similar region, however the stacked 19F NMR 
spectra (Figure 51) shows that each compound can be distinguished based 
on its chemical shift value. This can help to aid in the identification of unknown 
active components in seized street samples. This means that clear differences 
can be seen using the 60 MHz instrument for three regioiosmers using two 
different experiments in just 30 minutes. 
 
Table 21: 19F NMR chemical shift values for all fluorinated amphetamine and cathinone 
derivatives run on a 60 MHz instrument 
 
  
Compound 
no. 
Compound 19F chemical shift 
(δ ppm) 
4a 2-fluoroamphetamine -117.58 
4b 3-fluoroamphetamine -113.03 
4c 4-fluoroamphetamine -115.69 
8a 2-fluoromethcathinone -110.35 
8b 3-fluoromethcathinone -111.70 
8c 4-fluoromethcathinone -102.02 
9a 2-trifluoromethylmethcathinone -58.34 
9b 3-trifluoromethylmethcathinone -63.65 
9c 4-trifluoromethylmethcathinone -64.17 
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Figure 47: 1H NMR spectra for the fluoroamphetamine regioisomers (FA, 4a–4c), run on a 
60 MHz instrument in DMSO-d6 (δ ppm = 2.50) 
 
Figure 48: 1H NMR spectra for the fluoromethcathinone regioisomers (FMC, 8a–8c), run on 
a 60 MHz instrument in DMSO-d6 (δ ppm = 2.50) 
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Figure 49: 1H NMR spectra for the trifluoromethylmethcathinone regioisomers (TFMMC, 9a–
9c), run on a 60 MHz instrument in DMSO-d6 (δ ppm = 2.50) 
 
Figure 50: Stacked 19F NMR spectra for the trifluoromethylmethcathinone regioisomers 
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Figure 51: Stacked 19F NMR spectra for all fluoroamphetamine (FA, 4a–4c) and fluoromethcathinone (FMC, 8a–8c) regioisomers 
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3.6. GC-MS and 60 MHz NMR quantitative analysis 
Based on the acquisition of street samples from Greater Manchester Police 
(GMP), presumed to contain fluoroamphetamine, calibration series were 
created for the three fluoroamphetamine isomers using both GC-MS and 19F 
NMR spectroscopy on a 60 MHz instrument. This was done in order to be able 
to provide information on how much active ingredient is present in the street 
samples tested in section 3.7.  
A calibration series was created for all three FA regioisomers on the GC-MS 
using standards in the concentration range 100 μg mL-1 – 500 μg mL-1 with 
each concentration run in triplicate. An extra calibration standard was run for 
the 3-FA standard at a concentration of 50 μg mL-1 in order to show that 
positive correlation was achieved through the origin.  Eicosane was used at a 
constant concentration of 100 μg mL-1 for all standards and integrated area 
ratios calculated between sample peaks and the eicosane peaks. The 
developed GC-MS method used in section 3.4 was used to run all calibration 
samples. The calibration graph containing each isomer can be seen in Figure 
522 and shows a correlation coefficient (R2) greater than 0.99 in the case of 
the 2-FA (4a) and 4-FA (4c) isomers. The 3-FA (4b) isomers showed positive 
correlation with a coefficient only slightly below 0.99 (0.9874). This shows that 
the GC-MS method can be used for quantitative analysis of street samples. 
Based on the standard deviation and the response of the slope LOD and LOQ 
values were calculated for all three isomers. The 2-FA sample gave an LOD 
and LOQ of 20 and 68 μg mL-1 respectively. The 3-FA and 4-FA isomers gave 
LOD and LOQ values of 25 – 23 μg mL-1 and 80 – 75 μg mL-1 respectively. 
When compared to MDMA tablets this would be below the average amounts 
of active component that would be present in street samples so is acceptable 
for analysis. Average MDMA tablets contain 100 -150 µg mL-1, with weak 
tablets containing around 70 µg mL-1.144 As long as a controlled substance or 
NPS is detected then a prosecutor can be convicted so if there are extra minor 
components, trace levels of other compounds or cutting agents that fall below 
the LOD, within a sample, then these are not considered within analysis. The 
relative standard deviation percentage (RSD%), for the triplicate runs, with all 
concentration standards is below the acceptable 5%.  
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Figure 52: Calibration series performed using GC-MS on all three fluoroamphetamine (FA, 
4a-4c) regioisomers 
A calibration series for all three of the FA isomers was also performed on the 
60 MHz NMR using a 19F-based NMR experiment. Calibration standards were 
prepared over the concentration range 5 mg mL-1 – 15 mg mL-1 with 
trifluoroacetic acid (TFA) added as an internal standard at a concentration of 
0.1% v/v of DMSO used. 16 scans was used with a 3 second relaxation delay. 
Calibration graphs were then produced by calculating the integrated area ratio 
between sample peaks and TFA peaks and plotting against concentration. The 
calibration graphs can be seen in Figure 53. 
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Figure 53: Calibration graphs for the FA regioisomers using 19F NMR experiments on a 60 
MHz NMR 
The three isomers show acceptable correlation (>0.99) meaning the method 
can be used to perform quantitative analysis. The LOD and LOQ for the three 
regioisomers can be seen in Table 22 and shows that the highest LOQ is 
below 2 mg mL-1. This is acceptable as the majority of street samples will have 
active components greater than 2 mg per sample. The RSD % of the triplicate 
readings for each calibration standard is higher than those produced from GC-
MS, however they are still lower than the acceptable 5%. The calibration 
graphs for the NMR analysis does not go through the origin, due to the 
increased noise of the baseline compared to other analytical techniques. The 
integrated values for the baseline around each signal can be averaged and 
deducted from the integrated values of the signal and reference peak prior to 
performing the ratio calculations. This would then allow the calibration series 
to go through the origin, however the process would be complicated for 
untrained users, who the system is aimed towards. It is also clear that positive 
correlation is achieved without the baseline average and subtraction and 
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concentrations can be determined using this method.  The 60 MHz instrument 
is more favourable due to the ease of data processing and the quicker run time 
from around 40 minutes with the GC-MS to 5 minutes per run for the NMR. 
 
Table 22: LOD and LOQ values for the three FA (4a–4c) regioisomers from the calibration 
series produced on the 60 MHz NMR instrument 
Sample  LOD 
(mg mL-1) 
LOQ 
(mg mL-1) 
2-FA 0.49 1.63 
3-FA 0.33 1.10 
4-FA 0.28 0.93 
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3.7. Street samples analysis 
Two tablets (SS1 and SS2, Figure 544) were seized by Greater Manchester 
Police (GMP) initially thought to contain MDMA based on appearance. 
However after initial analysis performed using the GC-MS general screening 
method, the resulting GC trace did not produce the corresponding Rt for 
MDMA or a mass spectrum fragmentation pattern resembling MDMA. 
Consequently, samples were tested using presumptive colour test reagents, 
GC-MS again (using the method developed in this chapter) and 60 MHz NMR. 
The two tablets were weighed and masses of 275.2 and 248.0 mg recorded. 
As well as determining the active component in the tablet, qualitative analysis 
was also performed on the two tablets.  
 
 
Figure 54: Image of the seized street sample (SS1) 
The two street samples were both tested using the full range of presumptive 
test reagents used when testing the reference materials. Both tablets were 
dissolved in water (10 mg mL-1 solutions) and a couple of drops of test reagent 
were added to a couple of drops of the sample solution. Both solutions 
produced the same colour changes when each reagent was added. No colour 
changes were observed when Mandelin’s and Scott’s reagents were added, 
however none of the FA, FMC or TFMMC reference materials changed colour 
with these reagents so this does not help in distinguishing isomers. In a similar 
manner the solution changed to an orange colour with the Marquis reagent, 
however this occurred with all nine of the fluorinated compounds. A negative 
reaction was seen with the Zimmerman reagent, meaning it is possible that 
the unknown street samples are not cathinones. There was also a positive 
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reaction with the Robadope’s reagent with the solution changing to a brown 
colour in a similar manner to the fluoroamphetamine regioisomers. 
 
The street samples were then run on the 60 MHz NMR instrument using 
matching 1H and 19F experiments to the reference materials. Both street 
samples gave matching spectra to each other on both the 1H and 19F 
experiment. The spectra can be seen in Figure 55. The 1H NMR spectra for 
the street sample shows a doublet peak, representing three protons at 1.15 
ppm and two multiplet peaks, representing one proton each, in the region of 
2.80–3.20 ppm. There is also an amine singlet peak at 8.20 ppm representing 
two protons. This is similar to the aliphatic region of the FA isomers with a 
peak for DMSO and water at 2.50 and 3.30 ppm respectively.  
 
 
Figure 55: 1H NMR spectra for the street sample run in DMSO-d6 (δ ppm = 2.50) 
This region matches the aliphatic region of the FA isomers produced when the 
reference materials were run on a 60 MHz instrument. The aromatic regions 
for the street samples were then matched to the three FA isomers and a close 
match is seen with the 4-FA isomer.  
The 19F NMR spectra (Figure 56) for the street sample produced a sample 
chemical shift of -115.60 ppm. This is very close (-0.09 ppm) to the chemical 
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shift produced from the 19F NMR spectra of the 4-FA reference material and 
when added to the result for the 1H NMR experiment strongly suggests the 
possibility of the street sample having 4-FA as an active component. Both the 
1H and 19F NMR spectra suggest that there is only the one active ingredient in 
the street samples.     
 
Figure 56: 19F NMR spectrum for the street samples with TFA added as an internal 
reference (δ ppm = -76.55) 
After analysis of the two street samples had been performed on the 60 MHz 
NMR spectrometer, GC-MS was used to confirm the active component as 4-
FA. The developed method was used to analyse both street samples. The two 
chromatographs can be seen in Figure 57 with the mass spectra produced 
seen in Figure 58. The two street samples produced retention times of 5.43 
and 5.42 mins respectively, which both match up to the retention time for the 
4-FA isomer and the mass spectra produced matches that for all 
fluoroamphetamine regioisomers.  
 
The data acquired, its subsequent analysis, confirm that both street samples 
contain 4-FA as the single active component with no further adulteration or 
cutting agents added. 
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Figure 57: GC-MS chromatographs for the two street samples run with eicosane added as 
an internal standard (Rt = 30.85 mins) 
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Figure 58: Mass spectrum produced for the two street samples 
Based on the knowledge that both street samples contain 4-FA, qualitative 
analysis was performed using the calibration series created in section 3.6, 
using both GC-MS and 60 MHz NMR. Two samples for both street samples 
were made for GC-MS analysis firstly at a concentration of 300 μg mL-1 in 
order to fall in the centre of the calibration series. The two solutions for each 
street sample were both run in duplicate with the calculated concentrations, 
based on the equation of the calibration graph shown in Figure 52. These 
concentrations were then converted to weight of active ingredient and 
percentage weight per tablet based on original tablet weights and dilution 
factors. 
 
The GC-MS (Table 23) showed that SS1 contained 40% w/w active ingredient 
with the two samples differing by an acceptable 2%. SS2 gave a % weight of 
49% w/w. This equates to weights of 109–123 mg of 4-FA in the two street 
samples. This would not be considered a high amount of substance per tablet 
based on the common dosages found in MDMA, where a weight of around 
240 mg would be considered high.145    
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Table 23: Quantification results for active component, 4-FA, in the two street samples from GC-MS analysis 
 Integrated area Ratio (IAR) 
Concentration of diluted 
solution (μg mL-1) 
Active component weight in tablet  
(mg) 
 
% weight 
(% w/w) Sample Run 1 Run 2 Run 1 Run 2 
Run 1 Run 2 Average 
SS1 sample 1 0.053 0.055 118.0 121.4 
108.20 111.36 109.78 39.9 
SS1 sample 2 0.057 0.056 124.6 123.8 
114.26 113.60 113.93 41.4 
SS2 sample 1 0.067 0.070 144.6 151.4 
119.50 125.18 122.34 49.3 
SS2 sample 2 0.071 0.065 153.0 141.0 
126.48 116.56 121.52 49.0 
 
Table 24: Quantification results for active component, 4-FA, in the two street samples from 60 MHz NMR analysis 
 Integrated area Ratio (IAR) 
Concentration of NMR sample 
 (mg mL-1) 
Active component weight in tablet  
(mg) 
 
% weight 
(% w/w) Sample Run 1 Run 2 Run 1 Run 2 
Run 1 Run 2 Average 
SS1 sample 1 5.17 5.08 6.55 6.47 
120.20 118.72 119.46 43.4 
SS1 sample 2 5.00 5.06 6.40 6.45 
117.44 118.35 117.90 42.8 
SS2 sample 1 5.93 6.09 7.23 7.37 
119.51 121.83 120.67 48.7 
SS2 sample 2 6.16 6.06 7.43 7.34 
122.82 121.33 122.08 49.2 
140 
The street samples were then analysed quantitatively using the 60 MHz NMR 
calibration through the 19F experiments. Based on the knowledge from the GC-
MS results the NMR street samples were made at a concentration of 15 mg 
mL-1 in order to ensure the sample integrated area ratio (IAR) would fall within 
the linear range of the calibration graph. Two samples from both street 
samples were prepared using 0.1% TFA v/v in a similar manner to the 
calibration series with the IAR for each sample reported in Table 24. The table 
also shows calculations for the concentration of 4-FA in the NMR sample and 
the weight of FA in the original tablets based on original weights of the tablets 
and conversion factors. 
 
From the results both percentage weight compositions for both street samples 
is within 2% for the two runs. SS2 shows a very similar percentage 
composition and weight of 4-FA in the sample, while SS1 appear to produce 
a %weight slightly higher to that reported using GC-MS. The mean difference 
is 1.4% between the GC-MS and NMR techniques, which equates to 5–10 mg. 
This amount would not make a significant difference when reporting to 
healthcare services.  
The similarity of the results obtained from the two instrumentation methods 
shows the possibility of using 60 MHz NMR as a technique in law enforcement 
to determine active components of street sample not only qualitatively but 
quantitatively also. When compared to the GC-MS analysis the results both 
provide the same outcome, however the 60 MHz instrument produces the 
results 6 times quicker (5 mins compared to 30) with the same level of 
precision (both <5%). The quantitative analysis provides the same percentage 
composition, within 10 mg (4%) for the street samples under the same number 
of repeats, however for each run the 60 MHz is performing 32 scans which 
could be considered extra repeats.   
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3.8. Conclusions 
In conclusion regioisomers of fluoroamphetamine, fluoromethcathinone and 
trifluoromethylmethcathinone were taken and fully characterised allowing 
them to be used for further analysis. 
 
Presumptive colour tests have shown that the Zimmerman reagent is a clear 
indicator to the presence of cathinones with the Simon’s reagent allowing 
indication of a methcathinone (secondary amine). The Robadope’s reagent 
allows indication as to the presence of the fluoroamphetamine, however it 
does not allow the three regioisomers to be distinguished. The 
fluoromethcathinone regioisomers can be distinguished using both the 
Zimmerman and Simon’s reagents, however the combination does not 
distinguish between the trifluoromethylmethcathinone regioisomers. This 
means that the presumptive colour tests can only be used to narrow down 
possibilities of these compounds being present and if a specific compound 
needs to be known this technique cannot provide this information.  
 
A GC-MS method was developed which enabled all fluorinated amphetamines 
and cathinones to be distinguished from one another, although baseline 
separation has not been achieved for the 3’ and 4’ fluoroamphetamine 
isomers. All peaks were shown to have good symmetry with no fronting or 
tailing, which has reported previously through thermal degradation.4 The 
developed GC-Ms runs do not separate all the regioisomers, it would be 
considered that the run time of 24 minutes is too long.  
 
60 MHz NMR was shown to provide a possible presumptive test for 
determination of unknown sample identification. This is possible due to spectra 
produced matching those produced on a 400 MHz system and still showing 
distinguishing features for differing reference materials. All regioisomers can 
be separated from one another so if law enforcement need an initial statement 
as to what an unknown sample is the 60 MHz instrument can provide this 
information. Quantitative analysis was performed using both the developed 
GC-MS method and 19F NMR experiments on the 60 MHz NMR instrument. 
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Both techniques showed good linearity (R2 > 0.99) and repeatability of 
triplicated runs (RSD < 5%). This again shows the benefits of the 60 MHz as 
it can perform quantitative analysis in a quicker manner than the GC-MS 
instrumentation, which is currently considered the optimum technique, with no 
great loss to limits of detection, precision or accuracy. 
 
Street sample analysis was performed on two tablets originally thought to 
contain MDMA based on appearance. Both were shown to contain 4-FA based 
on GC-MS and NMR analysis using qualitative analysis. Further quantitative 
analysis via GC-MS and 60 MHz NMR analysis proved the two tablets 
contained 4-FA at a level of 40% and 49% respectively. This would equate to 
109 – 123 mg per tablet. The two techniques differ by 1.4% (mean value), 
which equates to 5–10 mg. This again shows that 60 MHz instrumentation can 
be used for street sample analysis as it provides the same result for the active 
ingredients of the tablets, as the GC-MS analysis, with percentage 
composition also matching. This is a key factor if the instrument is to be utilised 
in locations such as police custody and festivals, where samples can be 
identified correctly, rapidly (5 mins) by officers with little training, due to the 
ease of sample preparation and processing. The only disadvantage seen with 
the 60 MHz instrument in this instance is a higher LOD (0.5 mg max) but 
common tablet concentrations for MDMA have shown to be higher than this, 
with a weak tablet considered to contain around 100 mg. 144As long as a 
fluorinated amphetamine or cathinone is detected then a conviction can be 
made so it does not matter if other cutting agents or trace products are within 
the sample.            
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4. Chapter 4 - Separation and identification of 
diphenidine derivatives using GCMS analysis 
results 
4.1. Overview 
In the past few years diphenidine (13a) and its methoxy-substituted 
derivatives, 4-methoxphenidine (4-MXP, 13d), have increased in popularity on 
the recreational drugs market. This danger was enhanced with a number of 
fatalities in both Europe and Asia in both their pure forms and in combination 
with synthetic cannabinoids.97, 98, 112 Wallach et al. and McLaughlin et al. have 
already published characterisation data on diphenidine and the 
methoxphenidine regioisomers respectively.34, 102 Techniques have been 
developed for the toxicological screening of 2-methoxphenidine (2-MXP, 13b) 
in blood (using HPLC, LC-MS-MS or UPLC-QTOF-MS) and urine (using 
HPLC, LC-MS, LC-MS-MS or UPLC-QTOF-MS), due to recent fatalities and 
intoxications.99, 103 The increased use of diphenidine-derived dissociatives has 
required the development of rapid testing methods for the identification and 
quantification of these substances. There is a current lack of such methods in 
the literature, especially for new and emerging derivatives of currently 
available compounds.  
 
This chapter of work will seek to address the current gap in the literature and 
will report presumptive colour tests, thin layer chromatographic and GC-MS 
data for thirteen new diphenidine derivatives encountered by law enforcement. 
A validated GCMS method will be reported which, for the first time, will provide 
both a general screening method for the thirteen derivatives and quantification 
of the active components for seized solid samples, both in their individual pure 
forms and as mixtures containing common cutting agents and adulterants. 
Reference spectra and data will be produced from characterisation through 1H 
NMR, 13C NMR and 19F NMR for the compounds synthesised and prepared in 
this study. This will also provide a comparison for laboratories or environments 
that are engaged in the routine analysis of these compounds. 
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4.2. Synthesis 
Samples of thirteen diphenidine derivatives (13a–13m) were prepared as their 
corresponding hydrochloride salts prior to the project at Manchester 
Metropolitan University. All target compounds were synthesised, as racemic 
mixtures, using a modification of the previously reported methods from the 
prerequisite aromatic aldehydes (Figure 61).34, 102  
 
 
Figure 59: Reaction scheme for the synthesis of the diphenidine derivatives 
 
Reference materials were produced as stable, colourless to off-white powders 
with overall yields ranging from 21-77%. The hydrochloride salts were 
determined to be soluble (10 mg mL-1) in deionised water, methanol, 
dichloromethane and dimethylsulfoxide. To ensure the authenticity of the 
materials utilised in this study the synthesised compounds were fully 
structurally characterized, to produce reference spectra, by 1H NMR (Figure 
63-Figure 71), 13C NMR (supplementary data: Figure 1-Figure 13), and FTIR 
(supplementary data: Figure 50-Figure 62). 19F NMR was also run on the 
relative compounds (13e-13g) and the respective chemical shifts can be seen 
in Table 25. The purity of all samples was checked by elemental analysis and 
shown to be >95% in all cases.  
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Figure 60: Chemical structures for diphenidine (13a), the three methoxphenidine (MXP, 
13b–13d) and trifluoromethoxphenidine (TFMXP, 13e–13f) regioisomers along with the 
2,3,4-trimethoxphenidine (mescphenidine, 13h) derivative  
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Figure 61: Chemical structures for the methylenedioxyphenidine (MDDP, 13i–13j), 
naphthenidine (NPD, 13k–13l) and the IAS-013 (13m) derivatives 
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Due to the variation in chemical structures between each of the diphenidine 
derivatives there are slight differences in the 1H NMR spectra that is produced 
especially in the aromatic regions. Diphenidine (13a) provides the base 
structure for all the other derivatives and therefore spectra can be compared 
to that of diphenidine to help with identification (figure 61). In some cases 
acetone and water were present in the 1H NMR spectra produced at around 
2.2 ppm and 3.3 ppm respectively. All samples were run in deuterated 
dichloromethane (CD2Cl2 ) with a solvent peak at 5.32 ppm.  
 
Diphenidine contains thirteen aliphatic protons, ten of which come from the 
aliphatic piperidine ring. The remaining three aliphatic protons come from the 
chiral centre proton and the two protons on the adjacent carbon. 8 of the 10 
piperidine protons can be seen in the diphenidine spectra between 1.27 ppm 
– 3.47 ppm, with some overlap of peaks making splitting patterns hard to 
distinguish. The remaining two protons in the piperidine ring can be seen at 
3.40 ppm and 3.57 ppm. All protons in the piperidine ring clearly seem to exist 
in different chemical environments due to the differences in chemical shifts 
with most peaks showing multiplicity in the splitting. This could be due to the 
rotation of the compound and the interaction that the protons may experience 
from the nearby aromatic groups and potential induced magnetic fields.  
 
The piperidine protons were all linked together using the 2D Correlation 
Spectroscopy (COSY) NMR experiment, as all the protons in this piperidine 
ring showed coupling to one another where appropriate. Protons adjacent to 
the nitrogen showed coupling to two other protons as well as the amine proton. 
All other protons in the ring showed coupling to four other protons due to two 
lots of CH2 groups on either side. Due to some aliphatic protons bonded to the 
same carbon having different chemical shifts and chemical environments, a 
HMQC experiment was performed in order to confirm the coupling shown in 
the COSY experiment. The peaks at 3.46 ppm and 3.99 ppm represent the 
CH2 group, on the carbon adjacent to the chiral centre carbon, and is shown 
by both 1H NMR peaks showing coupling to the same carbon in the HMQC 
and coupling to the proton at 4.25 ppm in the COSY experiment, which 
represents the chiral centre proton.  
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All aromatic peaks fall between 7 ppm and 8 ppm and integrate to 10 protons 
which fits with the proposed structure of diphenidine with six peaks present 
due to the symmetrical nature of the aromatic regions. The peak representing 
the proton bonded to the nitrogen in the amine is present at 12.59 ppm as a 
singlet peak.  
 
The main significant peak that is produced in the three methoxphenidine 
derivatives (13b–13d, figure 64), that provides a clear difference to the 
diphenidine spectra is the methoxy substituted group on the phenyl ring that 
is shown through the singlet peak at 3.80 ppm in the three spectra with an 
integration of 3 protons. The main difference between the three 
methoxphenidine regioisomers comes in the aromatic region (figure 65). The 
2-MXP isomer appears to produce a difference with the chiral proton, 
compared to diphenidine, with the splitting pattern changing from a doublet of 
doublets to a broad singlet, possibly caused by coupling to the OCH3 group 
with rotation. All three compounds have 9 aromatic protons, compared to the 
10 of diphenidine, with the 2-MXP isomer having an individual peak at 7.75 
ppm, which will be the proton adjacent to the carbon bonded to the OCH3 
group. The 3-MXP spectra also contains more peaks in the aromatic region 
compared to that of the 4-MXP due to the non-symmetrical nature of the 
phenyl group in the 3-MXP compound.  
 
The three-trifluoromethoxphenidine regioisomers (13e–13g, figure 66 – figure 
67) 1H NMR spectra appears very similar to the methoxphenidine spectra. 
There is no clear difference with the aliphatic peaks and both sets of 
regioisomers contain nine aromatic protons, however there is no OCH3 peak 
as this is replaced by the OCF3 group and doesn’t produce a signal in the 1H-
NMR spectrum. In order to show this substituent group is present, a 19F NMR 
spectrum was obtained. The resulting 19F chemical shifts are reported in Table 
255. It is not possible to distinguish between the 3’ and 4’ positional isomers 
using just the fluorine signals, however the 2-TFMXP isomers provides a 
distinguishable signal.  
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Table 25: 19F NMR chemical shifts for the three trifluoromethoxphenidine regioisomers (13e 
– 13g) run in DMSO 
 
 
The 2,3,4-trimethoxphenidine (13h, mescphenidine, figure 68 – figure 69) 
compound provides a significant difference in the proton spectra through the 
singlet peak at 3.91 ppm that represents the nine OCH3 protons present in the 
same chemical environment. There is a slight shift in the chemical shifts of 
some of the aliphatic protons within the piperidine ring due to the difference in 
electron density caused by the new substituted methoxy groups. However, this 
is not significant enough to distinguish between mescphenidine and 
diphenidine. Mescphenidine also only contains seven aromatic protons 
compared to the ten of diphenidine and the nine of the MXP regioisomers. 
 
The two MDDP isomers (13i–13j, figure 68 – figure 69) shows a significant 
difference to the other diphenidine derivatives due to the two methylenedioxy 
protons and only having eight aromatic protons. The two CH2 protons present 
in the methylenedioxy substituted group can be seen at between 5.86 ppm – 
5.97 ppm for the 2,3-MDDP isomer while the peak for the 3,4-MDDP isomer 
can be seen at 5.99 ppm. This matches previous literature for substances such 
as MDMA where the two methylenedioxy protons appear at 5.83 ppm.  
 
The two naphthenidine isomers both contain the same aliphatic region as 
diphenidine and a number of its derivatives, however the main difference is 
the aromatic region as both isomers contain twelve aromatic protons and can 
be distinguished from one another, due to the difference in chemical 
environments that the protons exist (figure 70 – figure 71). A stacked image of 
the aromatic regions of naphthenidine show the clear difference between the 
two isomers (figure 62). 
Sample Abbreviation 
19F Chemical Shift 
(ppm) 
2’-trifluoromethoxphenidine  2-TFMXP -57.47 
3’-trifluoromethoxphenidine 3-TFMXP -58.82 
4’-trifluoromethoxphenidine 4-TFMXP -58.69 
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Finally, the IAS-013 compound is easily distinguishable based on its seven 
aromatic protons and the two OCH3 groups along with the CH3 group (figure 
70 – figure 71). Three peaks, each representing three protons, at different 
chemical shifts, show this. This shows each group containing the three protons 
is in a different chemical environment and that no protons are on the 
neighbouring carbon of the benzene ring, due to each peak appearing as a 
singlet.
Figure 62: Stacked 1H NMR aromatic region for the two-naphthenidine regioisomers (NP, 13k (top) – 13l (bottom)) 
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Figure 63: 1H NMR (400 MHz, CD2Cl2) spectrum of diphenidine hydrochloride (13a) 
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Figure 64: Stacked 1H NMR spectra for the aliphatic region of diphenidine (13a), 2-MXP (13b), 3-MXP (13c) and 4-MXP (13d)  
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Figure 65: Stacked 1H NMR spectra for the aromatic region of diphenidine (13a), 2-MXP (13b), 3-MXP (13c) and 4-MXP (13d)    
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Figure 66: Stacked 1H NMR spectra for the aliphatic region of diphenidine (13a), 2-TFMXP (13e), 3-TFMXP (13f) and 4-TFMXP (13g)  
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Figure 67: Stacked 1H NMR spectra for the aromatic region of diphenidine (13a), 2-TFMXP (13e), 3-TFMXP (13f) and 4-TFMXP (13g)  
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Figure 68: Stacked 1H NMR spectra for the aliphatic region of diphenidine (13a), 2,3-MDDP (13i), 3,4-MDDP (13j) and mescphenidine (13h)   
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Figure 69: : Stacked 1H NMR spectra for the aromatic region of diphenidine (13a), 2,3-MDDP (13i), 3,4-MDDP (13j) and mescphenidine (13h)   
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Figure 70: Stacked 1H NMR spectra for the aliphatic region of diphenidine (13a), 1-NPD (13k), 2-NPD (13l) and IAS-013 (13m)    
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Figure 71: Stacked 1H NMR spectra for the aromatic region of diphenidine (13a), 1-NPD (13k), 2-NPD (13l) and IAS-013 (13m)   
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4.3. Presumptive Testing 
The presumptive colour tests for all thirteen diphenidine derivatives (13a-13m) 
was carried out according to the United Nations recommended guidelines.118 
Literature regarding the presumptive testing of diphenidine and its substituted 
derivatives is limited, therefore a range of presumptive tests were applied to 
this study: (i) Marquis test; (ii) Mandelin test; (iii) Scott’s test and (iv) 
Zimmerman test. The preparation of the reagents is detailed in the 
experimental section (section 2.2). A solution of each reference standard (10 
mg mL-1) was prepared in deionised water and a couple of drops placed into 
a dimple well of a spotting tile. The required presumptive test reagent (1-2 
drops) was then added and any colour change upon initial addition of the 
reagents were noted and observations were made again after a five minute 
time period (Table 26).  
 
Marquis, Mandelin, Scott’s and Zimmerman’s reagents were the only test to 
provide a positive reaction and noticeable colour change when reacted with 
sample solutions. All samples were dissolved in deionised water in order to 
yield desired colour changes, however, methanol was initially tried but didn’t 
produce a colour change to the solution. Instead, evaporation of the methanol 
and sample was observed with a colour change beginning on the outer walls 
of the wells, rather than in solution. The order of addition also appeared vital 
as sample solution added to the test reagent yielded no colour change for any 
test. All diphenidine derivatives, that contain a tertiary amine, gave a positive 
reaction with the Marquis and Scott’s reagents, however, a gradual loss of 
intensity of the initial colour with Marquis reagent was observed over the five 
minute period. In the case of the Scott’s test, which is employed in the 
screening of cocaine, the coloured products may result from the coordination 
of the tertiary amines to the pink Co(II) octahedral complex affording the blue 
Co(II) tetrahedral complex.146(Figure 72)   
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Figure 72: Proposed scheme for the colour change in the Scott’s reagent 
The colour change that is observed when the Marquis reagent is used, may 
be afforded to the reaction of the drug molecules with sulfuric acid, in a similar 
way to that of the mechanism of MDMA (figure 73).3 The gradual loss of colour 
over 5 minutes may suggest that this product is not stable under the test 
conditions used. 
 
Figure 73: Proposed reaction scheme for the Marquis reagent with diphenidine 
The Mandelin reagent (acidified ammonium metavanadate) gave a positive 
reaction to all diphenidine derivatives, except for both the 3-
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trifluoromethoxdiphenidine (13f) and 4-trifluoromethoxdiphenidine (13g). Due 
to the lack of literature on both diphenidines and their presumptive testing, 
there is no readily available explanation as to why there is a lack of response 
for both 13f and 13g. The slightly different coloured products obtained with the 
MXP isomers [2-MXP (13b, dark yellow); 3-MXP (13c, brown) and 4-MXP 
(13d, pale yellow) respectively] could be potentially used to discriminate 
between these three positional isomers. 
 
 
Figure 74: Reaction scheme for the positive colour change in the Mandelin reagent 
When the diphenidine derivatives are tested against the Zimmerman reagent 
a white or pale yellow precipitate forms. This precipitate is believed to be the 
free-base form of the corresponding tertiary amines, which are insoluble in 
water, rather than a positive reaction of the substrates with the Zimmerman 
test.147 A positive test for the Zimmerman reagent usually relies on the 
presence of an activated methylene group, which can react with 1,3-
dinitrobenzene to give a positive colour change based on the Meisenheimer 
complex formed. This reaction has been previously reported for the 
identification of cathinone derivatives.143  
 
The observed colour changes reported for all diphenidine samples (Table 26) 
indicate that Scott’s reagent could provide a simple and rapid test for these 
materials. Cocaine also forms a blue Co(II) tetrahedral complex with Scott’s 
reagent, however, it does not give a positive reaction with the Marquis reagent. 
Therefore, in order to identify diphenidine samples the two presumptive tests 
(Marquis and Scott’s) should be employed together to discriminate between 
cocaine and these novel diphenidine-derived NPS. Presumptive testing 
provides difficulty in separating the isomers as colour changes would appear 
different to different observers and all positional isomers having identical UV 
λmax values when analysed through UV analysis. 
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Table 26: Colour changes observed with presumptive test reagents for 13 diphenidine 
derivatives (13a-13m) immediately after addition and after 5 minutes of addition 
 Marquis Mandelin  Scott’s Zimmerman 
 Immediate 
colour 
change 
Colour 
after 5 
minutes 
Immediate 
colour 
change 
Colour  after 
5 minutes 
Immediate 
colour 
change 
Colour 
after 5 
minutes 
Immediate 
colour 
change 
Colour 
after 5 
minutes 
13a orange 
 
pale 
brown 
dark yellow yellow green blue blue 
- 
pale 
yellow ppt 
- 
pale 
yellow 
ppt 
13b pink 
 
colourless 
dark yellow dark yellow blue blue 
- 
pale 
yellow ppt 
- 
pale 
yellow 
ppt 
13c red brown 
 
colourless 
brown brown blue blue 
- 
pale 
yellow ppt 
- 
pale 
yellow 
ppt 
13d pale pink colourless pale yellow pale yellow blue blue 
- 
pale 
yellow ppt 
- 
pale 
yellow 
ppt 
13e 
pale 
yellow 
colourless light yellow light yellow blue blue 
- 
white ppt 
- 
white 
ppt 
13f orange colourless - - blue blue 
- 
white ppt 
- 
white 
ppt 
13g orange colourless - - blue blue 
- 
pale 
yellow ppt 
- 
pale 
yellow 
ppt 
13h 
pale 
orange 
pale pink pale green pale green blue blue 
- 
pale 
yellow ppt 
- 
pale 
yellow 
ppt 
13i 
pale 
brown 
colourless 
 
brown 
brown blue blue 
- 
pale 
yellow ppt 
- 
pale 
yellow 
ppt 
13j purple colourless brown brown blue blue 
- 
pale 
yellow ppt 
- 
pale 
yellow 
ppt 
13k beige 
pale 
brown 
dark yellow brown blue blue 
- 
pale 
yellow ppt 
- 
pale 
yellow 
ppt 
13l grey blue colourless brown brown blue blue 
- 
pale 
yellow ppt 
- 
pale 
yellow 
ppt 
13m 
pale 
orange 
colourless green/yellow green/yellow blue blue 
- 
pale 
yellow ppt 
- 
pale 
yellow 
ppt 
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4.4. Thin Layer Chromatography 
It has previously been demonstrated by McLaughlin et al. that a specific test 
using TLC has been developed for the analysis of the three MXP isomers 
(13b-13d). All 13 diphenidine derivatives were analysed using TLC and all 
isomers produced an identical blood-red coloured spot when viewed with 
modified Dragendorff-Ludy-Tenger reagent.102 The examination of the 
Retention Factors (Rf) demonstrates separation of the compounds based upon 
this measure, particularly of the three MXP isomers (2-MXP (13b), 3-MXP 
(13c) and 4-MXP (13d): Rf = 0.76, 0.87 and 0.79 respectively) – which 
correlates with previously reported data. Separation is slightly less clear-cut 
for other isomeric derivatives: 2,3-MDDP (13i, Rf = 0.78) vs. 3,4-MDDP (13j, 
Rf = 0.84); 1-NPD (13k, Rf = 0.91) vs. 2-NPD (13l, Rf = 0.85) and in the case 
of the TFMXP isomers (13e – 13g) the three compounds co-eluted. The TLC 
data for each compound, including their Rf and Relative Retention Factor 
(RRf), with respect to diphenidine (13a), are presented in Table 27.  
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Table 27: Thin Layer Chromatography data for diphenidine (13a) and its substituted 
derivatives (13b-13m)  
 Compound name 
Spot colour 
under UV 
light (254 nm) 
 
Spot colour after 
staining with 
modified 
Dragendorff-
Ludy-Tenger 
Reagent 
Rf 
value 
RRfa 
13a Diphenidine Black spot Blood-red spot 0.85 1.00 
13b 2-methoxphenidine Black spot Blood-red spot 0.76 0.89 
13c 3-methoxphenidine Black spot Blood-red spot 0.87 1.02 
13d 4-methoxphenidine Black spot Blood-red spot 0.79 0.95 
13e 2-trifluoromethoxphenidine Black spot Blood-red spot 0.94 1.11 
13f 3-trifluoromethoxphenidine Black spot Blood-red spot 0.93 1.09 
13g 4-trifluoromethoxphenidine Black spot Blood-red spot 0.92 1.08 
13h Mescphenidine Black spot Blood-red spot 0.84 0.99 
13i 
2,3-
(Methylenedioxy)diphenidine 
Black spot Blood-red spot 0.78 0.92 
13j 
3,4-
(Methylenedioxy)diphenidine 
Black spot Blood-red spot 0.84 0.99 
13k 1-Naphthenidine Black spot Blood-red spot 0.91 1.07 
13l 2-Naphthenidine Black spot Blood-red spot 0.85 1.00 
13m IAS-013 Black spot Blood-red spot 0.74 0.87 
Key: a Relative Retention Factor (RRf) with respect to diphenidine (13a) 
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4.5. Gas Chromatography – Mass Spectrometry 
The qualitative GC-MS method used required an extremely straightforward 
dissolution of the samples in methanol (1 mg mL-1) followed by direct injection 
into the instrument. No derivatisation step was required. All thirteen 
diphenidine derivatives were resolved from each other and from three common 
adulterants: caffeine, benzocaine and procaine. An exemplar chromatogram 
is presented in Figure 75.   
 
 
Figure 75: GC-MS chromatogram demonstrating the separation of the thirteen diphenidine 
derivatives (13a–13m) along with the relevant adulterants: benzocaine (B); caffeine (C) and 
procaine (P), with eicosane (E) added as an internal standard.   
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Research has been on going into the possibilities of utilising GC-MS for the 
separation of diphenidine and the methoxphenidine regioisomers mainly in 
cases where solid samples have been seized at a crime scene. However, the 
issue with these reports is the lack of a validated quantitative chromatographic 
method (or limits of detection and quantification), which provides a general 
screening tool. This prevents the quantification of component psychoactive 
substances detected in forensic bulk samples.  
 
Calibration standards were prepared and all thirteen substituted diphenidines 
demonstrated a linear response (r2 = 0.996 – 0.998) over a 25.0 – 250.0 μg 
mL−1 range with satisfactory repeatability (RSD = 1.29 – 14.02%, n = 6). The 
limits of detection and quantification for the analytes were determined, based 
on the standard deviation of the response and the slope, as being 4.23 – 5.99 
and 12.83 – 17.51 μg mL−1 respectively. The method was also suitable for the 
detection and quantification of the three common adulterants (benzocaine, 
caffeine and procaine), demonstrating linear response (r2 = 0.996 – 0.998) 
over the same concentration range with reasonable repeatability (RSD = 1.80 
– 10.41%, n = 6). The limits of detection and quantification were also 
determined, for the adulterants, and found to be 5.97 – 11.82 μg mL−1 and 
18.10 – 35.82 μg mL−1 respectively. The validation parameters for the method 
are summarised in Table 28. The accuracy (percentage recovery study) of the 
assay was determined from spiked samples prepared in triplicate at three 
levels over a range of 80 – 120% of the target concentration (100 µg mL-1). 
Though the repeatability (%RSD) of the method was significantly lower than 
expected, which is believed to be a result of the manual injection of the 
calibration standards, the percentage recovery (% assay) and %RSD 
calculated for each of the three replicate samples demonstrated excellent 
recoveries for all thirteen analytes within the desired concentration range. All 
results are within acceptable limits (100 ± 2%) and the validated GC-MS 
method was deemed suitable for the analysis of street samples. 
 
The use of GC-MS also facilitated the visualization of the mass spectral data 
for each individual compound and these are presented in figure 82 and figure 
83. For all compounds a peak at a mass to charge ratio m/z of 91 is present, 
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which represents the benzyl cation, produced from the phenyl group being 
separated and any substituent group removed (Figure 76).  
 
Figure 76: structure of the benzyl cation 
All diphenidine derivatives have a similar structural backbone to diphenidine 
and therefore the fragmentation patterns for all derivatives can be compared 
to that of diphenidine. Diphenidine (13a) has a base peak of m/z = 174, which 
comes from the removal of the benzyl group to leave the piperidine ring and 
phenyl ring as shown in Figure 77. The secondary base peak in the 
diphenidine mass spectrum is then the benzyl cation mentioned earlier which 
comes from the further removal of the piperidine ring.  
 
Figure 77: GC-MS fragmentation for diphenidine (13a) base peak  
All other diphenidine derivatives fragment in a similar way to diphenidine with 
methoxphenidine and trifluoromethoxphenidine regioisomers losing the benzyl 
group before losing the piperidine ring to produce base and secondary peaks 
of m/z = 204 and m/z = 121 respectively for the MXP isomers and 258 and 
175 respectively for the TFMXP isomers (Figure 78). The peak at m/z of 91 is 
present in both cases.   
169 
 
Figure 78: GC-MS fragmentation of the MXP (13b–13d) and TFMXP (13e–13g) 
regioisomers 
  
The methylenedioxy and napthyl derivatives of diphenidine also produce 
characteristic base and secondary peaks from the mass spectrometer with m/z 
values of m/z = 218 and m/z = 136 respectively for MDDP and m/z = 224 and 
m/z = 141 respectively for the NP regioisomers. The fragmentation ions can 
be seen in Figure 79. 
 
Figure 79: GC-MS fragmentation of the MDDP (13i–13j) and NP (13k–13l) regioisomers  
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The TMXP and IAS-013 compound are the only main difference to the 
fragmentation pattern observed by diphenidine and its other derivatives due to 
the removal of OCH3 and CH3 groups from the base peak ion. These produce 
smaller peaks in the mass spectra due to the instability of the ions created 
meaning the benzyl cation becomes the secondary base peak for these two 
compounds. The fragmentation pattern including the secondary base peak ion 
for both compounds can be seen in figure 80 and figure 81. 
 
 
Figure 80: GC-MS fragmentation pattern for TMXP (13h) 
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Figure 81: GC-MS fragmentation pattern for IAS-013 (13m) 
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Figure 82: EI-MS spectra of (a) diphenidine (13a) and its substituted derivatives (b) 2-
methoxphenidine (2-MXP, 13b); (c) 3-methoxphenidine (3-MXP, 13c); (d) 4-
methoxphenidine (4-MXP, 13d); (e) 2-trifluoromethoxphenidine (2-TFMXP, 13e); (f) 3-
trifluoromethoxphenidine (3-TFMXP, 13f) and (g) 4-trifluoromethoxphenidine (4-TFMXP, 
13g). 
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Figure 83: EI-MS spectra of (a) mescphenidine (3,4,5-TMXP, 13h); (b) 2,3-
(methylenedioxy)diphenidine (2,3-MDDP, 13i); (c) 3,4-(methylenedioxy)diphenidine (3,4-
MDDP, 13j); (d) 1-naphthenidine (1-NPD, 13k); (e) 2-naphthenidine (2-NPD, 13l); (f) IAS-
013 (13m).
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Table 28: Summary of GC-MS validation data for the quantification of diphenidine (13a) and its substituted derivatives (13b–13m). NB. Rt (eicosane) = 21.55 
min.  See Figure 75 for representative chromatogram. 
 Precision (%RSD, n = 6) 
Analyte 
Rt 
(min) 
RRT 
Regression  
co-efficient 
LOD 
(g mL-1) 
LOQs 
(g mL-1) 
25 
g mL-1 
50 
g mL-1 
100 
g mL-1 
200 
g mL-1 
250 
g mL-1 
Benzocaine 10.98 0.46 0.996 5.97 18.10 7.81 7.81 5.25 4.13 2.19 
Caffeine 15.68 0.66 0.998 11.82 35.82 10.41 5.54 4.79 2.99 3.16 
10e 19.80 0.83 0.998 4.23 12.83 3.53 1.29 1.79 2.25 2.47 
10f 20.77 0.88 0.998 4.61 13.97 4.30 1.52 2.16 2.69 2.77 
10g 22.02 0.93 0.997 5.31 16.10 5.82 2.44 2.63 3.01 3.09 
10a 23.72 1.00 0.997 5.08 15.39 4.39 2.34 2.33 3.49 3.00 
Procaine 24.25 1.02 0.996 6.24 18.92 9.05 3.30 5.29 1.80 2.86 
10b 28.06 1.18 0.997 5.22 15.81 9.36 3.85 3.68 3.22 3.52 
10c 29.94 1.26 0.998 4.58 13.88 9.06 3.73 3.52 2.92 2.77 
10d 31.40 1.32 0.996 5.71 17.30 9.88 3.60 3.52 3.37 3.69 
10j 32.76 1.38 0.997 4.86 14.74 8.15 3.29 3.11 3.57 2.82 
10i 36.03 1.52 0.996 5.99 18.16 11.20 4.41 4.35 3.27 4.08 
10m 36.70 1.55 0.996 5.70 17.29 13.12 5.98 3.92 4.12 3.00 
10k 40.43 1.70 0.997 5.13 15.54 9.83 4.06 3.79 3.66 3.02 
10h 41.13 1.73 0.996 5.78 17.51 14.02 5.99 4.63 4.31 3.31 
10l 42.00 1.77 0.997 4.81 14.57 12.72 3.54 4.19 3.98 2.17 
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4.6.  Forensic application 
A sample of diphenidine (SS-1) and methoxphenidine (SS-2) were bought 
from “Buy Research Chemicals UK” (http://www.brc-chemicals.com, 
September 2015) and both were reported to be >99% pure and to contain 1 g 
of either diphenidine (13a, SS-1 Figure 84) or 2-methoxphenidine (13b, SS-2 
Figure 84). 
 
 
 
Figure 84: GC-MS analysis of the two street samples SS-1 and SS-2  
Initially, presumptive tests were carried out using the same procedures 
reported for the reference materials. The diphenidine sample (SS-1) gave a 
positive result to the Marquis (orange), Mandelin (dark yellow) and Scott’s 
(blue) tests to indicate the possible presence of diphenidine (13a). SS-2 also 
gave similar results to these tests producing the same positive colours with the 
Mandelin and Scott’s reagents, however a pink colour was obtained with the 
Marquis reagent leading to the possibility of the presence of 2-
methoxphenidine (2-MXP, 13b). Thin Layer Chromatographic (TLC) analysis 
of the two samples utilizing a silica gel stationary phase and a mobile phase 
consisting of dichloromethane-methanol (9:1 v/v) containing 0.8% ammonia (7 
N in methanol) indicated that both samples contained single components (SS-
1, Rf = 0.84 and SS-2, Rf = 0.77). Comparison of the samples with the 
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reference materials confirmed the presence of diphenidine (13a, Rf = 0.85) 
and 2-methoxphenidine (13b, Rf = 0.76) respectively. 
 
Qualitative analysis using GC-MS confirmed the presence of diphenidine and 
2-MXP for SS-1 and SS-2 respectively. This was shown due to a match in 
retention time and fragmentation pattern from the mass spectrometer (SS-1: 
Rt = 23.72 min, m/z (base peak) = 174 [M+H]+, 13a, figure 86 and SS-2: Rt = 
28.06 min, m/z (base peak) = 204 [M+H]+, 13b, figure 86). The two samples 
appeared to contain no further adulteration and this purity was confirmed with 
1H NMR analysis. 1H NMR (400 MHz, CD2Cl2) analysis and comparison with 
standards of diphenidine (13a) and 2-methoxphenidine (13b) showed that the 
samples were essentially pure and confirmed the absence of any adulterants 
or diluents within the samples (Figure 85). 
 
 
Figure 85: 1H NMR analysis of SS-1 (a) and SS-2 (b) run in CD2Cl2 (10 mg mL-1) 
  
With substantial evidence, supporting a quantitative GC-MS approach for 
detecting various substituted diphenidine derivatives in street samples, the 
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viability of the proposed protocol was tested. The samples were reanalysed 
(in triplicate) using the validated GC-MS method at a concentration of 100 μg 
mL−1. The GC-MS results (Figure 86), confirm that the samples only contained 
the two alleged components (SS-1: Rt = 23.72 min, 10a, 100.3% w/w, % RSD 
= 0.21%, n = 3) and SS-2: Rt = 28.06 min, 10b, 99.5% w/w, % RSD = 1.37%, 
n = 3). The majority of NPS that are encountered on the drugs market usually 
contain some sort of adulteration or inaccurate composition information of the 
packaging. However, these samples appeared to both comply with the 
vendors claims (in terms of principal ingredient), be of high purity (>99% w/w) 
and there was no evidence (confirmed by 1H NMR) that either contained any 
additional NPSs or commonly used diluents and/or adulterants.  
 
Figure 86: Quantitative GC-MS analysis containing both GC chromatographs and mass 
spectra data of SS-1 (a and b) and SS-2 (c and d) (0.1 mg mL-1 in methanol containing 0.1 
mg mL-1 eicosane, E)  
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4.7.  Conclusions and future work 
Based on the appearance of diphenidine and its methoxy substituted 
derivatives on the recreational drugs market a range of 13 derivatives have 
been synthesised. Yields were 21–77 %, showing an ease of production, with 
each synthesis only taking 2 hours, in clandestine labs with all purities 
appearing >95% by elemental analysis. Samples were analysed using 1H 
NMR, 13C NMR, 19F NMR (where necessary) in order to confirm their chemical 
identity and provide reference spectra to aid forensic laboratories and other 
organisations involved in trying to identify these compounds on a regular basis.  
 
Presumptive colour tests have been performed on all reference materials with 
Marquis and Mandelin reagents both providing a positive colour change. 
Scott’s reagent also produces a positive colour change for all diphenidine 
derivatives with a clear change from red to blue making it the optimum reagent 
to use for the detection of diphenidines. However, it also shows the potential 
for diphenidines to provide a false positive in the initial test for cocaine as that 
also turns Scott’s reagent blue. The production of so many false positives in 
relation to cocaine produces a big issue when determining a drug controlled 
by the Misuse of Drugs Act (1971) to a drug controlled by the Psychoactive 
Substances Act (2016). This is due to the differences in penalties when 
convicted under either law. If the colour tests continue to be used somebody 
could be in possession of diphenidine, which would be conviction under the 
Psychoactive Substances Act (2016), but penalised under the Misuse of Drugs 
Act (1971). 
 
Thin Layer Chromatography (TLC) analysis provided some initial separation 
of compounds and positional isomers. A 45-minute GC-MS method was 
developed in order to allow separation and identification of the thirteen 
diphenidine derivatives to be achieved. This method was validated, in order to 
provide a general screening method for qualitative analysis and general 
triaging of samples, but also a quantitative method, for both pure, individual 
component samples, and samples cut with common adulterants. 
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Two samples obtained from online vendors were analysed and shown to 
contain the active components (95–100% w/w) stated (diphenidine and 2-
methoxohenidine) with no adulteration. 
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5. Chapter 5 – Halogenated diphenidine derivatives 
5.1. Overview 
Based on the increased popularity of the diphenidine derivatives 96, 98, 112 and 
the difficulty experienced in keeping ahead of the increasing number of 
derivatives produced, it is important to enhance the library of compounds 
closely resembling the structure of diphenidine. Literature has already shown 
the increased metabolic stability of compounds with the inclusion of fluorine, 
through the greater stability of the C-F bond compared to the C-H bond and 
the increased lipophilicity of fluorine compared to hydrogen.2 Therefore, the 
three monofluorinated derivatives have been prepared along with the 
remaining halogenated substituted derivatives (20a–20l). This helps to 
increase the library of samples available for testing in order to improve the 
speed and reliability of compound identification in samples encountered by law 
enforcement.  
 
This chapter will include all characterisation data for all the halogenated 
diphenidine derivatives, through 1H NMR, 13C NMR, 19F NMR, ATR-FTIR, 
melting points and TLC experiments. A validated GC-MS method is reported 
which, for the first time, provides a general screening method for all of the 
halogenated derivatives. This GC-MS method is employed for the qualitative 
analysis of two street samples as well as the identification of adulterants and 
cutting agents.  
 
Presumptive testing through commonly used colour testing reagents will be 
performed in order to show the difficulty in initially identifying active 
components in samples. It will also highlight the increase in false-positive 
results for commonly controlled substance, under the Misuse of Drugs Act, as 
the number of clandestinely produced NPS increases. 60 MHz NMR will also 
be utilised in order to provide a possible new presumptive testing instrument 
that will provide more distinguishable features in results produced, while still 
being a rapid testing method with easy sample preparation.     
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5.2. Synthesis of the halogenated diphenidine derivatives 
Halogenated diphenidine derivatives (20a–20l) were synthesised as 
hydrochloride salts. All target compounds were prepared as racemic mixtures, 
using similar methods used to synthesize of diphenidine.34 The only difference 
in the synthesis method between the different halogenated derivatives was the 
prerequisite aldehyde used, with ortho-, para- and meta-substituted halogen 
functional groups added. Reference materials were produced as stable, 
colourless to off-white powders with overall yields ranging from 26-61%. A 
table containing all yields can be seen in Table 29. 
 
Table 29: Percentage yields for the halogenated regioisomers (20a–20l) 
Compound no. Compound Name Abbreviation Yield (%) 
20a 2-fluphenidine 2-FP 40 
20b 3-fluphenidine 3-FP 33 
20c 4-fluphenidine 4-FP 44 
20d 2-chlophenidine 2-CP 43 
20e 3-chlophenidine 3-CP 54 
20f 4-chlophenidine 4-CP 49 
20g 2-brophenidine 2-BP 47 
20h 3-brophenidine 3-BP 49 
20i 4-brophenidine 4-BP 61 
20j 2-iodophenidine 2-IP 26 
20k 3-iodophenidine 3-IP 54 
20l 4-iodophenidine 4-IP 60 
 
The hydrochloride salts were determined to be soluble (at the level of 10 mg 
mL-1) in deionised water, methanol, dichloromethane and dimethylsulfoxide. 
To ensure the authenticity of the materials utilised in this study the synthesised 
compounds were fully structurally characterized, to produce reference spectra, 
by 1H NMR, 13C NMR (supplementary data: Figure 20-Figure 31), and FTIR 
(supplementary data: Figure 78-Figure 89). 19F NMR was also run on the 
relative compounds (20a–20c) and the respective chemical shifts can been 
seen in Table 30. The purity of all samples was checked, using the NMR 
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experiments and GC-MS analysis, with internal standards and were shown to 
be >95% in all cases. 
 
 
Figure 87: Reaction scheme for the synthesis of the halogenated diphenidine derivatives 
(20a-20l) 
The structures of all the halogenated diphenidine samples are very closely 
related to diphenidine (13a). 1H NMR spectrum was previously acquired for 
diphenidine in deuterated DCM (figure 63) in chapter 4. In order to show a 
direct comparison to the halogenated derivatives, which were run in DMSO-
d6, the diphenidine sample was repeated in DMSO-d6. 
 
The spectrum produced from the deuterated DMSO shows slight differences 
to the deuterated DCM spectrum and can be seen through the stacked spectra 
(figure 88). The DMSO spectrum (figure 89) shows a greater splitting, 
regarding the proton environments of the aromatic and piperidine regions, with 
clearer splitting patterns from coupling. There is a slight change in the 
chemical shift values of the 1H NMR spectrum, as the solvent is changed from 
DCM-d2 to DMSO-d6, with the amine peak shifted more upfield and the chiral 
proton shifted more downfield. The assignment of protons still matches, with 
the change of solvent, with the chiral proton (4.64 ppm) still coupled to the two 
CH2 protons (3.86 ppm and 3.53 ppm) in the 1H-1H COSY spectra. The peak 
at 3.73 ppm belongs to the piperidine ring with coupling to the peak at 3.52 
ppm in the 1H-1H COSY spectra and showing coupling to the same carbon in 
the 1H-13C HMQC spectra. This also shows that there is overlap at 3.52 ppm 
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with two different proton environments being superimposed on one another in 
this region. The 1H NMR signal for water is also seen at 3.33 ppm so may 
coalesce with peaks representing piperidine protons, should this be present in 
a sample. 
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Figure 88: Stacked 1H-NMR spectra of diphenidine (13a) run in DMSO-d6 (δ ppm = 2.50) and CDCl3 (δ ppm = 7.26) 
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Figure 89: 1H-NMR spectrum of diphenidine (13a) run in DMSO-d6 (δ ppm = 2.50) 
186 
The 1H NMR spectrum for diphenidine allows direct comparisons to be made 
with the corresponding spectra of the halogenated derivatives, in order to show 
whether any distinguishable features are present and whether each isomer 
can be distinguished from one another. All halogenated derivatives show a 
very similar aliphatic region, showing that it is possible to detect the class of 
compound based on this region. There are very slight differences in this region 
between both the meta- and para-substituted derivatives, in each halogenated 
substituent, compared to the ortho-substituted isomers. The halogenated 
substituent being situated on the 2’ position of the phenyl group alters two 
proton environments in the piperidine ring, with 2 peaks moving downfield from 
2.09 and 1.84 ppm to 2.76 and 2.68 ppm respectively and also the chiral centre 
proton shifts from 4.68 ppm to 4.995 ppm. The change in the chemical shift 
values is linked to the de-shielding of the shifted protons, through the addition 
of an electronegative atom, drawing electron density away from those regions. 
The 3’ and 4’ positional isomers produce aliphatic regions that are identical to 
one another. The difference between the 3’ and 4’ isomers compared to the 2’ 
isomer can be visualised in figure 90. 
 
The aromatic regions for each halogenated regioisomer shows significant 
differences in the number and chemical shifts of proton peaks. The splitting 
patterns, in the aromatic region, are unique for each compound showing that 
each halogen atom produces a slightly different effect in the neighbouring 
protons. It also shows the power of NMR to help identify specific compounds 
and the possibility of using 1H NMR experiments as an initial test for the 
detection of halogenated diphenidine regioisomers. The stacked spectra for 
the ortho-, meta- and para-positional isomers of the fluorinated derivatives 
shows the difference in the 1H NMR shifts in the aliphatic regions between 
positional isomers (figure 90), along with an enlargement of the differences in 
the aromatic region (figure 91). The enlarged stacked spectra (figure 91– 
figure 94) of the aromatic region for all positional isomers has also been 
produced to show the clear differences observed in the aromatic region of 
each spectrum. All spectra were run in DMSO-d6 with a residual peak at 2.50 
ppm. All spectra also contained residual peaks at 3.30 ppm for water. All 
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aromatic regions integrate to nine protons for the halogenated regioisomers 
compared to ten present in the 1H NMR spectrum for diphenidine. 
 
19F NMR was also performed on the 400 MHz instrument to complete NMR 
characterisation for the three fluphenidine regioisomers (20a–20c). 
Trifluoroacetic acid (TFA) was added as an internal standard in order to 
achieve an accurate chemical shift value for the sample. The chemical shifts 
for the three compounds can be seen in Table 30. These show the similarity 
between the shifts for the 3’ and 4’ positional isomers, although they can be 
distinguished using 400 MHz instrument, with the 2’ positional isomer 
providing a much different chemical shift value (+5 ppm). 
 
Table 30: 19F NMR chemical shift values for the fluphenidine regioisomer (FP, 20a–20c) 
Compound 19F chemical shift (δ ppm) 
20a -115.71 
20b -110.96 
20c -110.78 
 
 
When the halogenated substituents are checked through a computational 
program and the substituent is changed from fluorine to Iodine the log P values 
increase. This means that the lipophilicity is increased for iodine compared to 
fluorine. The iodine compounds can have the potential for an increased 
permeability in the blood brain barrier. This can also have an increased effect 
on the potency of these isomers. No significant difference was seen in the log 
P values between different positional isomers. However, the log P values of 
both the bromine and Iodine substituents are both > 5 and this can result in a 
higher metabolic turnover, low solubility and poor oral absorption meaning 
these drugs may not be very effective. Highly lipophilic compounds tend to 
bind to hydrophobic targets other than the desired target, and, therefore, there 
is an increased risk of promiscuity and toxicity. 138  No current toxicology 
experiments have been performed on any of the halogenated derivatives.         
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Figure 90: Stacked 1H-NMR spectra for the fluphenidine regioisomers (20a–20c) run in DMSO-d6 (δ ppm = 2.50) 
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Figure 91: Stacked 1H NMR spectra showcasing the aromatic region of the fluphenidine regioisomers (20a–20c) 
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Figure 92: Stacked 1H NMR spectra showcasing the aromatic region of the 2’-positional isomers of the halogenated diphenidines 
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Figure 93: Stacked 1H NMR spectra showcasing the aromatic region of the 3’-positional isomers of halogenated diphenidines 
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Figure 94: Stacked 1H NMR spectra showcasing the aromatic region of the 4’-positional isomers of halogenated diphenidines 
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5.3. Presumptive Testing 
Presumptive testing was carried out on all of the halogenated diphenidine 
derivatives (20a–20l) using the United Nations recommended guidelines.118 
No previous presumptive testing has been reported for any of the halogenated 
diphenidines, so a range of test reagents were used to fully detail possible 
colour changes. (i) Marquis test; (ii) Mandelin test; (iii) Simon’s test; (iv) 
Robadope’s test; (v) Scott’s test and (vi) Zimmerman test reagents were 
prepared and used based on the procedures detailed in section 2.2. A solution 
of each reference standard (10 mg mL-1) was prepared in deionised water and 
a couple of drops placed into a dimple well of a spotting tile. The required 
presumptive test reagent (1-2 drops) was then added and any colour change 
upon initial addition of the reagents were noted, with observations being made 
again after a five-minute period. Blank solutions of deionised water were used 
in order to show the natural colour of the test reagents prior to being added to 
sample solution. 
 
The Marquis, Mandelin and Scott’s reagents were the only reagents to provide 
a positive colour change with the halogenated diphenidines and the colour 
changes can be seen in Table 3131. The Scott’s test reagent turned all 
halogenated compounds blue, with the colour remaining constant after a five-
minute observation. This reaction matches that of all the diphenidine 
derivatives, with the coordination of the tertiary amines to the pink Co(II) 
octahedral complex affording the blue Co(II) tetrahedral complex.146 In a 
similar manner to all the diphenidine derivatives, the halogenated 
regioisomers also provide a false-positive for cocaine for the Scott’s test, 
increasing the confusion of identification between substances controlled by the 
Misuse of Drugs Act (1971) and those controlled by the Psychoactive 
Substances Act (2016).  
 
The reaction of the halogenated derivatives with the Marquis and Mandelin 
reagents is also similar to that of diphenidine. The intense yellow/orange 
change with the Mandelin reagent also loses its intensity similar to diphenidine. 
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The colour changes observed when the Marquis and Mandelin reagents are 
used vary slightly in intensity from one halogenated isomer to another and 
provide slightly different colours to the non-halogenated diphenidine 
derivatives. The stability of the product formed with the Mandelin test does not 
show stability, however, as the intense colour produced initially fades over five 
minutes. The iodine substituents still keep a higher colour intensity, with the 
Marquis reagent, compared to the remaining halogenated substituents. The 
colour change for the Scott’s reagent is consistent for all halogenated 
diphenidines, meaning identification of specific isomers is impossible even 
with the full range of presumptive tests. However, combining the Scott’s test 
with the Marquis test will help to show the initial possibility of a halogenated 
diphenidine being present.  
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Table 31: Colour changes observed with presumptive test reagents for the 12 halogenated 
diphenidine derivatives (20a–20l) immediately after addition and after 5 minutes of addition 
 
  
 
 
Marquis Mandelin  Scott’s 
 Immediate 
colour change 
Colour after 
5 minutes 
Immediate 
colour change 
Colour  after 
5 minutes 
Immediate 
colour change 
Colour after 
5 minutes 
20a orange light orange dark yellow yellow blue blue 
20b light orange light orange dark yellow yellow blue blue 
20c light orange light orange dark yellow yellow blue blue 
20d dark orange light orange dark yellow yellow blue blue 
20e orange light orange dark yellow yellow blue blue 
20f orange light orange dark yellow yellow blue blue 
20g orange light orange dark yellow yellow blue blue 
20h orange light orange dark yellow yellow blue blue 
20i orange light orange dark yellow yellow blue blue 
20j dark orange orange  dark yellow yellow blue blue 
20k dark orange orange dark yellow yellow blue blue 
20l dark orange orange dark yellow yellow blue blue 
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5.4. Thin Layer Chromatography (TLC) 
Thin layer chromatography has been performed on all 12 of the halogenated 
diphenidine regioisomers, using the same method and mobile phase 
composition, as used for the thirteen diphenidine derivatives (see section 4.4). 
Average Rf values are reported (Table 32) based on the averages from six 
repeats. Based on Rf values it is difficult to separate each regioisomer from 
one another. There is a slight pattern with the halogenated substituent present 
as the more polar fluphenidine regioisomers move more slowly on the TLC 
plate, as the interaction with the silica is stronger that that observed for the 
iodophenidne regioisomers. The Rf values do not allow the regioisomers of 
each substituted halogen to be distinguished from one another.  
 
Table 32: Thin Layer Chromatography data for the halogenated diphenidine regioisomers 
(20a–20l) 
 Compound name 
Spot colour 
under UV 
light (254 nm) 
 
Spot colour after staining with 
modified Dragendorff-Ludy-
Tenger Reagent 
Rf value 
20a 2-fluphenidine Black spot red spot 0.65 
20b 3-fluphenidine Black spot red spot 0.61 
20c 4-fluphenidine Black spot red spot 0.62 
20d 2-chlophenidine Black spot red spot 0.71 
20e 3-chlophenidine Black spot red spot 0.73 
20f 4-chlophenidine Black spot red spot 0.73 
20g 2-brophenidine Black spot red spot 0.80 
20h 3-brophenidine Black spot red spot 0.77 
20i 4-brophenidine Black spot red spot 0.79 
20j 2-iodophenidine Black spot red spot 0.83 
20k 3-iodophendine Black spot red spot 0.80 
20l 4-iodophenidine Black spot red spot 0.84 
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5.5. Gas chromatography – mass spectroscopy 
The twelve halogenated diphenidine derivatives were all injected into the GC-
MS after simple dissolution of the sample in methanol (1 mg mL-1) and a 
tenfold dilution (100 μg mL-1). No derivatisation step was required. All 
halogenated derivatives (20a–20l) were ran individually initially, before being 
run as a mixture, in order to determine retention times. Retention times (Rt) 
and relative retention times (RRt), in relation to the diphenidine (13a), can be 
seen in Table 33.  
 
Table 33: GC retention times for the 12 halogenated diphenidine derivatives (20a–20l) 
including relative retention time (RRt) relative to diphenidine (15a, Rt = 15.262 mins) with 
eicosane (E) added as an internal standard (Rt = 14.464, RRt = 0.95)  
Compound 
no. 
Compound 
Abbreviation 
Compound retention time 
(Rt/mins) 
Relative Retention 
time (RRt) 
20a 2-FP 15.52 1.02 
20b 3-FP 15.22 1.00 
20c 4-FP 15.26 1.00 
20d 2-CP 18.01 1.18 
20e 3-CP 17.96 1.18 
20f 4-CP 18.50 1.21 
20g 2-BP 19.67 1.29 
20h 3-BP 19.92 1.31 
20i 4-BP 20.85 1.37 
20j 2-IP 21.99 1.44 
20k 3-IP 22.85 1.50 
20l 4-IP 24.59 1.61 
 
The relative retention times from the developed method show the difficulties in 
trying to separate the fluorinated derivatives of diphenidine (20a–20c). This is 
a problem with the increasing popularity of fluorinated compounds being 
produced. There is also co-elution of the ortho- and meta-chlorine substituted 
isomers (20d, 20e), showing there may be an issue with the polarity of 
compounds when trying to separate the compounds on a commonly used non-
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polar column. No experiments were performed on a polar column, so possible 
interactions between a polar stationary phase and polar compounds could not 
be tested. With a polar column it would be expected that the more polar 
fluorinated compounds would produce stronger interactions, with the polar 
column, eluting later than the less polar iodinated compound. However, when 
the diphenidine derivatives were ran on a polar column the isomeric pairings 
reacted in the same manner, with retention times altering by the same 
difference.  
 
The relative retention times (RRt) compared to diphenidine (13a) for the 
bromo- and iodo-substituted derivatives (20g–20l) shows clear separation that 
would provide baseline separation if the BP and IP regioisomers were to be 
run all as a mixture. Rather than all samples being run as a mixture, three 
mixtures were prepared containing all positional isomers. Each positional 
isomer shows clear baseline separation from one another when included as 
an isomeric mixture (figure 96–figure 98) Diphenidine was included in the three 
isomer mixtures to show where the compound would elute and shows that 
baseline separation is not possible between diphenidine and each of the 
fluorinated derivatives (RRt = 1). This means that diphenidine cannot be 
included as an internal standard for quantification and calculation of relative 
retention, so eicosane must be used. 
 
As well as the separation in the retention times for diphenidine derivatives with 
different halogenated substituents, there are clear differences between the 
mass spectroscopy data of each differing substituent. The main difference is 
seen in the base peaks produced, with all adulterants and cutting agents 
producing different mass spectra as well. All spectra are shown in figure 99–
figure 105 with the common base peak structure for all derivatives shown in 
figure 95. There is also a clear difference with the chloro- and bromo-
compounds based on the number of active isotopes present for each atom. 
Chlorine contains two active isotopes, 35Cl and 37Cl, which appears in a 3:1 
ratio and causes each mass fragmentation peak to appear in a 3:1 ratio in the 
spectra as well, with different masses for each different isotope. The bromine 
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atom also contains two active isotopes, 79Br and 81Br, in an abundance ratio 
of 1:1, meaning two peaks are produced for each fragmentation with equal 
intensities. Fluorine and iodine are both considered monoisotopic. This feature 
with the halogen substituents can help aid with the identification of street 
samples.  
The main problem with using the mass spectrometry data for identification 
purposes comes when looking at the regioisomers from each substituted 
halogen, with each producing identical spectra.  
 
Method validation was performed for all three of the isomer mixtures, without 
the inclusion of diphenidine, in order to show the linearity and repeatability of 
the developed method. Five calibration standards were prepared between the 
region of 100 μg mL-1 and 300 μg mL-1 and run using the matching method to 
the previous mixtures. All 12 halogenated derivatives, along with the three 
additional adulterants; benzocaine (B); caffeine (C) and paracetamol (P), 
demonstrated a linear response between this concentration range (R2 ≥ 0.99). 
The limits of detection and quantification for the analytes were determined, 
based on the standard deviation of the response and the slope, as being 0.5–
2.1 and 1.6–6.2 μg mL−1 respectively. All samples showed acceptable 
repeatability, with 6 repeats performed, producing a relative standard deviation 
percentage (%RSD) range from 0.8–5.8%. The only two samples that 
produced slightly higher deviations were the paracetamol and 4-IP samples 
(10.4% and 9.9% respectively). This was only seen with the 100 μg mL−1 
standards, however, due to the small change in concentration injection 
creating bigger alterations in the peak areas created. These %RSD values are 
still much lower than the values reported for the diphenidine derivatives 
(section 4.5) and this can be explained through the use of an automated 
injection system, compared to a manual injector, removing any possible errors 
in injection volume.  
 
Accuracy for the method was performed using three spiked samples ranging 
from 80-120% of the targeted value. In this case the target value was set at 
200 μg mL−1, meaning percentage recovery samples were prepared at 160 μg 
200 
mL−1, 200 μg mL−1 and 240 μg mL−1. 200 μg mL−1 was chosen due to the ease 
of sample preparation as well as the concentration falling at the centre of 
linearity for calibration standard range. All percentage recovery results for the 
triplicate runs at each concentration, for all compounds, are contained within 
the supplementary, (Supplementary information: Table S23-Table S34). All 
samples showed acceptable percentage recovery (% assay) with calculated 
concentrations falling within ± 2% of the prepared sample and acceptable 
%RSD values all falling below 2%. The 4’-position isomers showed the highest 
percentage recovery values with the closest values to 102%. Based on the 
accuracy and precision experiments it is considered acceptable that street 
samples can be tested both qualitatively and quantitatively using GC-MS 
analysis. 
 
Figure 95: Base peak fragmentation for all the halogenated diphenidine regioisomers 
 
Figure 96: GC chromatogram for the mixture of 2’-positional halogenated diphenidine 
compounds with the inclusion of common adulterants: benzocaine (B); paracetamol (P); 
caffeine (C) and the internal standard eicosane (E) 
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Figure 97: GC chromatogram for the mixture of 3’-positional halogenated diphenidine 
compounds with the inclusion of common adulterants: benzocaine (B); paracetamol (P); 
caffeine (C) and the internal standard eicosane (E)   
 
Figure 98: GC chromatogram for the mixture of 4’-positional halogenated diphenidine 
compounds with the inclusion of common adulterants: benzocaine (B); paracetamol (P); 
caffeine (C) and the internal standard eicosane (E) 
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Figure 99: Mass spectrum for all fluphenidine regioisomers (20a–20c) 
 
Figure 100: Mass spectrum for all chlophenidine regioisomers (20d–20f) 
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Figure 101: Mass spectrum for all brophenidine regioisomers (20g–20i) 
 
Figure 102: Mass spectrum for all iodophenidne regioisomers (20j–20l) 
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Figure 103: Mass spectrum for benzocaine (B) 
 
Figure 104: Mass spectrum for paracetamol (P) 
 
Figure 105: Mass spectrum for caffeine (C)
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Table 34: GC-MS validation figures for the halogenated diphenidine derivatives (20a-20l) and the three added adulterants: benzocaine (B); paracetamol (P) 
and caffeine (C). Key: x Relative Retention time with respect to eicosane (E, Rt = 14.464 min) 
 
      Precision (%RSD) n=6 
Analyte Rt (mins) RRt
x 
Regression 
Coefficient (R2) 
LOD 
(μg mL-1) 
LOQ 
(μg mL-1) 
100 
 μg mL-1 
150 
μg mL-1 
200 
μg mL-1 
250 
μg mL-1 
300 
μg mL-1 
Benzocaine 10.05 0.69 0.992 0.66 2.01 1.46 1.43 3.33 2.14 2.93 
Paracetamol 11.32 0.78 0.997 1.65 5.01 10.41 3.30 2.59 2.70 1.09 
Caffeine 13.03 0.90 0.991 1.13 3.42 5.27 3.38 1.66 1.37 2.74 
20a 15.52 1.07 0.993 0.91 2.76 2.30 2.49 3.96 3.53 1.62 
20b 15.22 1.05 0.990 1.73 5.24 3.87 0.86 0.43 2.14 1.38 
20c 15.26 1.06 0.990 2.05 6.22 2.19 2.63 2.10 2.58 2.03 
20d 18.01 1.25 0.994 0.53 1.60 3.44 3.66 4.14 1.17 2.51 
20e 17.96 1.24 0.990 1.66 5.03 2.78 4.00 0.80 2.61 1.63 
20f 18.50 1.28 0.993 1.62 4.90 5.23 2.96 2.82 1.82 0.84 
20g 19.67 1.36 0.991 0.86 2.61 3.97 4.68 3.29 4.75 2.03 
20h 19.92 1.38 0.993 1.91 5.78 3.56 3.02 0.89 3.23 1.93 
20i 20.85 1.44 0.993 0.99 3.00 5.06 3.79 1.81 0.90 2.20 
20j 21.99 1.52 0.992 0.96 2.91 4.89 4.42 2.42 4.96 2.12 
20k 22.85 1.58 0.994 1.81 5.49 5.32 3.47 0.90 3.88 1.08 
20l 24.59 1.70 0.994 1.66 5.03 9.87 4.56 3.10 2.33 1.33 
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5.6. 60 MHz NMR presumptive testing 
The 60 MHz Pulsar instrument was used to obtain 1H NMR experiments on all 
the halogenated diphenidine derivatives (20a–20l). The spectra produced 
showed very similar patterns to those produced when characterising 
compounds synthesised, using 400 MHz instruments. The 60 MHz 
measurements allows similar structural information to be attained, as with the 
400 MHz instruments, with less expense and less expertise required to 
perform experimentation. The 1H NMR spectra were obtained at a 
concentration of 10 mg mL-1. Samples were prepared in the same manner as 
those used to obtain spectra on the 400 MHz instrument and each spectrum 
was acquired using 8 scans.  
 
In a similar manner to the 400 MHz spectra, the 60 MHz 1H NMR experiment 
produces a matching aliphatic region for all the ortho-substituted derivatives 
as seen in figure 106, with the aromatic region providing the major clear 
difference. The 1H NMR spectra acquired at 60 MHz are equivalent to those 
acquired on the 400 MHz instrument, with the only difference being the splitting 
patterns produced. The peaks appear broader, with a loss of resolution due to 
a weaker magnetic field when measurements are conducted on a 60 MHz 
instruments compared to the 400 MHz. As well as the aromatic regions for all 
the 2’-substituted positions showing significant differences, there are also 
clear modifications in the 1H NMR spectra when looking at the aromatic 
regions of the ortho-, meta- and para-positions of the same substituted 
halogens. The stacked aromatic regions for the three regioisomers for each of 
the substituted halogens can be seen in figure 107–figure 110. 
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Figure 106: 60 MHz 1H NMR spectra for the 2’-positional halogenated derivatives acquired in DMSO-d6 (δ ppm = 2.50) 
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Figure 107: 1H NMR spectra showing the aromatic region only of the fluphenidine regioisomers (20a–20c) acquired on a 60 MHz instrument 
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Figure 108: 1H NMR spectra showing the aromatic region only of the chlophenidine regioisomers (20d–20f) acquired on a 60 MHz instrument 
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Figure 109: 1H NMR spectra showing the aromatic region only for the brophenidine regioisomers (20g–20i) acquired on a 60 MHz instrument   
 
211 
 
Figure 110: 1H NMR spectra showing the aromatic region only for the iodophenidne regioisomers (20j–20l) acquired on a 60 MHz instrument 
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19F NMR measurements were also performed on a 60 MHz Pulsar instrument, 
on the relevant fluorinated substances (20a-20c), in order to show possible 
distinguishable features in the spectra. The stacked fluorinated spectra (figure 
111) show the possibility of easily distinguishing 20a from 20b and 20c, 
however the latter two regioisomers cannot be distinguished from one another. 
The chemical shift values can be seen in Table 35, which are referenced to 
trifluoroacetic acid (0.01% v/v) which has a chemical shift value of -76.55 ppm.  
 
Table 35: Table containing 19F NMR chemical shift data for the fluphenidine regioisomers 
(20a–20c) run on a 60 MHz instrument   
Compound 
no. 
Compound name 19F chemical shift 
(δ ppm) 
20a 2-fluphenidine -115.71 
20b 3-fluphenidine -110.90 
20c 4-fluphenidine -110.81 
 
With the ease of sample preparation and distinguishable features in the 
aromatic regions of the 1H spectra, it is possible for the 60 MHz instrumentation 
to act as a presumptive test to identify the presence of a halogenated 
diphenidine regioisomer. The 19F NMR data also helps to aid with possible 
identification of the fluorinated derivatives. Current literature suggests that no 
prior measurements have been made into the detection of halogenated 
derivatives using NMR instrumentation as a presumptive test.  
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Figure 111: Stacked 19F NMR spectra for the fluphenidine regioisomers run in DMSO with 
the inclusion of trifluoroacetic acid (TFA, δ ppm = −76.55) 
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5.7. Forensic application 
Two unknown, white powder samples (SS-H1 and SS-H2) were analysed in 
order to show the possibility of using the 60 MHz NMR and GCMS instruments 
to detect the presence of halogenated regioisomers.  
 
Initially, presumptive tests were carried out using the same procedures 
reported for the reference materials (section 2.2). Both street samples 
presented a positive reaction when tested with the Marquis and Mandelin 
reagents, changing to a dark orange and dark yellow colour respectively. 
When the Scott’s test was employed, a blue colour was observed for both 
compounds showing the possible presence of a diphenidine derivative, as all 
diphenidine reference materials change the Scott’s reagent from a red to a 
blue colour. Although the colour tests do not show the exact compound that is 
present in the street samples, it helps to narrow down possibilities with the 2-
CP isomer and all the iodophenidines regioisomers reacting in a similar 
manner with the Marquis and Mandelin reagents.  
 
Thin layer chromatographic (TLC) analysis of the two samples utilizing a silica 
gel stationary phase and a mobile phase consisting of dichloromethane-
methanol (9:1 v/v) containing 0.8% ammonia (7 N in methanol) indicated that 
street sample 1 contained a single component (SS-H1, Rf = 0.71), while the 
second street sample appeared to contain two components with the second 
spot not appearing as clearly under UV as the primary spot (SS-H2, Rf = 0.70 
and 0.55). The Rf values for the two street samples appears to fall within the 
range created when the chlophenidine regioisomers are analysed using a 
matching experimental setup. The spot created at a retention factor of 0.55 
does not appear to matchup with any of the halogenated regioisomers.  
 
Both street samples were then analysed using the 60 MHz NMR instrument 
using a matching 1H and 19F experiment to the ones performed with the 
reference material. In both cases the 19F experiments were performed with 
TFA as reference (δ ppm = -76.55) and no sample peaks were generated. This 
shows that the street samples cannot be a fluorinated substituted substance, 
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narrowing down the possible compounds present in a 5 minute experiment. A 
matching 1H experiment was performed subsequent to this and the two 
spectra can be seen in figure 112.  
 
 
Figure 112: 1H NMR spectra run in DMSO (δ ppm = 2.50), measured on a 60 MHz 
instrument for the two street samples (SS-H1 and SS-H2) 
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SS-H1 shows very similar pattern matching in the aliphatic region with all the 
halogenated diphenidine derivatives. It then also shows a very similar pattern 
to the 2-Cl isomer (figure 113) in the aromatic region.  
 
Figure 113: Full 1H NMR spectrum for the 2-CP standard (20d), performed on a 60 MHz 
instrument in DMSO-d6 (δ ppm = 2.50) 
The second street sample (SS-H2) shows a very similar pattern, however 
there are additional peaks in the aliphatic region compared to all halogenated 
diphenidine derivatives. This is seen at 3.2 ppm with a peak that appears to 
overlap just below 4 ppm. The peaks at 1.65 ppm and 5 ppm do show a very 
similar splitting pattern between SS-H2 and SS-H1, with the reference 
materials, which suggests that the second street sample could be a 
halogenated diphenidine derivative with slight impurities, or a compound with 
a very similar chemical structure. The aromatic region for SS-H2 still also 
shows a very similar pattern to the 2-CP isomer’s aromatic region with an 
additional peak at 8.1 ppm. This could again be due to a slight adulterant in 
the street sample as the remaining peaks and pattern matches to the reference 
material. In both cases the 60 MHz NMR provides a good initial indication as 
to the active component present, suggesting a match to the 2-CP isomer, and 
allows easier identification to be made with the common confirmatory tests. 
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Both SS-H1 and SS-H2 were then tested on the GC-MS in order to confirm 
the active ingredients present in the samples. The two samples were prepared 
at a concentration of 100 μg mL-1, through dissolution in methanol and dilution, 
to match the qualitative analysis of the reference materials. The two 
chromatograms produced are shown in figure 114 and figure 115. 
 
Figure 114: GC-MS chromatograph for SS-H1 with the inclusion of internal reference 
eicosane (E, Rt = 14.464 min)
 
Figure 115: GC-MS chromatograph for SS-H2 with the inclusion of internal reference 
eicosane (E, Rt = 14.464 min) 
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One sample peak was produced for SS-H1, while SS-H2 yielded two sample 
peaks, showing the possibility of either two active components or the addition 
of an adulterant / cutting agent, which matches observations made from the 
1H NMR spectrum. Both street samples included eicosane as an internal 
reference standard in order to calculate relative retention times (RRt) for 
comparison with the reference compounds. The eicosane peak for both street 
samples appears at 14.468 min with both samples producing a sample peak 
at 17.9 and 17.9 min respectively. These peaks create an RRt  of 1.24, which 
matches closely to the RRt values of both 20d and 20e. This would suggest 
that the active component is 2-CP as the 1H NMR spectrum produced for the 
presumptive testing does not match in the aromatic region to the 3-CP isomer, 
however it does create a close match to that of 2-CP. The mass spectrum was 
obtained for the sample peaks on both street samples and shows the same 
fragmentation masses (figure 116), however this would not help distinguish 
between 2-CP and 3-CP as both isomers produce matching spectra as 
mentioned previously. 
 
 
Figure 116: Mass spectrum for the sample peak produced in both SS-H1 and SS-H2 
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The second sample peak produced from SS-H2 elutes at 13.028 min with an 
RRt of 0.90 when compared with eicosane. This matches the RRt for caffeine 
and would account for the extra proton peaks seen, in the aromatic and 
aliphatic regions, of the 60 MHz NMR measurements. The mass spectrum 
produced also matches that of the caffeine reference.  
 
Figure 117: Mass spectrum produced for the adulterant peak of SS-H2 
The two street samples were also run on the 400 MHz instrument in order to 
confirm the presence of 2-CP in both samples. The comparison spectra for the 
2-CP with SS-H1 and SS-H2 can be seen in figure 118. This appears to 
confirm that SS-H1 is pure 2-CP with no adulterants or impurities, while SS-
H2 appears to contain 2-CP with the presence of an adulterant. There are 
peaks present in the 1H-NMR spectrum for SS-H1 and SS-H2 that are present 
due to water (3.30 ppm), however this could have come from the DMSO 
solvent and is not considered an impurity. 
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Figure 118: Stacked 1H-NMR spectra comparison for SS-H1, SS-H2 and 2-CP run in DMSO (δ ppm = 2.50) acquired using a 400 MHz instrument 
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After confirmation of the presence of 2-CP in both SS-H1 and SS-H2 and 
caffeine in SS-H2, qualitative analysis was performed. The two street samples 
were prepared at 200 μg mL-1 in order to fit the middle of the calibration series 
for both 2-CP and caffeine. All street samples were run in triplicate in a similar 
manner to the percentage recovery samples and concentrations were 
calculated for each run based on rearrangement of the calibration graph 
equations (2-CP: y = 0.019x – 0.2916; Caffeine: y = 0.0115x + 0.0217). Tables 
showing integration ratios with eicosane along with concentration calculations 
can be seen in Table 36. Concentrations were then converted into a w/w 
percentage based on the original weights of the two powdered street samples 
(SS-H1 – 287 mg; SS-H2 – 350 mg) and averages taken. 
 
Based on the concentrations calculated from the calibration series of both CP 
and caffeine it can be seen that the percentage weights of active ingredients 
have a combined total weight equal to the overall weight of the samples ± 1%. 
This shows that there are no additional adulterants or filling agents with street 
sample H1 being a pure white powder and SS-H2 a 50:50 mix of 2-CP and 
caffeine. 
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Table 36: Table showing concentrations and percentage weights of active ingredients in both SS-H1 and SS-H2 of caffeine and 2-CP 
Sample 
Integrated ratio Concentration (μg mL-1)  
weight of active component in sample (mg) 
% w/w 
Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 
Run 1 Run 2 Run 3 Average 
SS-H1 
2-CP 
3.49 3.5 3.52 199.5 198.2 200.5 
286.3 
99.7 % 
284.4 
99.1 % 
287.7 
100.2 % 
286.1 
99.7 % 
SS-H2 
2-CP 
1.56 1.61 1.59 97.5 99.8 98.9 
170.6 
48.7 % 
174.7 
49.9 % 
173.1 
49.5 % 
172.8 
49.4 % 
SS-H2 
Caffeine 
1.13 1.15 1.17 96.4 98.4 99.7 
172.2 
49.2 % 
168.7 
48.2 % 
174.5 
49.8 % 
171.8 
49.1 % 
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5.8.  Conclusions 
This chapter has shown the synthesis of 12 halogenated diphenidine 
derivatives that have not previously been reported or analysed in order to show 
the possibility of detecting new compounds rapidly when NPS are created. All 
compounds synthesised are pure (> 95 %) with yields ranging from 26–61%, 
showing production can be achieved in clandestine laboratories.  
 
Presumptive testing analysis allowed a rapid positive/negative response for 
the initial presence of diphenidines with Scott’s test reagent. However, a 
positive response with the Scott’s reagent could also suggest the presence of 
cocaine. Use of the Marquis and Mandelin reagents, in combination with the 
Scott’s reagent, also allows identification of halogenated derivatives with slight 
differences between regioisomers of different substituents. However, it may 
be difficult to identify which isomer was present in an unknown street sample 
judging on just colour. The positional isomers of each halogenated substituted 
produce the same UV results so attachment of any UV device would not aid 
with separation.  Some initial separation was also achieved using conventional 
thin layer chromatography (TLC) methods.  
 
60 MHz NMR experiments were performed as a possible replacement 
presumptive test to the colour test reagents. Sample preparation for both the 
1H and 19F experiments is simplistic with experiments carried out in under 5 
minutes. Distinguishing features were shown in the aromatic region of each 
regioisomer in the 1H NMR spectra with a clearly identifiable pattern for 
diphenidine derivatives in the aliphatic region. Analysis of two street samples 
using 60 MHz NMR has shown that possible unknown halogenated 
diphenidines can be initially identified based on pattern matching of the spectra 
against reference spectra.   
 
Validated GC-MS runs have been developed and validated for the first time 
for halogenated derivatives. All isomers in matching positions on the benzene 
ring have been separated in under 23 minutes. The length of the GC-MS 
analysis shows that presumptive 60 MHz NMR test can provide the same 
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result in a quicker time (5 minutes). It is also possible for non-scientists to 
analyse the 60 MHz NMR and compare against reference spectrum compared 
to the GC-MS instrumentation.     
 
The method allows general triaging of samples, but also a quantitative method, 
for both pure, individual component samples, and samples cut with common 
adulterants. The two street samples have been analysed using the GC-MS to 
confirm that both contain 2-CP, with SS-H2 also containing caffeine. All active 
ingredients make up the full weight of the street samples (± 1%) with no further 
adulterations or filling agents.   
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6. Chapter 6 – Fluorinated diphenidine analogues 
6.1. Overview 
From the previous halogenated diphenidine derivatives (Chapter 4) it was 
observed that difficulties began when trying to separate fluorinated 
regioisomers. Based on this knowledge, a range of monofluorinated 
diphenidine analogues were prepared in order to show the ease of production 
and the ever changing chemical structure of NPS. Changes in chemical 
structures and constant appearances of NPS on the illicit drugs market 
provides difficulties in detection and separation through analytical techniques. 
Seven different amines were used, with subtle changes made between 
classes, to show how small changes in alkylamine sidechains can produce 
differences in spectra produced and possible chromatographic separation.  
 
Characterisation was performed on all compounds in order to provide 
reference measurements that can be used by forensic organisations and law 
enforcement in order to help with rapid and easy identification when 
encountered in illicit samples. 13C, 1H and 19F NMR spectroscopy was used to 
characterise the compounds in addition to IR and TLC. A range of presumptive 
tests were used to show the interactions that occur when a range of reagents, 
used by law enforcement, are added to the reference solutions. 
 
Gas chromatography was used to separate mixtures of regioisomers within 
classes, while providing mass spectroscopy data for use as reference spectra. 
60 MHz NMR was then used as a possible presumptive testing instrument, 
with 1H and 19F experiments again performed to show the ability to distinguish 
between classes and then isomers within a class. This could then be used as 
a replacement for commonly used presumptive tests.   
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6.2. Synthesis 
Fluorinated diphenidine regioisomers and its analogues were synthesised as 
hydrochloride salts. All target compounds were prepared as racemic mixtures, 
using a matching method to the synthesis of diphenidine, from previously 
reported methods.102 The synthesis of the fluorinated analogues differed 
through the alteration of the aldehyde and amine utilised, with the three 
isomeric fluorinated benzaldehydes used in each case. The different amines 
used along with the final products produced, abbreviations and percentage 
yields, can be seen in table 37. Reference materials were produced as stable, 
colourless to off-white powders.    
 
Table 37: Percentage yields of all fluorinated diphenidine analogues showing all names, 
abbreviations and different amines used in synthesis 
Compound 
no. 
Compound name Amine used Abbreviation 
Yield 
(%) 
20a – 20c fluphenidine piperidine FP 33 – 44 
15a – 15c fluoroephenidine ethylamine FEP 51 – 64 
19a – 19c fluorolintane pyrrolidine FL 51 – 59 
21a – 21c fluoromephenidine methylamine FMP 48 – 60 
22a – 22c fluorodimephenidine dimethylamine FDMP 41 – 46 
23a – 23c fluorodiephendine  diethylamine FDEP 54 – 68 
24a – 24c flurotrifluoroephenidine trifluoroethylamine FTFEP 37 – 45 
 
The percentage yields show how consistent the synthesis of these classes of 
compound can be and how easily clandestine labs can produce these 
substances. The hydrochloride salts were determined to be soluble (10 mg 
mL-1) in deionised water, methanol, dichloromethane and dimethylsulfoxide. 
To ensure the authenticity of the materials utilised in this study the synthesised 
compounds were fully structurally characterized, to produce reference spectra, 
by 1H NMR (figure 121-figure 132), 19F NMR (Table 43) and 13C NMR 
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(supplementary data: Figure 32-Figure 49). The purity of all samples was 
checked by GC-MS and NMR analysis and shown to be >95% in all cases. 
 
 
Figure 119: Reaction scheme for the synthesis of the fluorinated diphenidine analogues 
 
Figure 120: Chemical structures for all fluorinated diphenidine analogues synthesised 
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Although the fluorinated diphenidine analogues are closely related to the 
structure of diphenidine the alteration of the amine chain/group yields a 
different aliphatic region in the 1H NMR spectra. These clear differences can 
be seen for all seven of the different classes of diphenidine analogue, while 
each individual fluorine positional isomer, within a class, produces a different 
aromatic region. The difference in the aromatic regions for each class of 
compound can clearly be seen whilst differences are also observed between 
the aliphatic regions within a class, when the fluorine is substituted in the para-
position of the phenyl ring. All proton spectra show a solvent residual peak, for 
DMSO-d6, at 2.50 ppm with acetone and water peaks at 2.08 and 3.33 ppm 
respectively. 9 aromatic protons are seen in the aromatic region for all 
compounds. HMQC and COSY NMR experiments were also performed for all 
compounds in order to identify the assignments of the aliphatic protons, which 
provide the spectral differences for each class. 
 
The 1H NMR spectra for the fluphenidine regioisomers (FP, 20a–20c) has 
been described in chapter 6, producing a very similar aliphatic region to that 
of diphenidine (13a), with similar splitting and chemical shift values for the 
piperidine ring, CH2 of the benzyl chain and proton bonded to the chiral carbon. 
 
The fluorolintane regioisomers (FL, 19a–19c) produce the closest similarity to 
the fluphenidine regioisomers regarding structures. The use of pyrrolidine 
instead of piperidine creates a product with a five-membered ring instead of a 
six-membered ring, with 8 protons rather than 10 in the region of 1.74 ppm – 
3.33 ppm. The residual peak for water at 3.33 ppm also coalesces with these 
peaks and the multiplet at 3.64 ppm also belongs to the pyrrolidine ring, based 
on coupling seen in the COSY spectra and the HMQC showing it coupling to 
the same carbon as the proton at 3.29 ppm. The proton bonded to the chiral 
centre is seen as a multiplet at 4.98 ppm with coupling to the triplet and doublet 
of doublets peaks at 3.89 ppm and 3.47 ppm, representing the adjacent CH2 
protons.  
 
The fluoroephenidine regioisomers (FEP, 15a–15c) show similar aliphatic 
regions to all the polyfluorinated ephenidine regioisomers seen in chapter 5. 
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The chiral centre proton is seen at 4.70, with the CH2 proton peaks adjacent 
seen at 3.65 ppm and 3.17 ppm. The splitting observed matches that seen by 
all other diphenidine analogues. The CH3 protons from the ethyl chain are 
seen at the triplet peak at 1.22 ppm, with coupling in the COSY spectrum to 
the multiplet peaks at 2.73 ppm and 2.89 ppm, representing the adjacent CH2 
protons. In a similar manner to the CH2 protons of the benzyl chain, these two 
protons exist in different chemical environments with the proton more 
downfield being more deshielded due the closeness of the fluorine substituent.  
 
The fluoromephenidine regioisomers (FMP, 21a–21c) contain peaks at 4.68, 
3.67 and 3.17 ppm with the same assignment as the FEP regioisomers. There 
is also a CH3 peak, however this appears a singlet peak at 2.42 ppm as there 
are no other protons to couple with.   
 
In a similar manner to the similarity between the FEP and FMP isomers, there 
is also the same similarity between the FDEP and FDMP regioisomers. Both 
compounds produce spectra with peaks at 4.92 ppm, for the chiral centre 
proton, and at 3.78 and 3.41 ppm for the adjacent CH2 protons. The FDEP 
compounds show two triplet peaks at 1.19 ppm and 1.35 ppm representing the 
two CH3 protons of the ethyl chain. The CH2 protons of the ethyl chain are seen 
as two quartet peaks 2.73 ppm and 3.28 ppm. The FDMP compounds show a 
significant difference with no CH2 protons, but two singlet peaks at 2.86 ppm 
and 2.62 ppm representing the two methyl groups bonded to the amine.  
 
Finally, the three fluorotrifluoroephenidine (FTFEP, 24a–24c) regioisomers 
show significant differences in the aliphatic region to all other diphenidine 
analogue classes. The main difference in the FTFEP regioisomers comes in 
the region between 3.50 and 3.98 ppm as the multiplicity of the peaks 
produced becomes more complex and broader peaks are produced. The 
peaks observed in other spectra at 3.62 ppm, representing one of the protons 
on the CH2 group adjacent to the chiral centre, begins to coalesce with CH2 
protons of the trifluoroethyl chain seen between 3.50 and 3.98 ppm. These 
protons split into more complex multiplet splitting patterns due to close 
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coupling with the fluorine atoms in the CF3 of the trifluoroethyl chain, however 
this provides a clear region of identification for the FTFEP regioisomers. 
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Figure 121: 400 MHz 1H NMR spectrum for 2-fluoroephenidine (2-FEP, 15a) run in DMSO-d6 (δ ppm = 2.50) 
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Figure 122: Stacked 400 MHz 1H NMR spectra showing the aromatic region for the fluoroephenidine regioisomers (FEP, 15a – 15c)   
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Figure 123: 400 MHz 1H NMR spectrum for 2-fluorolintane (2-FL, 19a) run in DMSO-d6 (δ ppm = 2.50)  
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Figure 124: Stacked 400 MHz 1H NMR spectra showing the aromatic region for the fluorolintane regioisomers (FL, 19a – 19c)   
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Figure 125: 400 MHz 1H NMR spectrum for 2-fluoromephenidine (2-FMP, 21a) run in DMSO-d6 (δ ppm = 2.50) 
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Figure 126: Stacked 400 MHz 1H NMR spectra showing the aromatic region for the fluoromephenidine regioisomers (FMP, 21a – 21c)    
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Figure 127: 400 MHz 1H NMR spectrum for 2-fluorodimephenidine (2-FDMP, 22a) run in DMSO-d6 (δ ppm = 2.50) 
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Figure 128: Stacked 400 MHz 1H NMR spectra showing the aromatic region for the fluorodimephenidine regioisomers (FDMP, 22a – 22c)     
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Figure 129: 400 MHz 1H NMR spectrum for 2-fluorodiephenidine (2-FDEP, 23a) run in DMSO-d6 (δ ppm = 2.50) 
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Figure 130: Stacked 400 MHz 1H NMR spectra showing the aromatic region for the fluorodiephenidine regioisomers (FDEP, 23a – 23c)     
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Figure 131: 400 MHz 1H NMR spectrum for 2-fluorotrifluoroephenidine (2-FTFEP, 24a) run in DMSO-d6 (δ ppm = 2.50) 
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Figure 132: Stacked 400 MHz 1H NMR spectra showing the aromatic region for the fluorotrifluoroephenidine regioisomers (FTFEP, 24a – 24c)
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6.3.   Presumptive testing 
Presumptive testing was carried out on all of the halogenated diphenidine 
derivatives (20a–20l) using the United Nations recommended guidelines.118 
No previous presumptive testing has been reported for any of the halogenated 
diphenidines, so a range of test reagents were used to fully detail possible 
colour changes. (i) Marquis test; (ii) Mandelin test; (iii) Simon’s test; (iv) 
Robadope test; (v) Scott’s test and (vi) Zimmerman test reagents were 
prepared and used based on the procedures detailed in section 2.2. A solution 
of each reference standard (10 mg mL-1) was prepared in deionised water and 
a couple of drops placed into a dimple well of a spotting tile. The required 
presumptive test reagent (1-2 drops) was then added and any colour change 
upon initial addition of the reagents were noted and observations were made 
again after a five minute time period. Blank solutions of deionised water were 
used in order to show the natural colour of the test reagents prior to being 
added to sample solution. 
 
Due to each different class of diphenidine analogue having a different amine 
functional group or chain, the reactions with the testing reagents will differ in 
each case. This will especially be the case where the amines differ from 
tertiary to secondary amines. There are clear differences between different 
classes of analogue, however the regioisomers within a class tend to produce 
the same colour changes with each reagent, making identification of a specific 
compound difficult.  
 
The classes of compounds that contain tertiary amines: FL; FP; FDEP and 
FDMP, all turn the Scott’s reagent from a pink red colouration to a blue 
solution. This has been explained in previous chapters as the reaction of the 
octahedral Co(II) complex that produces the pink colour to the Co(II) 
tetrahedral complex. This can help to distinguish the tertiary amines from the 
secondary amines: FEP, FMP and FTFEP, which do not produce a reaction 
with Scott’s reagent. However, when used alone the reagent cannot 
distinguish between all the classes. In order to show that secondary amines 
were present, Simon’s reagent was used. The reaction involves the production 
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of the Simon-Awe complex. 3 This occurs through the reaction of the amine 
and the aldehyde to produce the enamine, which in turn reacts with sodium 
nitroprusside before being hydrolysed to the Simon-Awe complex. All the 
secondary amine compounds react with the Simon’s reagent producing 
slightly different coloured solutions, while the tertiary amines do not react. With 
all the secondary amines producing slightly different colours with the Simon’s 
reagent it helps to slightly distinguish between classes however, in a similar 
manner to the Scott’s reagent the isomers within a class do not show 
significant differences in colour. The Simon-Awe usually produces a dark 
purple colour but in the case of the diphenidine analogues the colours range 
from a darker brown to brown/red colour.  
 
In all cases the Robadope and Zimmerman’s reagents do not produce a 
positive response. The Robadope reagent remains the peach colour that is 
seen in the blank sample. The Zimmerman’s reagent is usually a colourless 
solution when both reagent solutions are added together with the water blank 
sample however, when the sample solutions are added a pale yellow 
precipitate is formed in solution. This is reported as a negative reaction in this 
experiment as it is believed that this is just the formation of the freebase 
precipitate of the samples, rather than a positive reaction with the 
dinitrobenzene. With all classes producing a negative response it is not 
advised to use either of these test reagents to help distinguish between the 
diphenidine analogues.  
 
The Marquis and Mandelin reagents are both used generally as tests to detect 
the presence of alkaloids. The Mandelin reagent occurs as a yellow solution 
when prepared and appears as a light yellow solution when added to the 
aqueous blank, which can be explained through the dilution of the reagent 
colour. The FEP and FMP isomers all show a negative reaction, producing 
light yellow solutions. The remaining analogues produce a positive dark yellow 
solution however, it is not possible to distinguish the colour between classes. 
In all cases the dark yellow colouration fades to a lighter yellow colour after 
five minutes, although this yellow colour is not lost completely. This could be 
explained through the instability of the product formed in the reaction with the 
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reagent. The Marquis reagent, which begins as a colourless solution in the 
blank, has a positive reaction with all the analogues tested. Each class yields 
a slightly different colour ranging from light-yellow to orange. The 
fluorotrifluoroephenidine (FTFEP) regioisomers shows the biggest colour 
change with the Marquis reagent with a light brown solution formed. In a similar 
manner to the Mandelin reagent the sample solutions begin to lose their colour 
over 5 minutes, ending with a colourless solution or a more diluted version of 
the original colours produced. This means that the presumptive testing must 
be observed and reported upon initial addition rather than waiting before 
observations are made. In a similar manner to the fluorinated diphenidine 
derivatives (section 4.3) the regioisomers of each fluorinated analogue contain 
very similar λmax values when analysed using UV instrumentation, meaning 
this technique is also incapable of separating isomers from one another as an 
alternative to colour tests.  
 
In order to allow comparisons to be made, by distinguishing the possible 
classes present, the Marquis, Mandelin, Scott’s and Simon’s reagents should 
all be used. This will help to suggest the classes present for further testing to 
help identify the specific compound present. The presumptive tests individually 
would not identify the specific isomers presents, as all isomers within a class 
interact in a similar manner with all reagents.     
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Table 38: Reported colour changes for a range of presumptive test reagents on multiple fluorinated diphenidine analogues 
 
 
Marquis Mandelin Scott’s Simon’s Robadope’s Zimmerman’s 
 
Immediate 
colour 
change 
Colour after 5 
minutes 
Immediate 
colour 
change 
Colour  after 
5 minutes 
Immediate 
colour 
change 
Colour after 
5 minutes 
Immediate 
colour 
change 
Colour after 
5 minutes 
Immediate 
colour 
change 
Colour after 
5 minutes 
Immediate 
colour 
change 
Colour after 
5 minutes 
15a yellow colourless - - - - brown light brown - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
15b yellow colourless - - - - brown light brown - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
15c yellow colourless - - - - brown light brown - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
19a light orange colourless dark yellow yellow blue blue - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
19b light orange colourless dark yellow yellow blue blue - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
19c light orange colourless dark yellow yellow blue blue - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
20a orange light orange dark yellow yellow blue blue - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
20b light orange light orange dark yellow yellow blue blue - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
20c light orange light orange dark yellow yellow blue blue - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
21a yellow colourless - - - - brown brown - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
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21b yellow colourless - - - - brown/red brown/red - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
21c yellow colourless - - - - brown brown - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
22a light yellow colourless dark yellow yellow blue blue no reaction 
- 
no reaction 
- - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
22b light yellow colourless dark yellow yellow blue blue - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
22c light yellow colourless dark yellow yellow blue blue - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
23a  orange colourless dark yellow  yellow blue blue - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
23b orange colourless dark yellow yellow blue blue - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
23c orange colourless dark yellow yellow blue 
blue 
- - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
24a light brown colourless dark yellow yellow - 
- 
dark brown dark brown - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
24b light brown colourless dark yellow yellow - - dark brown dark brown - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
24c light brown colourless dark yellow yellow - - dark brown dark brown - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
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6.4. Thin layer chromatography 
All the monofluorinated diphenidine analogues were also analysed using thin 
layer chromatography (TLC). All the Rf values for each compound were 
measured using a matching mobile phase composition to the diphenidine 
regioisomers and halogenated diphenidines tested previously. Average Rf 
values have been reported (Table 39) based on the averages from six repeats. 
All compounds show only one spot using TLC, which helps to show that all 
reference materials are clean with no impurities, which is supported by the 
NMR analysis used for characterisation. The same colours are produced 
under UV light and with the addition of the modified Dragendorff-Ludy-Tenger 
reagent.102 Each of the diphenidine analogues show very similar Rf values to 
one another making identification of a specific compound difficult. There is no 
clear separation in the values between different classes or in values between 
different isomers within classes, therefore no conclusions can be drawn on 
TLC data alone. The TLC data can help to aid with characterisation in order to 
help confirm the identify of a compound when used in combination with 
commonly used tests such as 1H, 13C and 19F NMR and GC-MS. 
  
 249 
 
Table 39: Rf values for all the monofluorinated diphenidine analogues 
 
 
  
 Compound name 
Spot colour 
under UV 
light (254 
nm) 
 
Spot colour after staining 
with modified Dragendorff-
Ludy-Tenger Reagent 
Rf value 
15a 2-fluoroephenidine Black spot Red spot 0.56 
15b 3-fluoroephenidine Black spot Red spot 0.61 
15c 4-fluoroephenidine Black spot Red spot 0.58 
19a 2-fluorolintane Black spot Red spot 0.64 
19b 3-fluorolintane Black spot Red spot 0.64 
19c 4-fluorolintane Black spot Red spot 0.67 
20a 2-fluphenidine Black spot Red spot 0.65 
20b 3-fluphenidine Black spot Red spot 0.61 
20c 4-fluphenidine Black spot Red spot 0.62 
21a 2-fluoromephenidine Black spot Red spot 0.58 
21b 3-fluoromephenidine Black spot Red spot 0.50 
21c 4-fluoromephenidine Black spot Red spot 0.52 
22a 2-fluorodimephenidine Black spot Red spot 0.63 
22b 3-fluorodimephenidine Black spot Red spot 0.64 
22c 4-fluorodimephendine Black spot Red spot  0.61 
23a 2-fluorodiephenidine Black spot Red spot 0.59 
23b 3-fluorodiephenidine Black spot Red spot 0.61 
23c 4-fluorodiephenidine Black spot Red spot 0.64 
24a 2-fluorotriflouroephenidine Black spot Red spot 0.55 
24b 3-fluorotrifluoroephenidine Black spot Red spot 0.48 
24c 4-fluorotrifluoroephenidine Black spot Red spot 0.50 
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6.5. Gas chromatography – mass spectroscopy 
All diphenidine analogues were analysed using Gas chromatography–mass 
spectroscopy (GC-MS). Samples were prepared with a simple solvation in 
methanol (1 mg mL-1) and dilution (100 μg mL-1) with no derivatisation 
required. All samples were run individually before being run as mixtures in 
order to determine retention times and elution orders. The three common 
cutting agent and adulterants: benzocaine (B), caffeine (C) and paracetamol 
(P) were also run on the initial screening method to determine where they 
would fit in the elution order. Retention times (Rt) and relative retention times 
(RRt), in relation to the eicosane (E), can be seen in Table 40. 
 
From the initial screening method and the Relative Retention Times (RRt) 
measured, it can be seen that classes of analogues begin to separate. 
However, if these compounds were to be run as a mixture, baseline separation 
would not be achieved for a number of the compounds, with the isomers within 
each class all producing very similar RRt values. The adulterants also coelute 
with the reference materials when run using the initial screen. The interesting 
point observed in the screening method comes in the elution order and 
separation of the FEP, FDMP, FDEP and caffeine compounds. In the ortho-
compounds the elution order follows: FEP  FDMP  FDEP  caffeine with 
the 2-FEP and 2-FDMP compounds having the same RRt values. In the meta-
substituted compounds the elution order remains the same, but there is a 
much greater separation in the RRt values. Finally, with the para-substituted 
compounds the elution order changes completely with the elution order 
becoming: FDMP  FEP  caffeine  FDEP.   
 
The mass spectrometry data produced for each class of compound provides 
another method to potentially differentiate between reference materials. All 
classes, aside from the FEP and FDMP classes, contain unique spectra with 
individual base peaks (figure 137–figure 143). The FEP and FDMP 
compounds contain matching mass spectra due to the matching fragmentation 
scheme that occurs for all the monofluorinated diphenidine analogues. The 
mass of the base peak fragments for both the FDMP and FEP is the same 
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(m/z = 152.1) due to the rearrangement of the dimethylated tertiary amine in 
the FDMP compound to the secondary amine with an attached ethyl chain in 
the FEP compounds. The differences in the mass spectrometry helps to 
identify the class of compound present even in the screening run where peaks 
may not be baseline separated. In a similar manner to previous compounds 
analysed the mass spectra produced for isomers within the same class are the 
same, meaning isomers cannot be distinguished from mass spectroscopy data 
alone.  
 
Due to the screening method producing very similar RRt values for the majority 
of compounds, the method was developed in order to slow the incremental 
rate of temperature change in order to increase separation. The retention 
times and relative retention times compared to eicosane for the newer 
developed method can be seen in Table 41. From the RRt it can be seen that 
there is a greater separation in the values measured between classes. There 
are still similarities in the RRt values between isomers within a class, especially 
in the FP and FL classes where the amine is ringed due to the use of piperidine 
and pyrrolidine respectively, meaning baseline separation is still not possible 
even with the developed method. As the ramp is already at 1°C/min it is not 
possible for this to be slowed any further to improve separation and a method 
was attempted with the temperature held isothermally at 140°C for 40 minutes. 
No further separation was achieved compared to the developed method used.    
 
Mixtures were prepared, splitting all the compounds into three based on 
position of substitution on the benzene ring. The chromatographs (figure 134–
figure 136) further show the extended separation achieved between classes. 
In the meta (3’) and para (4’) mixtures all reference materials are baseline 
separated, however when the adulterants are added the FMP samples coelute 
with paracetamol. The caffeine peak also coelutes with the FDEP in the 3’ and 
4’ mixtures. In the ortho (2’) mixture the adulterants are baseline separated 
from all the reference materials. The 2-FEP and 2-FDEP samples are the only 
samples in the ortho-mixture that are not baseline separated from one another. 
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Further to using the developed GC method to help distinguish compounds a 
single ion monitoring (SIM) mode was used for the mass spectrometer 
detector. This helps to target specific ion fragments based on m/z values. In 
this case the SIM mode was selected with all base peak fragment weights 
chosen, apart from in the case of paracetamol where m/z=151.1 was used 
instead of m/z=109, as this is seen as a secondary peak in the majority of the 
reference material spectra. This means all samples produced two peaks when 
viewing chromatographs in SIM mode, one for the eicosane peak and one for 
sample. This helps to clearly identify individual peaks, with the only exception 
being the 2-FEP and 2-FDEP isomers with coelution occurring in the full scan 
mode and SIM mode, due to both compounds having an identical mass 
spectrum. When a mass of m/z=124.0 is used as a fragment in SIM mode it 
will produce a peak for the FEP, as a secondary base peak, but not for the 
FDEP isomer. This is not a problem in the meta- and para-mixtures where the 
FEP and FDEP peaks are resolved from one another. 
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Table 40: GC retention times for the diphenidine analogues, including relative retention time 
(RRt) relative to eicosane (E, Rt = 7.281 mins) 
 
  
Compound 
no. 
Compound 
Abbreviation 
Compound retention time 
(Rt / mins) 
Relative Retention 
time (RRt) 
15a 2-FEP 6.37 0.88 
15b 3-FEP 6.42 0.88 
15c 4-FEP 6.43 0.88 
19a 2-FL 7.25 1.00 
19b 3-FL 7.24 0.99 
19c 4-FL 7.25 1.00 
20a 2-FP 7.58 1.04 
20b 3-FP 7.59 1.04 
20c 4-FP 7.60 1.04 
21a 2-FMP 6.23 0.86 
21b 3-FMP 6.28 0.86 
21c 4-FMP 6.27 0.86 
22a 2-FDMP 6.37 0.88 
22b 3-FDMP 6.86 0.94 
22c 4-FDMP 6.40 0.88 
23a 2-FDEP 6.82 0.94 
23b 3-FDEP 6.85 0.94 
23c 4-FDEP 6.86 0.94 
24a 2-FTFEP 6.03 0.83 
24b 3-FTFEP 6.07 0.83 
24c 4-FTFEP 6.08 0.84 
P Paracetamol 6.25 0.86 
B Benzocaine 5.84 0.80 
C Caffeine 6.25 0.86 
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Table 41: GC retention times for the diphenidine analogues on the developed GC method, 
including relative retention time (RRt) relative to eicosane (E, Rt = 7.281 mins) 
Compound 
no. 
Compound 
Abbreviation 
Compound retention time 
(Rt / mins) 
Relative Retention 
time (RRt) 
15a 2-FEP 18.14 0.57 
15b 3-FEP 18.01 0.57 
15c 4-FEP 18.83 0.60 
19a 2-FL 28.13 0.89 
19b 3-FL 28.00 0.89 
19c 4-FL 28.08 0.89 
20a 2-FP 33.64 1.07 
20b 3-FP 33.72 1.07 
20c 4-FP 33.91 1.07 
21a 2-FMP 17.06 0.54 
21b 3-FMP 17.50 0.55 
21c 4-FMP 17.51 0.55 
22a 2-FDMP 18.31 0.58 
22b 3-FDMP 18.76 0.59 
22c 4-FDMP 18.08 0.57 
23a 2-FDEP 22.85 0.72 
23b 3-FDEP 23.18 0.73 
23c 4-FDEP 23.35 0.74 
24a 2-FTFEP 16.00 0.51 
24b 3-FTFEP 16.38 0.52 
24c 4-FTFEP 16.36 0.52 
P Paracetamol 17.60 0.56 
B Benzocaine 14.55 0.46 
C Caffeine 23.26 0.74 
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Figure 133: GC-MS chromatograph for the 2’ positional isomers of the monofluorinated diphenidine analogues including internal standard eicosane (E) and 
common adulterants: benzocaine (B); paracetamol (P) and caffeine (C), run in a full scan mode. 
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Figure 134: GC-MS chromatograph for the 3’ positional isomers of the monofluorinated diphenidine analogues including internal standard eicosane (E) and 
common adulterants: benzocaine (B); paracetamol (P) and caffeine (C), run in a full scan mode. 
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Figure 135: GC-MS chromatograph for the 4’ positional isomers of the monofluorinated diphenidine analogues including internal standard eicosane (E) and 
common adulterants: benzocaine (B); paracetamol (P) and caffeine (C), run in a full scan mode.
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Figure 136: Mass spectrum for the fluoroephenidine (FEP) regioisomers (15a–15c) 
 
Figure 137: Mass spectrum for the fluorolintane (FL) regioisomers (19a–19c) 
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Figure 138: Mass spectrum for the fluphenidine (FP) regioisomers (20a–20c) 
 
Figure 139: Mass spectrum for the fluoromephenidine (FMP) regioisomers (21a–21c) 
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Figure 140: Mass spectrum for the fluorodimephenidine (FDMP) regioisomers (22a–22c) 
 
Figure 141: Mass spectrum for the fluorodiephenidine (FDEP) regioisomers (23a–23c) 
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Figure 142: Mass spectrum for the fluorotrifluoroephenidine (FTFEP) regioisomers 
(24a–24c) 
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Table 42: GC-MS validation figures for the monofluorinated diphenidine analogues and the three added adulterants: benzocaine (B); paracetamol (P) and 
caffeine (C). Key: x Relative Retention time with respect to eicosane (E, Rt = 31.58 min)  
 
 
      Precision (%RSD) n=6 
Analyte Rt (mins) RRt
x 
Regression 
Coefficient 
(R2) 
LOD 
(μg mL-1) 
LOQ 
(μg mL-1) 
100 
 μg mL-1 
200 
μg mL-1 
300 
μg mL-1 
400 
μg mL-1 
500 
μg mL-1 
Benzocaine 14.55 0.46 0.9975 6.58 19.94 1.81 2.15 0.71 0.86 0.31 
24a 16.00 0.51 0.9951 9.25 28.03 2.04 2.13 1.20 0.29 0.08 
24b 16.38 0.52 0.9934 10.79 32.68 3.83 2.13 1.72 0.66 0.17 
24c 16.36 0.52 0.9987 11.81 35.81 0.69 1.35 2.15 2.79 0.06 
21a 17.06 0.53 0.9953 9.09 27.55 2.71 1.44 0.62 0.63 3.73 
21b 17.50 0.55 0.9939 10.37 31.42 4.22 2.60 3.50 0.32 0.04 
21c 17.51 0.55 0.9975 11.31 34.27 1.03 4.33 2.78 3.08 0.33 
Paracetamol 17.66 0.56 0.9906 8.01 21.46 2.18 1.75 2.26 1.53 1.88 
15a 18.14 0.57 0.9924 11.57 35.05 3.12 1.50 0.42 0.78 2.87 
15b 18.01 0.57 0.9918 12.05 36.50 5.28 2.75 1.41 0.27 1.62 
15c 18.83 0.60 0.9963 12.83 38.89 0.52 3.43 1.45 4.20 0.77 
22a 18.31 0.58 0.9954 8.96 27.14 5.20 2.21 1.51 0.28 0.12 
22b 18.76 0.59 0.9911 12.52 37.95 5.59 2.33 0.79 0.17 0.75 
22c 18.08 0.57 0.9919 15.14 45.88 0.71 3.04 1.42 4.04 0.91 
23a 22.85 0.72 0.9923 11.65 35.30 4.10 2.26 0.60 0.14 0.22 
23b 23.18 0.73 0.9906 12.92 39.14 4.03 1.14 2.51 0.08 0.09 
23c 23.35 0.74 0.9997 14.01 42.46 0.60 3.33 1.19 3.73 0.93 
caffeine 23.30 0.74 0.9928 8.79 26.64 5.16 3.48 0.42 0.38 0.34 
19a 28.13 0.89 0.9933 10.92 33.08 3.52 1.93 1.56 1.05 0.25 
19b 28.00 0.89 0.9911 12.57 38.10 3.89 1.90 1.20 0.09 0.33 
19c 28.08 0.89 0.9953 14.44 43.76 0.18 4.09 1.45 3.26 0.30 
20a 33.64 1.07 0.9907 12.84 38.92 3.57 1.66 0.63 0.89 0.26 
20b 33.72 1.07 0.9910 12.63 38.27 3.78 2.39 0.36 0.22 0.44 
20c 33.91 1.07 0.9961 14.29 33.61 0.69 4.04 1.49 3.21 0.15 
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Five calibration standards were prepared between the region of 100 μg mL-1 
and 500 μg mL-1 and run using the matching developed method to the previous 
three mixtures. All monofluorinated diphenidine analogues, along with the 
three additional adulterants, benzocaine (B); caffeine (C) and paracetamol (P), 
demonstrated a linear response between this concentration range (R2 ≥ 0.99). 
The limits of detection and quantification for the analytes were determined, 
based on the standard deviation of the response and the slope, as being 6.58–
15.14 and 19.94–45.88 μg mL−1 respectively (Table 42). The concentration 
range used was based on the response of the 100 μg mL−1 due to baseline 
being slightly increased due to repetitive sample analysis prior to inlet clean. 
This had no effect on sample correlation or ratio response between sample 
and eicosane signals, meaning a positive correlation could still be achieved. 
Apart from the 3-FEP, 2FDMP and 3-FDMP 100 μg mL−1 samples, all solutions 
showed acceptable repeatability, over 6 repeats, with RSD values <5%.  
 
Accuracy for the method was performed using three spiked samples ranging 
from 80-120% of the targeted value. In this case the target value was set at 
300 μg mL−1, meaning percentage recovery samples were prepared at 240 μg 
mL−1, 300 μg mL−1 and 360 μg mL−1. 200 μg mL−1 was chosen due to the ease 
of sample preparation as well as the concentration falling at the centre of 
linearity for the calibration standard range. All percentage recovery tables can 
be seen in supplementary info, (Supplementary info: Table S35-S52). All 
samples showed acceptable percentage recovery (% assay) with calculated 
concentrations falling within ± 2 μg mL−1 of the prepared sample and %RSD 
values all falling below an acceptable 2%. Based on the accuracy and 
precision experiments it is considered acceptable that street samples can be 
tested both qualitatively and quantitatively using GC-MS analysis. No street 
samples were tested for this GC-MS method. 
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6.6. 60 MHz NMR presumptive testing 
60 MHz NMR was used to obtain 1H and 19F NMR spectra for all the 
monofluorinated diphenidine analogues. The 1H NMR spectra produced 
showed very similar characteristic patterns to those produced when 
structurally elucidating the compounds synthesised, using a 400 MHz 
instrument. The 19F NMR chemical shift values produced (Table 43) also 
match those produced using the 400 MHz instrument.  
 
In all cases the 1H NMR spectra were acquired in DMSO-d6 (δ ppm = 2.50) in 
order to provide a clear reference point for all spectra to then be stacked such 
that comparisons could be made easier. In a similar way to the halogenated 
derivatives, the spectra produced by the 60 MHz instrument still provides some 
splitting for peaks, although the resolution is reduced from the 400 MHz 
instrument. This means that peaks appear broader even though the pattern 
shape of the spectra will match between different powered magnets. This 
allows the 60 MHz instrument to be employed in a presumptive test, as it still 
provides vital information on the distinguishing features of the compounds 
investigated. The 400 MHz can then be used as a conformational tool for 
structural characterisation along with the GC-MS method developed to identify 
a specific isomer.  
 
In all cases, each different class produced a “signature pattern” in the aliphatic 
region that matches with the spectra produced from the 400 MHz instrument, 
which can help distinguish it from other classes. The stacked spectra for all 
ortho-substituted mono-fluorinated analogues, with the aliphatic region 
enlarged, are seen in figure 144, to demonstrate the ease that different classes 
can be differentiated.  
 
When it has been determined what class is present the three regioisomers 
within the class can be determined based on the aromatic region of the three 
regioisomers. All three positional isomers produce individual aromatic regions 
based on the coupling effected by the positioning of the fluorine and 
surrounding proton environments. The stacked aromatic regions for each 
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class can be seen in figure 145–figure 151, showing how easily each particular 
compound can be identified.  
 
It was shown from the fluorinated diphenidine regioisomers previously that 
there is limited resolution between the 19F signals for the 3’ and 4’ isomers and 
this pattern continues in all the monofluorinated diphenidine analogues. This 
means that both the 19F and 1H NMR experiments must be used in conjunction 
in order to ascertain the compounds present. The only compounds to produce 
slightly different 19F NMR spectra are the FTFEP regioisomers. These produce 
one peak for the monofluorinated substituent in the benzene ring and another 
peak representing all fluorines in the CF3 of the ethyl chain. The stacked 
spectra for the compounds can be seen in figure 162. Trifluoroacetic acid (δ 
ppm = -76.55) was added as an internal standard. The peaks representing the 
CF3 group appear at -66.20 ppm for each isomer, with the peaks for the 
fluorine in the benzene ring being similar for the 3- and 4- isomers but different 
for the 2- isomer. 
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Figure 143: Stacked 60 MHz 1H NMR spectra showcasing the aliphatic regions for the 
monofluorinated diphenidine analogues run in DMSO-d6 (δ ppm = 2.50)
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Figure 144: Stacked 60 MHz 1H NMR spectra showcasing the aromatic region for the fluoroephenidine regioisomers (4-FEP, 15a–15c) 
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Figure 145: Stacked 60 MHz 1H NMR spectra showcasing the aromatic region for the fluorolintane regioisomers (FL, 19a–19c) 
 
 269 
 
 
Figure 146: Stacked 60 MHz 1H NMR spectra showcasing the aromatic region for the fluphenidine regioisomers (FP, 20a–20c) 
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Figure 147: Stacked 60 MHz 1H NMR spectra showcasing the aromatic region for the fluoromephenidine regioisomers (FMP, 21a–21c) 
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Figure 148: Stacked 60 MHz 1H NMR spectra showcasing the aromatic region for the fluorodimephenidine regioisomers (FDMP, 22a–22c) 
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Figure 149: Stacked 60 MHz 1H NMR spectra showcasing the aromatic region for the fluorodiephenidine regioisomers (FDEP, 23a–23c) 
 
 273 
 
Figure 150: Stacked 60 MHz 1H NMR spectra showcasing the aromatic region for the fluorotrifluoroephenidine regioisomers (FTFEP, 24a–24c) 
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Figure 151: Stacked 60 MHz 19F NMR spectra for the fluorotrifluoroephenidine regioisomers (FTFEP, 24a–24c) 
 275 
 
Table 43: Table containing 19F NMR chemical shift data for all monofluorinated diphenidine 
analogues 
Compound 
no. 
Compound name 19F chemical shift 
(δ ppm) 
15a 2-fluoroephenidine -118.64 
15b 3-fluoroephenidine -111.36 
15c 4-fluoroephenidine -112.16 
19a 2-fluorolintane -118.86 
19b 3-fluorolintane -111.96 
19c 4-fluorolintane -112.43 
20a 2-fluphenidine -115.20 
20b 3-fluphenidine -110.96 
20c 4-fluphenidine -110.89 
21a 2-fluoromephenidine -118.24 
21b 3-fluoromephenidine -111.26 
21c 4-fluoromephenidine -111.94 
22a 2-fluorodimephenidine -115.80 
22b 3-fluorodimephenidine -110.71 
22c 4-fluorodimephenidine -110.64 
23a 2-fluorodiephenidine -117.89 
23b 3-fluorodiephenidine -111.03 
23c 4-fluorodiephenidine -111.29 
24a 2-fluorotrifluoroephenidine -66.20 (CF3), 
 -117.81 
24b 3-fluorotrifluoroephenidine -66.20 (CF3), 
 -110.54 
24c 4-fluorotrifluoroephenidine -66.20 (CF3), 
 -110.79 
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6.7. Quantitative 60 MHz analysis 
Quantitative analysis was attempted on the 60 MHz Pulsar instrument in order 
to show the possibility of being able to determine how much active component 
is present in a street sample. The 4-FEP sample was chosen for the 
quantitative analysis with trifluoroacetic acid (TFA, 0.1 % v/v) used as an 
internal standard to calculate peak area ratios. 5 samples were prepared in a 
concentration range of 5 mg mL -1 to 15 mg mL -1. A 19F NMR spectrum was 
acquired for each of these samples, with each spectrum being acquired in 
triplicate. The sample 19F signals and that of the TFA were integrated and a 
ratio was calculated (Table 44).  
 
Table 44: Integrated area values for the calibration solutions from 19F NMR experiments on 
a 60 MHz instrument 
Concentration 
(mg mL -1)  
Integrated area ratios 
Run 1 Run 2 Run 3 
5 5.73 5.8 5.68 
7.5 7.07 7.16 6.89 
10 8.34 8.28 8.22 
12.5 9.59 9.62 9.58 
15 10.8 10.76 10.91 
 
The graph (figure 152) shows that there is a good potential to perform 
quantitative analysis on a low field NMR system. The correlation coefficient for 
the calibration graph is acceptable (0.9985) and results show good 
repeatability with RSD values for each concentration samples < 2%. The LOD 
and LOQ of the system are 1.68 and 3.20 mg mL-1 respectively and these are 
below the usual amounts of sample that are obtained from seized samples.  
 
In a similar manner to the fluoroamphetamine (FA, chapter 3) quantitative 
analysis using 19F NMR, on the Pulsar instrument, the calibration graph does 
not go through the origin (x = 0, y = 0). This is due to noise of the baseline 
associated with the collection of the spectrum. In order to avoid this an average 
integration of the noise around each signal would be needed and subtracted 
from the integration value of this peak. This is not performed due to time 
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restraints associated with the processing of each spectrum and multiple 
repeats. Also the main aim is for this to be performed by people with less 
scientific background who would not be familiar with processing techniques 
and the calibration graph has shown it is not necessary. A 5 second relaxation 
delay ensures that there is enough of a gap in between pulses to allow a full 
90° relaxation. A 2.5 mg mL-1 was ran and fell within the linear response, 
however adding another standard below this would fall below the limit of 
detection (LOD).      
 
Further testing would be needed to confirm optimisation related to the number 
of scans and spectral window in order to show that the LOD and LOQ of the 
system have been fully optimised. Testing on further classes would be needed 
in order to show that qualitative analysis can be performed on multiple classes 
and not just diphenidine analogues. 
 
 
Figure 152: Calibration graph for the 4-FEP isomer using 19F NMR spectroscopy on a 60 
MHz instrument 
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6.8. Conclusions  
Twenty-one monofluorinated diphenidine analogues were synthesised in order 
to show the ease of production within clandestine labs. All reference materials 
were shown to be >95% pure with yields ranging from 33-68%. All compounds 
were fully characterised using a range of analytical techniques. 
 
Presumptive testing using a range of test reagents showed initial presence of 
possible classes within a solution. This was especially true when distinguishing 
between secondary and tertiary amines. The Marquis, Mandelin, Scott’s and 
Simon’s reagents should be used in combination with one another to help 
show the class present. In a similar manner to the halogenated diphenidines, 
it is not possible to distinguish regioisomers within a class using colour test 
reagents.  
 
A GC-MS method was developed which helped to separate different classes 
with mixtures used where the fluorine substituent were in matching positions 
on the benzene ring. This when combined with the mass spectrometry data 
provides identification of the class within 35 minutes. Changing the amine does 
show some difficulties in separation of the regioisomers within a class, 
especially those where the amine is a group rather than a chain, as with the 
FP and FL compounds. However, it is unlikely that samples would appear as 
a mixture, on the illicit drugs market, containing more than one of the same 
class of fluorinated diphenidine analogue. No street samples were tested as 
no street samples have been encountered containing compounds synthesised 
in this instance.  
 
Finally, 60 MHz NMR can help to identify the class of compound present as 
well as the specific isomer within a class. This was achieved using a 
combination of both 1H and 19F experiments. It was observed that using the 
aliphatic region of the 1H spectrum would help to identify the class, while the 
aromatic region helps to identify the isomer within the class. It was also shown 
from initial testing that the 60 MHz instrument can also be used to perform 
quantitative analysis, with more testing needed to clearly show its ability to 
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determine amounts of active ingredients within street samples. This 
demonstrates that 60 MHz NMR spectroscopy can be employed in a 
presumptive testing technique due to the speed and ease of testing, as 
experiments are performed in under 5 minutes with little sample preparation 
needed. 
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7. Chapter 7 - Separation and identification of 
polyfluorinated ephenidine regioisomers 
7.1. Overview 
Ephenidine has been reported in the literature previously-111, 112, however 
there has been no previous reports of any fluorinated derivatives emerging 
onto the drugs market. One major problem encountered by forensic 
laboratories and law enforcement agencies is the ability to detect new 
compounds as soon as they emerge, with little reference data available to help 
in the identification. Difficulties also emerge when more than one fluorine atom 
appears within a compound as a spectrum can become more confusing and 
difficult to interpret. 
 
This chapter will aim to synthesise the difluorinated derivatives of ephenidine 
along with the tri, tetra and pentafluorinated derivatives. Full characterisation 
will be performed using a range of analytical techniques including GC-MS and 
NMR. 19F NMR will be utilised in order to provide spectra that are easier to 
interpret compared to the 1H NMR spectra.  
 
A GC-MS method will be developed in order to try and separate the nine 
polyfluorinated ephenidine derivatives. 60 MHz NMR will also be used to 
acquire 1H and 19F spectra in order to show the possibility of using “low field” 
NMR as a new presumptive testing device. Comparisons will be made in order 
to show the possibility of distinguishing between the different regioisomers. 
Two dimensional experiments will be developed on the 60 MHz NMR in order 
to further help with the identification of the different regioisomers. 
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7.2. Synthesis 
The six difluoroephenidine derivatives (DFEP, 15d–15i) along with the trifluoro 
(TriFEP, 15j), tetrafluoro (TeFEP, 15k) and pentafluoroephenidine (PFEP, 
15l) samples were prepared as their corresponding hydrochloride salts. These 
were prepared to show possible compounds that could be made in future, as 
popularity in the production of fluorinated derivatives has been reported to be 
increasing.2   
  
All target compounds were synthesised, as racemic mixtures, using the same 
methodology as the diphenidine derivatives using the requisite aldehyde. 
Reference materials were produced as stable, colourless to off-white powders 
with overall yields ranging from 48–64%. Solubility tests showed the 
hydrochloride salts to be soluble in water, methanol, dichloromethane and 
dimethylsulfoxide at a concentration of 10 mg mL-1. In order to show 
compounds had been correctly synthesised, ready for analysis, full structural 
characterisation was carried out using 1H NMR, 13C NMR and 19F NMR. The 
purity of all samples was ascertained by NMR and GC-MS analysis and shown 
to be >95% in all cases. 
 
 
Figure 153: Reaction scheme for the synthesis of the polyfluorinated ephenidine 
compounds (15d – 15l) 
 
The backbone of the polyfluorinated ephenidine isomers provides a very 
similar aliphatic region when using 1H NMR. The only main difference between 
these compounds comes in the aromatic region of the proton spectra, with 19F 
NMR being utilised in order to better show the possibility of distinguishing 
between isomers. All spectra were run in DMSO-d6 with a solvent peak at 2.50 
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ppm. Some spectra contain acetone and water residual peaks at 2.09 ppm 
and 3.33 ppm respectively. Acetone is used in the recrystallization process 
and so trace amounts may be present in the NMR spectra, which may account 
for slight losses in purities reported. Trace amounts of water may also be 
present in DMSO-d6. In addition, as hydrochloride salts were produced, some 
compounds may present as a hydrated salt. 
 
All polyfluorinated ephenidine isomers show a triplet peak at 1.23 ppm 
representing the three CH3 protons of the ethyl chain. There are also two 
multiplet peaks, representing the CH2 of the ethyl chain, at 2.80–2.90 ppm that 
show both protons exist in different chemical environments. This could be due 
to potential coupling with fluorines in the phenyl ring, as the 2,6-DFEP isomer 
does show a difference with only one quartet peak representing two protons, 
seen at 2.94 ppm. The fluorines in 2,6-DFEP may not interact with the ethyl 
chain, which would then result in both protons in the CH2 existing in the same 
chemical environment. In a similar way to the diphenidine regioisomers, there 
is a multiplet at 4.80 ppm that represents the chiral centre proton. Two peaks 
at 3.15 ppm and 3.80 ppm with a splitting pattern of a triplet and a doublet of 
doublets respectively represent the CH2 of the benzyl group and exist in 
different chemical environments based on the rotation of the compounds. All 
aliphatic regions show the same pattern for all polyfluorinated ephenidine 
regioisomers, meaning they cannot be distinguished based on this region. 
 
Two amine protons are present for all compounds (that were isolated as the 
hydrochloride salts) and the chemical shifts of these vary between 9.20 and 
10.50 ppm for each sample. The main difference between each 1H NMR 
spectrum comes in the aromatic regions. For the tri-, tetra- and 
pentafluoroephenidine samples the number of protons stated through the 
integration helps to identify, which sample is present, as the number of protons 
in the aromatic region decreases from seven to five as the number of fluorine 
atoms added to the benzene ring increases.  However, these differences in 
the aromatic regions only help when identifying compounds found as individual 
components. When multiple difluoroephenidine regioisomers are seen as a 
mixture, there is overlap in these aromatic peaks making it difficult to 
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determine which compound is present or how many samples are present. 
Stacked 1H NMR spectra, acquired using a 400 MHz instrument, for the 
aromatic region of DFEP is shown in figure 155 whilst the full range (0-12 ppm) 
1H NMR spectra of the 2,3-difluoroephenidine isomer (2,3-DFEP, 15d) is 
shown in Figure 154. 
 
19F NMR spectroscopy is required in order to help distinguish which isomer 
may be present in street samples and also to aid with mixture analysis. The 
19F NMR chemical shift data (Table 45), obtained from a 60 MHz “benchtop” 
Pulsar® NMR spectrometer, shows that identification can be aided using this 
experiment in conjunction with the 1H NMR experiment.  
 
Table 45: Chemical shift values for a number of polyfluorinated ephenidine regioisomers. 
TFA used as an internal standard (δ ppm = -76.55 
Compound no. Compound abbreviation Chemical shift (δ ppm) 
15d 2,3 – DFEP -140.18, -144.23 
15e 2,4 – DFEP -110.70, -114.48 
15f 2.5 – DFEP -118.58, -124.18 
15g 2,6 – DFEP -113.68 
15h 3,4 – DFEP -139.56, -139.70 
15i 3,5 – DFEP -110.62 
15j TriFEP -163.00, -138.89, -135.30 
15k TeFEP -157.68, -156.32, -142.77, -139.52 
15l PFEP -163.30, -153.79, -140.90 
 
The 2,6-DFEP and 3,5-DFEP isomers are both easily identifiable based on the 
19F NMR screening experiment due to only having one peak, through the 
symmetry of the benzene ring. The chemical shifts are also far enough apart 
that the two compounds are easily distinguishable from one another. The 2,3-
DFEP; 2,4-DFEP; 2,5-DFEP and 3,4-DFEP samples all give two peaks when 
using 19F NMR and can be identified as single components. The TriFEP and 
PFEP samples both give three 19F NMR signals, based on symmetry of the 
fluorine atoms, while the TeFEP is the only derivative that gives rise to four 
peaks in the 19F NMR spectra. When using a 60 MHz benchtop NMR the 
speed of the analysis is quicker than most presumptive testing methods with 
the experiment only taking 3 minutes to perform. However, when some of the 
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compounds are run as mixtures there is some overlap due to the broadness 
of the peaks (e.g. 2,4-DFEP and 3,5-DFEP) meaning further experiments are 
needed in order to fully distinguish between the regioisomers. 19F NMR in this 
case provides a useful experiment due to the simplicity of the spectra 
produced. 
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Figure 154: 1H NMR spectrum (400 MHz) of the 2,3-difluoroephenidine (2,3-DFEP, 15d) isomer run in DMSO-d6 (δ ppm = 2.50)  
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Figure 155: Stacked 1H NMR spectra for the DFEP regioisomer aromatic regions run in DMSO-d6 (δ ppm = 2.50) acquired using a 400 MHz instrument 
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7.3. Presumptive testing 
The presumptive testing for difluorinated and polyfluorinated ephenidine 
regioisomers have not previously been reported and were performed using the 
United Nations recommended guidelines, in a similar way to the diphenidine 
regioisomers.118 A range of test reagents were used in this study including (i) 
Marquis test; (ii) Mandelin test; (iii) Simon’s test; (iv) Robadope’s test; (v) 
Scott’s test and (vi) Zimmerman test. The preparation of the reagents and test 
procedure is detailed in the experimental section (section 2.2). A solution of 
each reference standard (10 mg mL-1) was prepared in deionised water and a 
couple of drops placed into a dimple well of a spotting tile. The required 
presumptive test reagent (1-2 drops) was then added and any colour change 
upon initial addition of the reagents were noted and observations were made 
again after a five minute time period (Table 46). 
 
Marquis, Simon’s and Zimmerman’s reagents were the only tests to produce 
a noticeable colour change from the blank water solution. All solutions gave a 
positive reaction with the Marquis reagent, creating a yellow colour, which 
fades to a colourless solution after being left for five minutes. All solutions 
reacted in a similar way which makes identification of a specific isomer difficult. 
All samples also reacted in a similar way with the Zimmerman reagent and 
created a pale yellow precipitate, in a similar manner to the diphenidine 
reagents, which is believed to be the free base form of the drug, which is 
insoluble in water. Similar to the Marquis reagent all regioisomers reacted the 
same with the Zimmerman reagent making it difficult to distinguish between 
compounds.  
 
The final reagent to give a positive colour change was Simon’s reagent. 
Simon’s test works through the reaction of the secondary amine with aldehyde, 
followed by a reaction with sodium nitroprusside to produce the imine. This 
iminium salt is hydrolysed to produce the Simon-Awe complex. The 
difluorinated ephenidine samples produce a red/brown colour when reacted 
with Simon’s reagent, which could result from the reaction of sample with the 
nitroprusside coordination centre to produce a complex, while producing a 
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sodium salt that would have a natural red colour when dissolved as an 
aqueous solution. Each compound produces a slightly different colour when 
reacted with Simon’s reagent; however, it is not a reliable difference as it relies 
on the user’s discretion to determine the difference in colour change and 
intensities of colour may vary with concentrations used. As a presumptive test, 
Simon’s reagent should be used in combination with the Marquis reagent in 
order to determine the possible presence of a polyfluorinated ephenidine 
isomer.  
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Table 46: Colour changes observed with presumptive test reagents for the DFEP (15d-15i) regioisomers, TriFEP (15j), TeFEP (15k) and PFEP (15l) 
compounds immediately after addition and after 5 minutes of addition 
 
 
Marquis Mandelin Simon’s Robadope Scotts Zimmerman 
Colour 
change 
Colour after 
5 minutes 
Colour 
change 
Colour  
after 5 
minutes 
Colour 
change 
Colour after 
5 minutes 
Colour 
change 
Colour after 
5 minutes 
Colour 
change 
Colour 
change 
after 5 
minutes 
Colour 
change 
Colour 
change 
after 5 
minutes 
15d yellow colourless - - light brown light brown - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
15e light yellow colourless - - dark brown dark brown - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
15f light yellow colourless - - brown brown - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
15g yellow colourless - - red red - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
15h light yellow colourless - - brown brown - - - - 
- 
pale yellow 
ppt 
- 
pale yellow 
ppt 
15i yellow colourless - - brown brown - - - - 
-  
pale yellow 
ppt 
- 
pale yellow 
ppt 
15j yellow colourless - - dark red dark red - - - - 
-  
pale yellow 
ppt 
- 
pale yellow 
ppt 
15k yellow colourless - - brown brown - - - - 
-  
pale yellow 
ppt 
- 
pale yellow 
ppt 
15l yellow colourless - - brown brown - - - - 
-  
pale yellow 
ppt 
- 
pale yellow 
ppt 
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7.4. Thin layer chromatography 
Thin layer chromatography has been performed on the six difluoroephenidine 
regioisomers and the three polyfluorinated compounds using the same 
method as used for the thirteen diphenidine derivatives (see section 4.4). 
Average Rf values have been reported (Table 47) based on the averages from 
six repeats. The examination of these Rf values show that there is limited 
separation based on this measurement. The TriFEP (15j), TeFEP (15k) and 
PFEP (15l) compounds all show a much lower Rf value when compared to the 
difluoroephenidine isomers, apart from the 2,4-DFEP isomer (15e). The 
remaining DFEP compounds (15d, 15f–15i) all have very similar Rf values and 
so cannot be separated based on TLC experiments. 
 
 
Table 47: Thin Layer Chromatography data for the nine polyfluorinated ephenidine 
regioisomers (15d–15l) 
 Compound name 
Spot colour 
under UV light 
(254 nm) 
 
Spot colour after 
staining with 
modified 
Dragendorff-Ludy-
Tenger Reagent 
Rf value 
15d 2,3-difluoroephenidine Black spot Blood-red spot 0.87 
15e 2,4-difluoroephenidine Black spot Blood-red spot 0.75 
15f 2,5-difluoroephenidine Black spot Blood-red spot 0.80 
15g 2,6-difluoroephenidine Black spot Blood-red spot 0.83 
15h 3,4-difluoroephenidine Black spot Blood-red spot 0.84 
15i 3,5-difluoroephenidine Black spot Blood-red spot 0.80 
15j 2,3,4-trifluoroephenidine Black spot Blood-red spot 0.72 
15k 2,3,4,5-tetrafluoroephenidine Black spot Blood-red spot 0.74 
15l 2,3,4,5,6-pentafluroephenidine Black spot Blood-red spot 0.70 
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7.5. Gas chromatography – mass spectroscopy 
The employed qualitative GC-MS method required an extremely 
straightforward solvation of the samples in methanol (1 mg mL-1) followed by 
direct injection into the instrument. No derivatisation step was required. All 
polyfluorinated regioisomers (15d–15l) were run individually initially, using the 
general screening method (section 2.4.3), before being run as a mixture in 
order to determine retention times. Retention times (Rt) and relative retention 
times (RRt), in relation to the internal standard eicosane, can be seen in Table 
48, while the overlapped spectra of the chromatograms along with the 
polyfluorinated ephenidine mixture can be seen in figure 165. 
  
Table 48: GC-MS retention times for the polyfluorinated ephenidine regioisomers along with 
relative retention times compared to eicosane 
Compound 
no. 
Compound 
abbreviation 
Compound 
Retention time 
(Rt / mins) 
Eicosane 
Retention time 
(mins) 
Relative Retention 
time (RRt) 
15d 2,3-DFEP 9.96 12.67 0.77 
15e 2,4-DFEP 9.51 12.67 0.75 
15f 2,5-DFEP 9.67 12.67 0.76 
15g 2,6-DFEP 9.53 12.67 0.75 
15h 3,4-DFEP 10.09 12.67 0.80 
15i 3,5-DFEP 9.58 12.67 0.77 
15j TriFEP 9.77 12.67 0.77 
15k TeFEP 9.33 12.67 0.74 
15l PFEP 8.59 12.67 0.68 
 
The relative retention times show that all polyfluorinated ephenidine isomers 
can be separated using GC-MS, apart from the 2,4-DFEP and 2,6-DFEP 
compounds. The two compounds cannot be distinguished from one another 
when run as a mixture (figure 165) as the two peaks co-elute making it 
impossible to identify one from the other. Even when the oven temperature 
programme was slowed to a ramp of 1°C/min or held on an isothermal ramp, 
the two compounds do not separate from one another. The GC-MS method 
was not validated in this case due to both peaks co-eluting and a new 
separation technique is needed to be able to identify these compounds from 
one another. 
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Figure 156: GC-MS chromatographs for all nine polyfluorinated ephenidines (15d–15l)
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There is also no way to distinguish these two DFEP compounds based on the 
mass spectroscopy data as the spectra is the same for all of the regioisomers 
and can be seen in figure 157. The base peak, with a mass to charge (m/z) 
value of 170.1, is derived in a similar way to the diphenidine regioisomers 
explained previously with the benzyl group removed to leave just the ethyl 
chain and phenyl ring with the di-substituted fluorine. The ethyl chain is then 
removed to produce a secondary peak of m/z 142.0, with a peak also present 
at m/z 91.0 representing the benzyl cation. This fragmentation pattern can be 
seen in figure 158. The m/z ratio for the base and secondary peaks, for the tri, 
tetra and pentafluorinated derivatives, then increases by a mass of one 
fluorine atom per compound and has distinguishable mass spectra (figure 
159), creating unique values and distinguishable mass spectra. 
 
The mass spectrometry in combination with GC allows identification of these 
three compounds in under 15 minutes, however the co-elution of the 2,4 and 
2,6-DFEP isomers and matching mass spectra means a new instrument and 
technique is needed for identification purposes.  
 
 
Figure 157: Mass spectrometry fragmentation pattern for polyfluorinated ephenidine 
regioisomers 
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Figure 158: EI-MS spectra for all the DFEP regioisomers (15d–15i) 
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Figure 159: EI-MS spectra for the TriFEP, TeFEP and PFEP compounds 
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7.6. 60 MHz NMR screening 
Due to the poor ability of current presumptive test reagents to distinguish 
between the polyfluorinated regioisomers, and the coelution of the 2,4 and 2,6 
isomers using GC-MS, a new technique is needed that will be able to identify 
specific isomers in a quick, reliable manner. A 60 MHz Pulsar NMR instrument 
(Oxford Instruments, Abingdon, Oxfordshire) was used to obtain both 1H and 
19F NMR spectra to help distinguish between the nine compounds. This 
instrument allows complex structural analysis to be performed similar to the 
400 MHz NMR spectrometer, with less expense and less expert knowledge 
required to perform experimentation. The 1H NMR spectra were obtained for 
each individual compound at a concentration of 10 mg mL-1. Samples were 
prepared in the same manner as those used to obtain spectra on the 400 MHz 
instrument and each spectrum was acquired using 8 scans. It was observed 
from the 400 MHz that the aliphatic region of the spectrum matches for all 
ephenidine isomers and that the main differences can be seen in the aromatic 
region. The 60 MHz instrument still shows similarities in this aliphatic region 
for all regioisomers and the main pattern of the whole spectra carries over, 
even though slight resolution is lost and peaks broaden with the loss of splitting 
patterns, as the magnetic field is weaker for the 60 MHz measurements 
compared to those conducted on the 400 MHz instrument (figure 160).   
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Figure 160: 1H NMR comparison using 400 MHz and 60 MHz instruments for the 2,3-DFEP 
(15d) and 2,6-DFEP (15g) isomers 
The main differences between each isomer still appears in the aromatic region, 
even with the broadening of peaks and loss of splitting patterns, meaning this 
can be used to help with identification of samples. Although the aliphatic 
regions of each regioisomer are very similar there are clear differences in the 
patterns of spectra, for all the DFEP isomers (15d-15i) samples in the aromatic 
regions between 6 ppm and 8.5 ppm (figure 161). 
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Figure 161: Stacked 1H NMR spectra for all DFEP regioisomers (15d–15i) focusing on the 
aromatic region 
The ability of this 1H NMR experiment to distinguish between the 2,4-DFEP 
(15e) and 2,6-DFEP (15g) is important, as it is difficult to distinguish these two 
compounds using both GC-MS and presumptive colour tests, as individual 
components. This shows the potential of the 60 MHz Pulsar instrument to 
become a new presumptive test with the ability to provide an initial idea as to 
the sample present in under five minutes. This 1H NMR experiment works well 
with one component samples, however identifying samples becomes more 
difficult if multiple polyfluorinated ephenidines are present, as the spectra 
becomes more complex and peaks begin to coalesce. Hence, further 
experiments were performed using the 60 MHz Pulsar NMR in order to help 
identify samples present in mixtures.   
 
A 19F NMR experiment was performed using the 60 MHz instrument. Again, 
all samples were run individually using matching number of scans and 
relaxation delay to create another run that would be performed in 3.5 minutes. 
All samples were run with the inclusion of TFA as an internal standard (δ = -
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75.66 ppm) in order to gain an accurate 19F shift for the samples. All sample 
chemical shifts can be seen in Table 49. 
 
Table 49: 19F chemical shift data for the polyfluorinated ephenidine regioisomers (15d – 15l) 
using 60 MHz NMR instrument   
Compound no. Compound abbreviation Chemical shift (δ ppm) 
15d 2,3 – DFEP -140.22, -144.25 
15e 2,4 – DFEP -110.32, -114.25 
15f 2.5 – DFEP   -118.41, -124.27 
15g 2,6 – DFEP -113.67 
15h 3,4 – DFEP -139.61 
15i 3,5 – DFEP -110.48 
15j TriFEP -163.00, -138.89, -135.30 
15k TeFEP -137.68, - 142.50, -156.31, -157.48 
15l PFEP -140.80, -153.79, - 163.20 
 
All samples show very similar chemical shifts to the 400 MHz NMR data gained 
from characterisation of the samples. The main significant difference between 
the 400 MHz and 60 MHz measurements is the broadening of peaks due to a 
loss of resolution. This creates a merging of fluorine peaks for the 3,4-DFEP 
sample, which shows 2 peaks using 400 MHz NMR but combines to one using 
60 MHz NMR, although the splitting of the peaks still suggests two chemical 
environments are present. All DFEP isomers show distinctive chemical shifts 
and due to the simplicity of the spectra can be separated on both chemical 
shifts and the number of peaks (Error! Reference source not found.71). 
When combined with 1H NMR, this data can be used in the identification of a 
poly-fluorinated ephenidine isomer that prior to the measurement had not been 
detected before. Again some peaks may overlap when certain combinations 
of isomers are observed in the same sample and so a 19F J-resolved and 19F 
TOCSY experiment were developed on the 60 MHz instrument to help identify 
samples in mixtures. 
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Figure 162: Stacked 19F NMR spectra for all DFEP isomers (15d–15i) 
The tri, tetra and pentafluoroephenidine regioisomers can also be identified 
based on the number of peaks and shifts. The trifluoroephenidine (15j) and 
pentafluoroephenidine samples (15l) both produce three peaks in the 19F-
NMR spectra, due to matching chemical environments in the pentafluoro 
derivative, through symmetry in the phenyl ring. However, the peaks are easily 
distinguishable from one another and from the four peaks produced by the 
tetrafluoroephenidine isomer (15k) as seen in figure 162.  
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Figure 163: Stacked 19F NMR spectra for the tri (bottom), tetra (middle) and 
pentafluoroephenidine (top) regioisomers (15j–15k) using 60 MHz NMR 
The simplicity of the 19F NMR spectra makes it an ideal experiment to use as 
a replacement presumptive test to show the possibility of a DFEP isomer being 
present in a sample. This can then be used in combination with 1H NMR data 
to further solidify the identification of the regioisomer present.   
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7.7. 60 MHz NMR J-resolved experiments 
 
J-resolved NMR experiments were performed, for all six DFEP regioisomers, 
using the 60 MHz Pulsar instrument. Development of the experimental 
protocol with respect to the number of scans and points to acquire along both 
dimensions was optimised in order to produce sufficiently resolved signals in 
the J-resolved spectra. Spectra produced shows the relevant chemical shift of 
peaks along the f2 axis, with the multiplicity from the splitting displayed along 
the f1 axis. This helps to further identify the compound present, using the 60 
MHz instrument, as 19F NMR experiments show little of the coupling and 
splitting details produced using 400 MHz instruments. The 19F J-resolved 
experiment can also further distinguish between the six DFEP isomers based 
on the coupling and splitting information produced. The spectra produced for 
the DFEP regioisomers (15d–15i) can be seen in figure 164–figure 169 and 
shows the difference in appearance between each of the spectra.  
 
The 2,3-DFEP (15d) and 3,4-DFEP (15h) regioisomers both show the highest 
coupling constants with a distance of 0.2 and 0.22 ppm respectively from the 
centre alignment to each signal on the spectra. This equates to a coupling 
constant value between 12–13.2 Hz, and is consistent with 3JFF coupling being 
manifest. There is a major difference between the two spectra as more 
coupling is observed in the 3,4-DFEP spectra. This could be explained through 
the presence of proton nuclei on the 2’- and 5’-positions of the benzene ring 
coupling to the fluorine, which would not occur when fluorine is present on the 
2’-positon of the benzene ring. The extra coupling is observed in the 3,5-DFEP 
(15i) isomer as well which shows a 4JFF coupling of 4.8 Hz. This 4JFF coupling 
constant value is also seen with the 2,4-DFEP isomer (15e), however no extra 
coupling is observed. 2,5-DFEP (15f) displays 5JFF coupling with a coupling 
constant value of 10.2 Hz. The main DFEP isomer which can be easily 
identified using a 19F J-resolved experiment is the 2,6-DFEP (15g) compound 
based on the inability of the experiment to show any coupling.  
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This 2D experiment helps to clearly distinguish between the regioisomers and 
with a longer experimental run time should be used after the 1H and 19F NMR 
presumptive testing has been performed to provide a more confirmatory 
response. A 2D TOCSY NMR was also performed in order to show the ability 
of 60 MHz NMR to distinguish between the DFEP regioisomers.  
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Figure 164: 19F NMR J-resolved spectrum for the 2,3-difluoroephenidine (15d) sample 
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Figure 165: 19F NMR J-resolved spectrum for the 2,4-difluoroephenidine (15e) sample 
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Figure 166: 19F NMR J-resolved spectrum for the 2,5-difluoroephenidine (15f) sample 
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Figure 167: 19F NMR J-resolved spectrum for the 2,6-difluoroephenidine (15g) sample 
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Figure 168: 19F NMR J-resolved spectrum for the 3,4-difluoroephenidine (15h) sample 
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Figure 169: 19F NMR J-resolved spectrum for the 3,5-difluoroephenidine (15i) sample 
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7.8. 19F-TOCSY NMR 
 
19F Total Correlation Spectroscopy (TOCSY) NMR experiments were run on 
the 60 MHz Pulsar instrument in order to try to resolve the six DFEP 
regioisomers. In a similar manner to the 19F J-resolved experiments the 
number of scans and collection points was optimised in order to gain sufficient 
signal-to-noise. The spectrum produced is a product of the spin-spin coupling 
observed from the fluorine atoms in the molecule. The offset value was set in 
the middle of all chemical shifts, and was uncorrected, hence the reason the 
chemical shifts in both the f1 and f2 dimension does not match the 19F NMR 
chemical shifts reported previously. The TFA peak is observed as an individual 
signal as no coupling is seen with the internal standard, however it can be 
used to track back to the chemical shift values. Cross-peaks are generated in 
the spectrum when coupling between fluorine nuclei occurs. The easiest 
cross-peak to observe is for 2,5-DFEP which has chemical shifts of -118.41 
ppm and -124.27 ppm, which is seen around -2 ppm and -10 ppm on the 
TOCSY spectrum (Error! Reference source not found.). The 3,4-DFEP 
contains two peaks, that overlap at a chemical shift of -139.61 ppm, and this 
signal can be seen in the TOCSY spectrum when it is enlarged (Error! 
Reference source not found.80). This signal appears close to one of the 
signals responsible for generating a cross peak for the coupling of 2,3-DFEP 
at 0–5 ppm in the TOCSY spectrum. The 2,6-DFEP and 2,5-DFEP isomers 
both only contain one peak for 19F-NMR, due to symmetry, and these appear 
as individual signals in the TOCSY spectrum. The remaining cross-peak is 
created by the coupling of the fluorine nuclei in 2,4-DFEP. This observed 
between -23 ppm and -30 ppm in the TOCSY spectrum, representing peaks 
at -110.32 ppm and -114.25 ppm from the 19F NMR experiments.  
 
This TOCSY experiment can distinguish between mixtures of DFEP 
regioisomers and can be used in combination with the J-resolved experiment 
to further identify compounds present. These experiments take longer to run 
than the 1H and 19F NMR experiments, and so would be used afterwards to 
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confirm the chemical identity ascertained from running the two presumptive 
NMR experiments on the 60 MHz instrument. 
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Figure 170: 19F NMRTOCSY spectrum of a mixture of six DFEP (15d-15i) regioisomers   
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Figure 171: Truncated 19F NMR TOCSY spectrum shown in figure 190 to highlight the coupling interactions   
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7.9. Conclusions  
The six difluoroephenidine regioisomers (15d-15i) were fully synthesised 
along with the tri (15j), tetra (15k) and pentafluoroephenidine (15l) 
compounds. All samples were shown to be pure (>95%) in order for full 
characterisation to be performed and reference spectra to be produced.  
 
Presumptive testing was performed and showed that a combination of the 
Marquis and Simon’s reagents can help to show the possibility of the presence 
of a polyfluorinated ephenidine isomer. However, the use of both reagents 
does not allow the nine compounds to be distinguished from one another.  
 
A GC-MS method was also developed and showed difficulties separating the 
2,4-DFEP and 2,6-DFEP isomers, even with further methods attempted. The 
remaining polyfluorinated ephenidines were fully baseline separated using the 
method developed in under 11 minutes. 
 
60 MHz NMR was used a possible presumptive test replacement with 1H and 
19F experiments performed. Spectra for all compounds showed that 
distinguishing features are found in all compounds to allow possible 
identification between isomers. 19F chemical shifts began to show that the 
isomers could also be distinguished from one another. Two dimensional 19F 
experiments (COSY and TOCSY) were then developed which further 
distinguished the six difluoroephenidine regioisomers from one another, with 
less sample preparation required. The ability of the 60 MHz Pulsar 
spectrometer to perform the 2-dimensional experiments to help confirm the 
isomer present as well as a unique aromatic region to each of the other difluoro 
derivatives mean that the technique can start to be considered as a 
confirmatory test as well as a presumptive test.  
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8. Final conclusions and future work 
A range of diphenidine derivatives and analogues including both mono and 
poly fluorinated and non-fluorinated compounds have been synthesised with 
yields all greater than 20%. Diphenidine analogues were also produced by 
altering the amine in the synthesis method. This shows the ability to alter 
structures and the ease of clandestine labs to produce these samples with 
synthesis only taking 2 hours. It also shows the difficulties facing analytical 
and forensic scientists for detection with new substances produced so easily 
and reference spectra constantly changing.  
 
All diphenidine and ephenidine derivatives along with the fluorinated 
cathinones and amphetamines were all analysed using a full range of 
presumptive colour test reagents. In the case of the fluoromethcathinone and 
trifluoromethylmethcathinone regioisomers the Zimmerman reagent is able to 
provide a characteristic test. The Simon’s reagent provides the ability to 
distinguish between the fluoromethcathinone regioisomers, however the 
difference in colour between the trifluoromethylmethcathinone regioisomers is 
less clear. The Robadope reagent can provide a characteristic test for the 
detection of amphetamines, however no difference is seen between the three 
fluorinated isomers. The Scott’s reagent is characteristic for the diphenidine 
derivatives as well as providing more false positives for the detection of 
cocaine. This false positive provides difficulties for law enforcement as it 
produces confusion as to whether charging occurs under the Misuse of Drugs 
Act (1971) or the Psychoactive Substances Act (2016). All fluorinated 
ephenidine and diphenidine analogues can be identified using a combination 
of the Marquis, Mandelin’s, Scott’s and Simon’s reagents, however different 
regioisomers cannot be distinguished from another. In the case of 
regioisomers they will produce the same λmax values which means UV 
attachments would not further separation and detection. In the case of 
presumptive colour tests a reagent testing kit could cost between £10-£20 with 
no way of determining an exact class with confidence.    
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A validated GC-MS method was developed for the separation and detection 
of the fluorinated cathinone and amphetamine regioisomers, diphenidine 
derivatives, halogenated derivatives and fluorinated diphenidine analogues. 
All FMC, TFMMC and FA isomers could be distinguished from one another 
within 11 minutes, however baseline separation could not be achieved for the 
3’- and 4’-fluoroamphetamine regioisomers.  LOD for all compounds ranged 
from 7.9 – 13.2 μg mL-1. All diphenidine derivatives were baseline separated 
in 45 minutes with LOD ranging from 4.5 – 12 μg mL-1. The halogenated 
diphenidines and fluorinated diphenidine analogues were split into positional 
isomer mixes for validation with all compounds distinguished from one another 
with the aid of SIM mode. LOD ranged from 6.5 – 16 μg mL-1. For all mixtures 
the run times for separation exceed 25 minutes which limits the number of 
samples that could be performed on these methods. The limits of detection 
and quantification are the lowest out of all analytical methods used in these 
studies. 
 
60 MHz NMR was used for all compounds to show the similarities compared 
to 400 MHz NMR analysis. Spectra patterns and splitting patterns were 
consistent between both instruments with the 60 MHz instrument able to 
distinguish between regioisomers. A combination of 19F and 1H NMR 
experiments could be performed in 10 minutes. The spectra produced for both 
allowed regioisomers to be distinguished from one another based on both 
aliphatic regions, for class of compound, and aromatic regions for the position 
of the substituent groups on the benzene ring. Compounds containing fluorine 
also showed characteristic chemical shifts that aid with identification. 2D 19F 
NMR experiments were also developed for the differentiation of difluorinated 
ephenidine derivatives. Quantitative analysis was performed on both 
fluoroephenidine (FEP) and fluoroamphetamine (FA) isomers in order to show 
the potential of using 60 MHz NMR as a new presumptive test for quantitative 
analysis as well as qualitative.   
 
Finally two tablets, presumed to be MDMA, were analysed both qualitatively 
and quantitatively. Analysis was performed using colour tests, GC-MS 
analysis and 60 MHz NMR. The Robadope reagent produced a positive 
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reaction, resembling the response of the fluoroamphetamine regioisomers, 
however it was not possible to identify which isomer was present. Both the 
GC-MS and 60 MHz NMR confirmed that both tablets contained 4-
fluoroamphetamine. The GC-MS showed that the tablets contained 40% and 
49% of 4-FA respectively, with the 19F NMR calibration of 4-FA agreeing with 
the %composition within ±2%. This again shows the ability of 60 MHz 
instruments to become a presumptive test for the initial identification of NPS. 
 
When comparing the presumptive testing side of analysis between the 60 MHz 
NMR and presumptive colour tests there are some similarities. Both 
techniques allow classes to be originally identified when a combination of 
colour tests are used and the aliphatic region of NMR spectrum is studied. 
Both techniques could be used by personal in law enforcement due to ease of 
use and at public environments such as festivals and airports due to being 
“field deployable”. However, the presumptive colour tests cannot distinguish 
between regioisomers which makes it less favourable to the 60 MHz NMR, 
which when using the aromatic and aliphatic regions of the 1H NMR 
experiment and 19F NMR experiment, where necessary, can distinguish 
between regioisomers.   
 
When comparing the 60 MHz NMR approach and the various methods 
employed in terms of which technique is more advantageous, there are 
multiple points to consider. Table 50 shows the comparison between the 60 
MHz NMR approach and GC-MS methods with points made throughout the 
study and taking into account operational costs, instrumental cost and ease of 
operation.      
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Table 50: Instrumental comparison between the 60 MHz NMR and the GC-MS 
60 MHz NMR  GC-MS 
 Instrument costs around £50k 
 Not currently utilised in forensic labs 
 Low operational costs but high 
maintenance costs 
 Can be used and processed by non-
scientists  
 Easier sample preparation compared to 
GC-MS 
 Easy sample processing especially for 
19F NMR where only a couple of signals 
will be observed. 
 Both 1H and 19F NMR experiments can 
be performed within 5 minutes. 
 Regioisomers can be easily 
distinguished from another when run as 
individual components. Difficulties may 
be seen when mixtures are run, however 
longer 2-D experiments can help to 
distinguish compounds.  
 Field deployable 
 Instrument can cost upwards of 
£200k 
 Can cost £200 per sample when 
sent off for testing 
 Low operational cost but high 
maintenance costs 
 Expertise needed for running and 
processing samples 
 Sample runs last 20 minutes and 
longer 
 Easily separates mixtures with only 
a couple of examples showing co-
elution. 
 Currently used by forensic 
laboratories and can be used for 
evidence collection 
 No portability available 
 
 
 
This shows that the 60 MHz NMR has an ability to identify compounds easily 
when individual components are analysed. 60 MHz NMR instrumentation 
would be more favourable in the instance of finance, due to a cheaper 
operating system and matching operational costs. For law enforcement and 
organisations such as Greater Manchester Police the 60 MHz NMR would be 
ideal to initially test street samples to show what samples could potentially 
contain. This would then cut down on costs currently spent to send samples 
for forensic testing, that may not be needed if samples contain only non-
controlled substances such as caffeine or paracetamol. Use of the 60 MHz 
NMR in environments such as police custody and festivals is possible due to 
the system being field deployable, which is not possible with the GC-MS 
instrument. Difficulties with mixtures does occur with the 60 MHz instrument 
and requires more complex and longer 2-D experiments such as TOCSY to 
begin to distinguish compounds in a complete mixture.  
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As a final conclusion the 60 MHz NMR would provide a better initial 
presumptive test to instruments and techniques already available due to costs, 
ease of sample preparation, ease of data processing and the sample 
throughput speed already mentioned. Techniques such as UV analysis and 
reagent colour testing provide a possible identification of class, however they 
do not distinguish between regioisomers and cannot pick out an individual 
component. The GC-MS would then be used as the confirmatory test to clarify 
what has been stated by the 60 MHz NMR.     
 
Future work will include further quantification analysis using 60 MHz on a 
greater range of NPS classes. This can also include the possibility of using 1H 
NMR experiments to produce calibration graphs with maleic acid as a possible 
alternative as an internal standard. Maleic acid would act in a similar manner 
to trifluoroacetic acid in the fact that it would only produce a single peak in the 
1H NMR spectra. A greater range of compounds must also be run on 60 MHz 
NMR instruments in order to produce a bigger database. This will then help 
further with the identification of NPS and can also aid with identification when 
new emerging compounds are first encountered. Further work on 2-D 
experiments such as TOCSY can be performed to help show the ability of the 
60 MHz to further analyse mixtures. A final process would be to test the 60 
MHz instrument in locations such as police custodies and festival locations to 
show whether the instrument can analyse samples as and when they are 
seized in a repetitive and accurate manner.              
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